Cochrane
Library

Cochrane Database of Systematic Reviews

Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)

Schuit E, Panagiotou OA, Munafò MR, Bennett DA, Bergen AW, David SP

Schuit E, Panagiotou OA, Munafò MR, Bennett DA, Bergen AW, David SP.
Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.
Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No.: CD011823.
DOI: [10.1002/14651858.CD011823.pub2](https://doi.org/10.1002/14651858.CD011823.pub2).

www.cochranelibrary.com

Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
(Review)

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	3
BACKGROUND	13
OBJECTIVES	14
METHODS	14
RESULTS	17
Figure 1.	19
Figure 2.	21
Figure 3.	22
DISCUSSION	25
AUTHORS' CONCLUSIONS	27
ACKNOWLEDGEMENTS	28
REFERENCES	29
CHARACTERISTICS OF STUDIES	41
DATA AND ANALYSES	89
Analysis 1.1. Comparison 1 Active NRT vs placebo - rs1051730 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	90
Analysis 1.2. Comparison 1 Active NRT vs placebo - rs1051730 - non-Hispanic white, Outcome 2 End of Treatment.	91
Analysis 2.1. Comparison 2 Active NRT vs placebo - rs16969968 - non-Hispanic white, Outcome 1 End of Treatment.	92
Analysis 3.1. Comparison 3 Active NRT vs placebo - rs16969968 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.	93
Analysis 3.2. Comparison 3 Active NRT vs placebo - rs16969968 - non-Hispanic black or African American, Outcome 2 End of Treatment.	93
Analysis 4.1. Comparison 4 Active NRT vs placebo - rs 588765 - non-Hispanic white, Outcome 1 End of Treatment.	94
Analysis 5.1. Comparison 5 Active NRT vs placebo - rs2036527 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.	95
Analysis 5.2. Comparison 5 Active NRT vs placebo - rs2036527 - non-Hispanic black or African American, Outcome 2 End of Treatment.	96
Analysis 6.1. Comparison 6 Active NRT vs placebo - DRD4 (exon 3 48 bp) - non-Hispanic white, Outcome 1 Six-Month Abstinence.	97
Analysis 6.2. Comparison 6 Active NRT vs placebo - DRD4 (exon 3 48 bp) - non-Hispanic white, Outcome 2 End of Treatment. ...	98
Analysis 7.1. Comparison 7 Active NRT vs placebo - NMR - non-Hispanic black and white, Outcome 1 Six-Month Abstinence. ...	99
Analysis 7.2. Comparison 7 Active NRT vs placebo - NMR - non-Hispanic black and white, Outcome 2 End of Treatment.	99
Analysis 8.1. Comparison 8 Bupropion vs placebo - rs1051730 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	100
Analysis 8.2. Comparison 8 Bupropion vs placebo - rs1051730 - non-Hispanic white, Outcome 2 End of Treatment.	101
Analysis 9.1. Comparison 9 Bupropion vs placebo - rs1051730 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.	102
Analysis 9.2. Comparison 9 Bupropion vs placebo - rs1051730 - non-Hispanic black or African American, Outcome 2 End of Treatment.	103
Analysis 10.1. Comparison 10 Bupropion vs placebo - rs16969968 - non-Hispanic white, Outcome 1 End of Treatment.	104
Analysis 11.1. Comparison 11 Bupropion vs placebo - rs16969968 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.	105
Analysis 11.2. Comparison 11 Bupropion vs placebo - rs16969968 - non-Hispanic black or African American, Outcome 2 End of Treatment.	106
Analysis 12.1. Comparison 12 Bupropion vs placebo - rs588765 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	107
Analysis 12.2. Comparison 12 Bupropion vs placebo - rs588765 - non-Hispanic white, Outcome 2 End of Treatment.	107
Analysis 13.1. Comparison 13 Bupropion vs placebo - rs2036527 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	109
Analysis 13.2. Comparison 13 Bupropion vs placebo - rs2036527 - non-Hispanic white, Outcome 2 End of Treatment.	109
Analysis 14.1. Comparison 14 Bupropion vs placebo - rs2036527 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.	111
Analysis 14.2. Comparison 14 Bupropion vs placebo - rs2036527 - non-Hispanic black or African American, Outcome 2 End of Treatment.	111

Analysis 15.1. Comparison 15 Bupropion vs placebo - rs3733829 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	112
Analysis 15.2. Comparison 15 Bupropion vs placebo - rs3733829 - non-Hispanic white, Outcome 2 End of Treatment.	113
Analysis 16.1. Comparison 16 Bupropion vs placebo - rs3733829 - non-Hispanic black or African American, Outcome 1 End of Treatment.	114
Analysis 17.1. Comparison 17 Bupropion vs placebo - rs7937 - non-Hispanic white, Outcome 1 End of Treatment.	115
Analysis 18.1. Comparison 18 Bupropion vs placebo - rs7937 - non-Hispanic black or African American, Outcome 1 End of Treatment.	116
Analysis 19.1. Comparison 19 Bupropion vs placebo - rs1329650 - non-Hispanic white, Outcome 1 End of Treatment.	117
Analysis 20.1. Comparison 20 Bupropion vs placebo - rs1329650 - non-Hispanic black or African American, Outcome 1 End of Treatment.	118
Analysis 21.1. Comparison 21 Bupropion vs placebo - rs1028936 - non-Hispanic white, Outcome 1 End of Treatment.	119
Analysis 22.1. Comparison 22 Bupropion vs placebo - rs1028936 - non-Hispanic black or African American, Outcome 1 End of Treatment.	120
Analysis 23.1. Comparison 23 Bupropion vs placebo - rs215605 - non-Hispanic white, Outcome 1 End of Treatment.	120
Analysis 24.1. Comparison 24 Bupropion vs placebo - rs215605 - non-Hispanic black or African American, Outcome 1 End of Treatment.	121
Analysis 25.1. Comparison 25 Bupropion + any NRT vs placebo - rs1051730 - non-Hispanic white, Outcome 1 End of Treatment.	122
Analysis 26.1. Comparison 26 Bupropion + any NRT vs placebo - rs1051730 - non-Hispanic black or African American, Outcome 1 End of Treatment.	123
Analysis 27.1. Comparison 27 Bupropion + any NRT vs placebo - rs16969968 - non-Hispanic white, Outcome 1 End of Treatment.	124
Analysis 28.1. Comparison 28 Bupropion + any NRT vs placebo - rs16969968 - non-Hispanic black or African American, Outcome 1 End of Treatment.	125
Analysis 29.1. Comparison 29 Bupropion + any NRT vs placebo - rs2036527 - non-Hispanic white, Outcome 1 End of Treatment.	126
Analysis 30.1. Comparison 30 Bupropion + any NRT vs placebo - rs2036527 - non-Hispanic black or African American, Outcome 1 End of Treatment.	127
Analysis 31.1. Comparison 31 Bupropion + any NRT vs placebo - rs3733829 - non-Hispanic white, Outcome 1 End of Treatment.	128
Analysis 32.1. Comparison 32 Bupropion + any NRT vs placebo - rs3733829 - non-Hispanic black or African American, Outcome 1 End of Treatment.	129
Analysis 33.1. Comparison 33 Bupropion + any NRT vs placebo - rs7937 - non-Hispanic white, Outcome 1 End of Treatment. ...	130
Analysis 34.1. Comparison 34 Bupropion + any NRT vs placebo - rs7937 - non-Hispanic black or African American, Outcome 1 End of Treatment.	131
Analysis 35.1. Comparison 35 Bupropion + any NRT vs placebo - rs1329650 - non-Hispanic white, Outcome 1 End of Treatment.	132
Analysis 36.1. Comparison 36 Bupropion + any NRT vs placebo - rs1329650 - non-Hispanic black or African American, Outcome 1 End of Treatment.	133
Analysis 37.1. Comparison 37 Bupropion + any NRT vs placebo - rs1028936 - non-Hispanic white, Outcome 1 End of Treatment.	134
Analysis 38.1. Comparison 38 Bupropion + any NRT vs placebo - rs1028936 - non-Hispanic black or African American, Outcome 1 End of Treatment.	135
Analysis 39.1. Comparison 39 Bupropion + any NRT vs placebo - rs215605 - non-Hispanic white, Outcome 1 End of Treatment. .	136
Analysis 40.1. Comparison 40 Bupropion + any NRT vs placebo - rs215605 - non-Hispanic black or African American, Outcome 1 End of Treatment.	137
Analysis 41.1. Comparison 41 Bupropion + any NRT vs bupropion - rs1051730 - non-Hispanic white, Outcome 1 End of Treatment.	138
Analysis 42.1. Comparison 42 Bupropion + any NRT vs bupropion - rs1051730 - non-Hispanic black or African American, Outcome 1 End of Treatment.	139
Analysis 43.1. Comparison 43 Bupropion + any NRT vs bupropion - rs16969968 - non-Hispanic white, Outcome 1 End of Treatment.	139
Analysis 44.1. Comparison 44 Bupropion + any NRT vs bupropion - rs16969968 - non-Hispanic black or African American, Outcome 1 End of Treatment.	141
Analysis 45.1. Comparison 45 Bupropion + any NRT vs bupropion - rs2036527 - non-Hispanic white, Outcome 1 End of Treatment.	141
Analysis 46.1. Comparison 46 Bupropion + any NRT vs bupropion - rs2036527 - non-Hispanic black or African American, Outcome 1 End of Treatment.	143
Analysis 47.1. Comparison 47 Bupropion + any NRT vs bupropion - rs3733829 - non-Hispanic white, Outcome 1 End of Treatment.	143

Analysis 48.1. Comparison 48 Bupropion + any NRT vs bupropion - rs3733829 - non-Hispanic black or African American, Outcome 1 End of Treatment.	145
Analysis 49.1. Comparison 49 Bupropion + any NRT vs bupropion - rs7937 - non-Hispanic white, Outcome 1 End of Treatment. .	145
Analysis 50.1. Comparison 50 Bupropion + any NRT vs bupropion - rs7937 - non-Hispanic black or African American, Outcome 1 End of Treatment.	147
Analysis 51.1. Comparison 51 Bupropion + any NRT vs bupropion - rs1329650 - non-Hispanic white, Outcome 1 End of Treatment.	147
Analysis 52.1. Comparison 52 Bupropion + any NRT vs bupropion - rs1329650 - non-Hispanic black or African American, Outcome 1 End of Treatment.	149
Analysis 53.1. Comparison 53 Bupropion + any NRT vs bupropion - rs1028936 - non-Hispanic white, Outcome 1 End of Treatment.	149
Analysis 54.1. Comparison 54 Bupropion + any NRT vs bupropion - rs1028936 - non-Hispanic black or African American, Outcome 1 End of Treatment.	151
Analysis 55.1. Comparison 55 Bupropion + any NRT vs bupropion - rs215605 - non-Hispanic white, Outcome 1 End of Treatment.	151
Analysis 56.1. Comparison 56 Bupropion + any NRT vs bupropion - rs215605 - non-Hispanic black or African American, Outcome 1 End of Treatment.	153
Analysis 57.1. Comparison 57 Active NRT - rs1051730 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	154
Analysis 57.2. Comparison 57 Active NRT - rs1051730 - non-Hispanic white, Outcome 2 End of Treatment.	154
Analysis 58.1. Comparison 58 Active NRT - rs1051730 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.	155
Analysis 59.1. Comparison 59 Active NRT - rs16969968 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.	156
Analysis 59.2. Comparison 59 Active NRT - rs16969968 - non-Hispanic black or African American, Outcome 2 End of Treatment.	156
Analysis 60.1. Comparison 60 Active NRT - rs588765 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	157
Analysis 60.2. Comparison 60 Active NRT - rs588765 - non-Hispanic white, Outcome 2 End of Treatment.	158
Analysis 61.1. Comparison 61 Active NRT - rs2036527 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	159
Analysis 61.2. Comparison 61 Active NRT - rs2036527 - non-Hispanic white, Outcome 2 End of Treatment.	159
Analysis 62.1. Comparison 62 Active NRT - rs2036527 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.	160
Analysis 62.2. Comparison 62 Active NRT - rs2036527 - non-Hispanic black or African American, Outcome 2 End of Treatment. .	160
Analysis 63.1. Comparison 63 Active NRT - DRD-4 (exon 3 48 bp) - non-Hispanic white, Outcome 1 Six-Month Abstinence.	161
Analysis 63.2. Comparison 63 Active NRT - DRD-4 (exon 3 48 bp) - non-Hispanic white, Outcome 2 End of Treatment.	162
Analysis 64.1. Comparison 64 Active NRT - SLC6A4 (Promoter) - non-Hispanic white, Outcome 1 Six-Month Abstinence.	163
Analysis 64.2. Comparison 64 Active NRT - SLC6A4 (Promoter) - non-Hispanic white, Outcome 2 End of Treatment.	163
Analysis 65.1. Comparison 65 Active NRT-NMR - non-Hispanic white or black or African American, Outcome 1 Six-Month Abstinence.	164
Analysis 65.2. Comparison 65 Active NRT-NMR - non-Hispanic white or black or African American, Outcome 2 End of Treatment.	164
Analysis 66.1. Comparison 66 Bupropion - rs1051730 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	165
Analysis 66.2. Comparison 66 Bupropion - rs1051730 - non-Hispanic white, Outcome 2 End of Treatment.	165
Analysis 67.1. Comparison 67 Bupropion - rs1051730 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.	166
Analysis 67.2. Comparison 67 Bupropion - rs1051730 - non-Hispanic black or African American, Outcome 2 End of Treatment. .	167
Analysis 68.1. Comparison 68 Bupropion - rs16969968 - non-Hispanic white, Outcome 1 End of Treatment.	167
Analysis 69.1. Comparison 69 Bupropion - rs16969968 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.	168
Analysis 69.2. Comparison 69 Bupropion - rs16969968 - non-Hispanic black or African American, Outcome 2 End of Treatment.	169
Analysis 70.1. Comparison 70 Bupropion - rs588765 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	169
Analysis 70.2. Comparison 70 Bupropion - rs588765 - non-Hispanic white, Outcome 2 End of Treatment.	170
Analysis 71.1. Comparison 71 Bupropion - rs2036527 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	171
Analysis 71.2. Comparison 71 Bupropion - rs2036527 - non-Hispanic white, Outcome 2 End of Treatment.	171
Analysis 72.1. Comparison 72 Bupropion - rs2036527 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.	172
Analysis 72.2. Comparison 72 Bupropion - rs2036527 - non-Hispanic black or African American, Outcome 2 End of Treatment. .	173

Analysis 73.1. Comparison 73 Bupropion - rs3733829 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	173
Analysis 73.2. Comparison 73 Bupropion - rs3733829 - non-Hispanic white, Outcome 2 End of Treatment.	174
Analysis 74.1. Comparison 74 Bupropion - rs3733829 - non-Hispanic black or African American, Outcome 1 End of Treatment. .	175
Analysis 75.1. Comparison 75 Bupropion - rs7937 - non-Hispanic white, Outcome 1 End of Treatment.	175
Analysis 76.1. Comparison 76 Bupropion - rs7937 - non-Hispanic black or African American, Outcome 1 End of Treatment.	176
Analysis 77.1. Comparison 77 Bupropion - rs1329650 - non-Hispanic white, Outcome 1 End of Treatment.	177
Analysis 78.1. Comparison 78 Bupropion - rs1329650 - non-Hispanic black or African American, Outcome 1 End of Treatment. .	178
Analysis 79.1. Comparison 79 Bupropion - rs1028936 - non-Hispanic white, Outcome 1 End of Treatment.	178
Analysis 80.1. Comparison 80 Bupropion - rs1028936 - non-Hispanic black or African American, Outcome 1 End of Treatment. .	179
Analysis 81.1. Comparison 81 Bupropion - rs215605 - non-Hispanic white, Outcome 1 End of Treatment.	180
Analysis 82.1. Comparison 82 Bupropion - rs215605 - non-Hispanic black or African American, Outcome 1 End of Treatment. ..	180
Analysis 83.1. Comparison 83 Varenicline - rs16969968 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	181
Analysis 83.2. Comparison 83 Varenicline - rs16969968 - non-Hispanic white, Outcome 2 End of Treatment.	181
Analysis 84.1. Comparison 84 Varenicline - rs588765 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	182
Analysis 84.2. Comparison 84 Varenicline - rs588765 - non-Hispanic white, Outcome 2 End of Treatment.	183
Analysis 85.1. Comparison 85 Bupropion + any NRT - rs1051730 - non-Hispanic white, Outcome 1 End of Treatment.	184
Analysis 86.1. Comparison 86 Bupropion + any NRT - rs1051730 - non-Hispanic black or African American, Outcome 1 End of Treatment.	184
Analysis 87.1. Comparison 87 Bupropion + any NRT - rs16969968 - non-Hispanic white, Outcome 1 End of Treatment.	185
Analysis 88.1. Comparison 88 Bupropion + any NRT - rs16969968 - non-Hispanic black or African American, Outcome 1 End of Treatment.	186
Analysis 89.1. Comparison 89 Bupropion + any NRT - rs2036527 - non-Hispanic white, Outcome 1 End of Treatment.	186
Analysis 90.1. Comparison 90 Bupropion + any NRT - rs2036527 - non-Hispanic black or African American, Outcome 1 End of Treatment.	187
Analysis 91.1. Comparison 91 Bupropion + any NRT - rs3733829 - non-Hispanic white, Outcome 1 End of Treatment.	188
Analysis 92.1. Comparison 92 Bupropion + any NRT - rs3733829 - non-Hispanic black or African American, Outcome 1 End of Treatment.	189
Analysis 93.1. Comparison 93 Bupropion + any NRT - rs7937 - non-Hispanic white, Outcome 1 End of Treatment.	189
Analysis 94.1. Comparison 94 Bupropion + any NRT - rs7937 - non-Hispanic black or African American, Outcome 1 End of Treatment.	190
Analysis 95.1. Comparison 95 Bupropion + any NRT - rs1329650 - non-Hispanic white, Outcome 1 End of Treatment.	191
Analysis 96.1. Comparison 96 Bupropion + any NRT - rs1329650 - non-Hispanic black or African American, Outcome 1 End of Treatment.	191
Analysis 97.1. Comparison 97 Bupropion + any NRT - rs1028936 - non-Hispanic white, Outcome 1 End of Treatment.	192
Analysis 98.1. Comparison 98 Bupropion + any NRT - rs1028936 - non-Hispanic black or African American, Outcome 1 End of Treatment.	193
Analysis 99.1. Comparison 99 Bupropion + any NRT - rs215605 - non-Hispanic white, Outcome 1 End of Treatment.	193
Analysis 100.1. Comparison 100 Bupropion + any NRT - rs215605 - non-Hispanic black or African American, Outcome 1 End of Treatment.	194
Analysis 101.1. Comparison 101 Placebo - rs1051730 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	195
Analysis 101.2. Comparison 101 Placebo - rs1051730 - non-Hispanic white, Outcome 2 End of Treatment.	196
Analysis 102.1. Comparison 102 Placebo - rs1051730 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.	197
Analysis 102.2. Comparison 102 Placebo - rs1051730 - non-Hispanic black or African American, Outcome 2 End of Treatment. ..	197
Analysis 103.1. Comparison 103 Placebo - rs16969968 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	198
Analysis 103.2. Comparison 103 Placebo - rs16969968 - non-Hispanic white, Outcome 2 End of Treatment.	198
Analysis 104.1. Comparison 104 Placebo - rs16969968 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.	199
Analysis 104.2. Comparison 104 Placebo - rs16969968 - non-Hispanic black or African American, Outcome 2 End of Treatment.	199
Analysis 105.1. Comparison 105 Placebo - rs588765 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	200
Analysis 105.2. Comparison 105 Placebo - rs588765 - non-Hispanic white, Outcome 2 End of Treatment.	201
Analysis 106.1. Comparison 106 Placebo - rs588765 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.	202
Analysis 106.2. Comparison 106 Placebo - rs588765 - non-Hispanic black or African American, Outcome 2 End of Treatment. ...	202

Analysis 107.1. Comparison 107 Placebo - rs2036527 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	203
Analysis 107.2. Comparison 107 Placebo - rs2036527 - non-Hispanic white, Outcome 2 End of Treatment.	203
Analysis 108.1. Comparison 108 Placebo - rs2036527 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.	204
Analysis 108.2. Comparison 108 Placebo - rs2036527 - non-Hispanic black or African American, Outcome 2 End of Treatment. ..	204
Analysis 109.1. Comparison 109 Placebo - DRD-4 (exon 3 48 bp) - non-Hispanic white, Outcome 1 Six-Month Abstinence.	205
Analysis 109.2. Comparison 109 Placebo - DRD-4 (exon 3 48 bp) - non-Hispanic white, Outcome 2 End of Treatment.	206
Analysis 110.1. Comparison 110 Placebo - rs3733829 - non-Hispanic white, Outcome 1 Six-Month Abstinence.	207
Analysis 110.2. Comparison 110 Placebo - rs3733829 - non-Hispanic white, Outcome 2 End of Treatment.	207
Analysis 111.1. Comparison 111 Placebo - rs7937 - non-Hispanic white, Outcome 1 End of Treatment.	208
Analysis 112.1. Comparison 112 Placebo - rs7937 - non-Hispanic black or African American, Outcome 1 End of Treatment.	209
Analysis 113.1. Comparison 113 Placebo - rs1329650 - non-Hispanic white, Outcome 1 End of Treatment.	209
Analysis 114.1. Comparison 114 Placebo - rs1329650 - non-Hispanic black or African American, Outcome 1 End of Treatment. ..	210
Analysis 115.1. Comparison 115 Placebo - rs1028936 - non-Hispanic white, Outcome 1 End of Treatment.	210
Analysis 116.1. Comparison 116 Placebo - rs1028936 - non-Hispanic black or African American, Outcome 1 End of Treatment. ..	211
Analysis 117.1. Comparison 117 Placebo - rs215605 - non-Hispanic white, Outcome 1 End of Treatment.	212
Analysis 118.1. Comparison 118 Placebo - rs215605 - non-Hispanic black or African American, Outcome 1 End of Treatment. ...	213
Analysis 119.1. Comparison 119 Placebo - SLC6A4 (Promoter) - non-Hispanic white, Outcome 1 Six-Month Abstinence.	213
Analysis 119.2. Comparison 119 Placebo - SLC6A4 (Promoter) - non-Hispanic white, Outcome 2 End of Treatment.	214
Analysis 120.1. Comparison 120 Placebo - NMR - non-Hispanic white or black or African American, Outcome 1 Six-Month Abstinence.	214
Analysis 120.2. Comparison 120 Placebo - NMR - non-Hispanic white or black or African American, Outcome 2 End of Treatment.	214
ADDITIONAL TABLES	215
WHAT'S NEW	229
CONTRIBUTIONS OF AUTHORS	229
DECLARATIONS OF INTEREST	229
SOURCES OF SUPPORT	229
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	229
INDEX TERMS	229

[Intervention Review]

Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers

Ewoud Schuit^{1,2,3}, Orestis A. Panagiotou⁴, Marcus R Munafò⁵, Derrick A Bennett⁶, Andrew W Bergen⁷, Sean P David⁸

¹Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA. ²Cochrane Netherlands, University Medical Center Utrecht, Utrecht, Netherlands. ³Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands. ⁴Department of Health Services, Policy & Practice, School of Public Health, Brown University, Providence, RI, USA. ⁵School of Experimental Psychology and MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK. ⁶Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. ⁷Biorealm, Culver City, CA, USA. ⁸Division of Primary Care and Population Health, Department of Medicine, Stanford University, Stanford, California, USA

Contact address: Ewoud Schuit, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands. e.schuit@umcutrecht.nl.

Editorial group: Cochrane Tobacco Addiction Group.

Publication status and date: Edited (no change to conclusions), published in Issue 2, 2018.

Citation: Schuit E, Panagiotou OA, Munafò MR, Bennett DA, Bergen AW, David SP. Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. *Cochrane Database of Systematic Reviews* 2017, Issue 9. Art. No.: CD011823. DOI: [10.1002/14651858.CD011823.pub2](https://doi.org/10.1002/14651858.CD011823.pub2).

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Smoking cessation therapies are not effective for all smokers, and researchers are interested in identifying those subgroups of individuals (e.g. based on genotype) who respond best to specific treatments.

Objectives

To assess whether quit rates vary by genetically informed biomarkers within pharmacotherapy treatment arms and as compared with placebo. To assess the effects of pharmacotherapies for smoking cessation in subgroups of smokers defined by genotype for identified genome-wide significant polymorphisms.

Search methods

We searched the Cochrane Tobacco Addiction Group specialised register, clinical trial registries, and genetics databases for trials of pharmacotherapies for smoking cessation from inception until 16 August 2016.

Selection criteria

We included randomised controlled trials (RCTs) that recruited adult smokers and reported pharmacogenomic analyses from trials of smoking cessation pharmacotherapies versus controls. Eligible trials included those with data on a priori genome-wide significant ($P < 5 \times 10^{-8}$) single-nucleotide polymorphisms (SNPs), replicated non-SNPs, and/or the nicotine metabolite ratio (NMR), hereafter collectively described as biomarkers.

Data collection and analysis

We used standard methodological procedures expected by Cochrane. The primary outcome was smoking abstinence at six months after treatment. The secondary outcome was abstinence at end of treatment (EOT). We conducted two types of meta-analyses- one in which we assessed smoking cessation of active treatment versus placebo within genotype groups, and another in which we compared smoking cessation across genotype groups within treatment arms. We carried out analyses separately in non-Hispanic whites (NHWs) and non-Hispanic blacks (NHBs). We assessed heterogeneity between genotype groups using T^2 , I^2 , and Cochrane Q statistics.

Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Main results

Analyses included 18 trials including 9017 participants, of whom 6924 were NHW and 2093 NHB participants. Data were available for the following biomarkers: nine SNPs (rs1051730 (*CHRNA3*); rs16969968, rs588765, and rs2036527 (*CHRNA5*); rs3733829 and rs7937 (in *EGLN2*, near *CYP2A6*); rs1329650 and rs1028936 (*LOC100188947*); and rs215605 (*PDE1C*)), two variable number tandem repeats (VNTRs; *DRD4* and *SLC6A4*), and the NMR. Included data produced a total of 40 active versus placebo comparisons, 16 active versus active comparisons, and 64 between-genotype comparisons within treatment arms.

For those meta-analyses showing statistically significant heterogeneity between genotype groups, we found the quality of evidence (GRADE) to be generally moderate. We downgraded quality most often because of imprecision or risk of bias due to potential selection bias in genotyping trial participants.

Comparisons of relative treatment effects by genotype

For six-month abstinence, we found statistically significant heterogeneity between genotypes (rs16969968) for nicotine replacement therapy (NRT) versus placebo at six months for NHB participants ($P = 0.03$; $n = 2$ trials), but not for other biomarkers or treatment comparisons. Six-month abstinence was increased in the active NRT group as compared to placebo among participants with a GG genotype (risk ratio (RR) 1.47, 95% confidence interval (CI) 1.07 to 2.03), but not in the combined group of participants with a GA or AA genotype (RR 0.43, 95% CI 0.15 to 1.26; ratio of risk ratios (RRR) GG vs GA or AA of 3.51, 95% CI 1.19 to 10.3).

Comparisons of treatment effects between genotype groups within pharmacotherapy randomisation arms

For those receiving active NRT, treatment was more effective in achieving six-month abstinence among individuals with a slow NMR than among those with a normal NMR among NHW and NHB combined participants (normal NMR vs slow NMR: RR 0.54, 95% CI 0.37 to 0.78; $n = 2$ trials). We found no such differences in treatment effects between genotypes at six months for any of the other biomarkers among individuals who received pharmacotherapy or placebo.

Authors' conclusions

We did not identify widespread differential treatment effects of pharmacotherapy based on genotype. Some genotype groups within certain ethnic groups may benefit more from NRT or may benefit less from the combination of bupropion with NRT. The reader should interpret these results with caution because none of the statistically significant meta-analyses included more than two trials per genotype comparison, many confidence intervals were wide, and the quality of this evidence (GRADE) was generally moderate. Although we found evidence of superior NRT efficacy for NMR slow versus normal metabolisers, because of the lack of heterogeneity between NMR groups, we cannot conclude that NRT is more effective for slow metabolisers. Access to additional data from multiple trials is needed, particularly for comparisons of different pharmacotherapies.

PLAIN LANGUAGE SUMMARY

Do people's genes affect how effective medicines can be in helping people to quit smoking?

Background

Quitting smoking dramatically reduces risk of premature death, but rates of smoking cessation remain low, even with the help of smoking cessation treatments. Recent research has suggested that differences in parts of our genes, called 'genotypes', may help us to tell which smokers could be helped most by different treatments. However, more research is needed to confirm whether or not our genes affect how effective different treatments are at helping people to quit.

Study characteristics

We searched for studies of smokers treated with medicine to help them quit. We looked at people's genes and at how well their bodies could process nicotine, as this might help us to identify people more likely to quit successfully. We found 33 studies relevant to our review, and we were able to get enough information for 18 clinical trials, including over 9000 smokers, that looked at different medicines used to help people to stop smoking.

Key results

The results suggest that smokers with specific genotypes may be more likely to be successful quitting smoking with the use of nicotine replacement therapies compared with smokers who do not have those specific genotypes. Smokers whose bodies process nicotine more slowly may also benefit more from nicotine replacement therapy. We did not see effects of genes on the effectiveness of medicines other than nicotine replacement therapy.

Quality of evidence

These results should be interpreted with caution because the included studies did not assign treatments to smokers on the basis of genotype or the rate at which they process nicotine, and because a small number of clinical trials were included in some comparisons.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. Active NRT compared with placebo - rs1051730 - non-Hispanic white for smoking cessation

Active NRT compared with placebo - rs1051730 - non-Hispanic white for smoking cessation^a

Patient or population: people who smoke
Setting: community and healthcare settings
Intervention: active NRT
Comparison: placebo

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with active NRT - rs1051730 - non-Hispanic white	Risk with placebo				
Abstinence at end of treatment	Study population		RR 1.63 (1.14 to 2.32)	1391 (2 RCTs)	⊕⊕⊕⊖ MODERATE ^{b,c}	Pooled result across studies, including all genotypes. Between-genotype group heterogeneity P value = 0.004 (see results for individual subgroups in below rows)
	327 per 1000 (228 to 465)	200 per 1000				
Abstinence at end of treatment - homozygous major	Study population		RR 1.09 (0.85 to 1.41)	582 (2 RCTs)	⊕⊕⊖⊖ LOW ^{c,d}	For participants with homozygous major genotype, low-quality evidence suggests no effect.
	286 per 1000 (223 to 370)	263 per 1000				
Abstinence at end of treatment - heterozygous	Study population		RR 2.13 (1.52 to 2.97)	631 (2 RCTs)	⊕⊕⊕⊖ MODERATE ^c	For participants with heterozygous genotype, moderate-quality evidence shows effect in favour intervention.
	335 per 1000 (239 to 467)	157 per 1000				
Abstinence at end of treatment - homozygous minor	Study population		RR 2.18 (1.04 to 4.58)	178 (2 RCTs)	⊕⊕⊖⊖ LOW ^{c,e}	For participants with homozygous minor genotype, low-quality evidence shows effect in favour intervention.
	338 per 1000 (161 to 710)	155 per 1000				

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; NRT: nicotine replacement therapy; RCT: randomised controlled trial; RR: risk ratio.

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

^aThis is the first of seven 'Summary of findings' tables for the main comparison. For a complete list, see the 'Additional summary of findings' section.

^bNot downgraded owing to inconsistency, as large statistical heterogeneity can be explained by differences between genotypes.

^cDowngraded one level owing to risk of bias: high potential for selection bias in GRPG 1993 due to low fraction of genotyped participants.

^dDowngraded one level owing to imprecision: optimal information size criterion is met, but 95% CIs include the null effect and fail to exclude important benefit or important harm.

^eDowngraded one level owing to imprecision: optimal information size criterion is not met in this stratum. Counts in this stratum are smaller than in a single adequately powered trial.

Summary of findings 2. Active NRT compared with placebo - rs16969968 - non-Hispanic white for smoking cessation

Active NRT compared with placebo - rs16969968 - non-Hispanic white for smoking cessation

Patient or population: people who smoke

Setting: community and healthcare settings

Intervention: active NRT

Comparison: placebo

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo - rs16969968 - non-Hispanic white	Risk with active NRT				
End of treatment	Study population		RR 1.38 (0.97 to 1.98)	1127 (2 RCTs)	⊕⊕⊕⊖ MODERATE ^{a,b}	Pooled result across studies, including all genotypes. Between-genotype group heterogeneity P value = 0.03 (see results for individual subgroups in below rows)
	251 per 1000	346 per 1000 (243 to 496)				
End of treatment - homozygous major	Study population		RR 1.01 (0.77 to 1.33)	449 (2 RCTs)	⊕⊕⊖⊖ LOW ^{a,c}	For participants with homozygous major genotype, low-quality evidence suggests no effect.
	333 per 1000	337 per 1000 (257 to 443)				
End of treatment - heterozygous	Study population		RR 1.85 (1.33 to 2.59)	550 (2 RCTs)	⊕⊕⊕⊕ HIGH	For participants with heterozygous genotype, high-quality evidence shows effect in favour of intervention.
	193 per 1000	358 per 1000				

	(257 to 501)					
End of treatment - homozygous minor	Study population		RR 1.80 (0.45 to 7.23)	128 (2 RCTs)	⊕⊕⊕⊕ LOW ^d	For participants with homozygous minor genotype, low-quality evidence shows that point estimate favours intervention, but 95% CI crosses null effect.
	233 per 1000	420 per 1000 (105 to 1000)				

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; NRT: nicotine replacement therapy; RCT, randomised controlled trial; RR: risk ratio.

GRADE Working Group grades of evidence.

High quality: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

^aDowngraded one level owing to imprecision: Optimal information size criterion is met, but 95% CIs include the null effect and fail to exclude important benefit or important harm.

^bNot downgraded owing to inconsistency, as large statistical heterogeneity can be explained by differences in genotypes.

^cDowngraded one level owing to inconsistency: unexplained heterogeneity.

^dDowngraded two levels owing to serious imprecision: optimal information size criterion not met, and 95% CIs include the null effect and fail to exclude important benefit or important harm.

Summary of findings 3. Active NRT compared with placebo - rs16969968 - non-Hispanic black or African American for smoking cessation

Active NRT compared with placebo - rs16969968 - non-Hispanic black or African American for smoking cessation

Patient or population: people who smoke

Setting: community and healthcare settings

Intervention: active NRT

Comparison: placebo

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with active NRT - rs16969968 - non-Hispanic black or African American	Risk with placebo				
Abstinence at 6 months	Study population		RR 1.11 (0.55 to 2.26)	709 (2 RCTs)	⊕⊕⊕⊕ MODERATE ^{a,b}	Pooled result across studies, including all genotypes. Between-genotype group heterogeneity P

	203 per 1000 (101 to 414)	183 per 1000				value = 0.03 (see results for individual subgroups in below rows)
Abstinence at 6 months - homozygous major	Study population		RR 1.47 (1.07 to 2.03)	637 (2 RCTs)	⊕⊕⊕⊕ HIGH	For participants with homozygous major genotype, high-quality evidence shows effect in favour of intervention.
	254 per 1000 (185 to 350)	173 per 1000				
Abstinence at 6 months - heterozygous or homozygous minor	Study population		RR 0.43 (0.15 to 1.26)	72 (2 RCTs)	⊕⊕⊕⊖ LOW ^c	For participants with heterozygous or homozygous minor genotype, point estimate favours control, but 95% CI crosses null effect.
	117 per 1000 (41 to 344)	273 per 1000				
Abstinence at end of treatment	Study population		RR 1.03 (0.36 to 2.94)	709 (2 RCTs)	⊕⊕⊕⊖ MODERATE ^{a,b}	Pooled result across studies, including all genotypes. Between-genotype group heterogeneity P value = 0.003 (see results for individual subgroups in below rows)
	201 per 1000 (70 to 575)	196 per 1000				
Abstinence at end of treatment - homozygous major	Study population		RR 1.57 (1.15 to 2.15)	637 (2 RCTs)	⊕⊕⊕⊕ HIGH	For participants with homozygous major genotype, high-quality evidence shows effect in favour of intervention.
	276 per 1000 (202 to 379)	176 per 1000				
Abstinence at end of treatment - heterozygous or homozygous minor	Study population		RR 0.29 (0.10 to 0.86)	72 (2 RCTs)	⊕⊕⊕⊖ MODERATE ^d	For participants with heterozygous or homozygous minor genotype, moderate-quality evidence shows effect in favour of control.
	105 per 1000 (36 to 313)	364 per 1000				

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; NRT: nicotine replacement therapy; RCT: randomised controlled trial; RR: risk ratio.

GRADE Working Group grades of evidence.

High quality: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

^aNot downgraded owing to inconsistency, as large statistical heterogeneity can be explained by differences in genotypes.

^bDowngraded one level owing to imprecision: Optimal information size criterion is met, but 95% CIs include the null effect and fail to exclude important benefit or important harm.

^cDowngraded two levels owing to serious imprecision: optimal information size criterion not met, but 95% CIs include the null effect and fail to exclude important benefit or important harm.

^dDowngraded one level owing to imprecision: low number of events; optimal information size criterion not met.

Summary of findings 4. Active NRT compared with placebo - rs 588765 - non-Hispanic white for smoking cessation

Active NRT compared with placebo - rs 588765 - non-Hispanic white for smoking cessation

Patient or population: people who smoke
Setting: community and healthcare settings
Intervention: active NRT
Comparison: placebo

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo - rs 588765 - non-Hispanic white	Risk with active NRT				
End of treatment	Study population		RR 1.33 (1.04 to 1.71)	923 (2 RCTs)	⊕⊕⊕⊖ MODERATE ^a	Pooled result across studies, including all genotypes. Between-genotype group heterogeneity P value = 0.92 (see results for individual subgroups in below rows)
	211 per 1000	281 per 1000 (220 to 361)				
End of treatment - homozygous major	Study population		RR 1.39 (0.89 to 2.16)	296 (2 RCTs)	⊕⊕⊖⊖ LOW ^b	For participants with homozygous major genotype, low-quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.
	208 per 1000	288 per 1000 (185 to 448)				
End of treatment - heterozygous	Study population		RR 1.27 (0.89 to 1.79)	469 (2 RCTs)	⊕⊕⊖⊖ LOW ^b	For participants with heterozygous genotype, point estimate favours intervention, but 95% CI crosses null effect.
	208 per 1000	265 per 1000 (185 to 373)				
End of treatment - homozygous minor	Study population		RR 1.50 (0.74 to 3.06)	158 (2 RCTs)	⊕⊕⊖⊖ LOW ^b	For participants with homozygous minor genotype, low-quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.
	226 per 1000	339 per 1000 (167 to 691)				

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; NRT: nicotine replacement therapy; RCT: randomised controlled trial; RR: risk ratio.

GRADE Working Group grades of evidence.

High quality: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

^aDowngraded one level owing to imprecision: low number of events; optimal information size criterion not met.

^bDowngraded two levels owing to serious imprecision: optimal information size criterion not met, but 95% CIs include the null effect and fail to exclude important benefit or important harm.

Summary of findings 5. Active NRT compared with placebo - rs2036527 - non-Hispanic black or African American for smoking cessation

Active NRT compared with placebo - rs2036527 - non-Hispanic black or African American for smoking cessation

Patient or population: people who smoke

Setting: community and healthcare settings

Intervention: active NRT

Comparison: placebo

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo - rs2036527 - non-Hispanic black or African American	Risk with active NRT				
6-Month abstinence	Study population		RR 1.18 (0.75 to 1.87)	708 (2 RCTs)	⊕⊕⊕⊕ LOW ^a	Pooled result across studies, including all genotypes. Between-genotype group heterogeneity P value = 0.19 (see results for individual subgroups in below rows)
	177 per 1000	208 per 1000 (132 to 330)				
6-Month abstinence - homozygous major	Study population		RR 1.95 (0.46 to 8.26)	425 (2 RCTs)	⊕⊕⊕⊕ VERY LOW ^{a,b}	For participants with homozygous major genotype, very low-quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.
	171 per 1000	333 per 1000 (79 to 1000)				

6-Month abstinence - heterozygous or homozygous minor	Study population		RR 0.90 (0.40 to 2.03)	283 (2 RCTs)	⊕⊕⊕⊖ MODERATE ^c	For participants with heterozygous or homozygous minor genotype, moderate-quality evidence shows no effect.
	185 per 1000	167 per 1000 (74 to 377)				
End of treatment	Study population		RR 1.22 (0.77 to 1.93)	708 (2 RCTs)	⊕⊕⊖⊖ LOW ^a	Pooled results across studies, including all genotypes. Between-genotype group heterogeneity P value = 0.19 (see results for individual subgroups in below rows)
	199 per 1000	242 per 1000 (153 to 384)				
End of treatment - homozygous major	Study population		RR 2.39 (0.43 to 13.35)	425 (2 RCTs)	⊕⊕⊖⊖ LOW ^{b,c}	For participants with homozygous major genotype, low-quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.
	197 per 1000	471 per 1000 (85 to 1000)				
End of treatment - heterozygous or homozygous minor	Study population		RR 0.89 (0.55 to 1.46)	283 (2 RCTs)	⊕⊕⊕⊖ MODERATE ^c	For participants with heterozygous or homozygous minor genotype, moderate-quality evidence shows no effect.
	202 per 1000	179 per 1000 (111 to 294)				

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; NRT: nicotine replacement therapy; RCT: randomised controlled trial; RR: risk ratio.

GRADE Working Group grades of evidence.

High quality: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

^cDowngraded one level owing to imprecision: low number of events; optimal information size criterion not met.

Summary of findings 6. Active NRT compared with placebo - DRD4 (exon 3 48 bp) - non-Hispanic white for smoking cessation

Active NRT compared with placebo - DRD4 (exon 3 48 bp) - non-Hispanic white for smoking cessation

Patient or population: people who smoke

Setting: community and healthcare settings

Intervention: active NRT

Comparison: placebo

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo - DRD4 (exon 3 48 bp) - non-Hispanic white	Risk with active NRT				
6-Month abstinence	Study population		RR 1.44 (1.08 to 1.92)	900 (2 RCTs)	⊕⊕⊕⊕ LOW ^{a,b}	Pooled result across studies, including all genotypes. Between-genotype group heterogeneity P value = 0.85 (see results for individual subgroups in below rows)
	141 per 1000	203 per 1000 (152 to 271)				
6-month abstinence - homozygous major	Study population		RR 1.34 (0.93 to 1.93)	566 (2 RCTs)	⊕⊕⊕⊕ VERY LOW ^{a,b,c}	For participants with homozygous major genotype, very low-quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.
	155 per 1000	207 per 1000 (144 to 299)				
6-Month abstinence - heterozygous	Study population		RR 1.76 (1.00 to 3.10)	290 (2 RCTs)	⊕⊕⊕⊕ LOW ^{a,b}	For participants with heterozygous genotype, low-quality evidence suggests effect in favour of intervention.
	113 per 1000	198 per 1000 (113 to 349)				
6-Month abstinence - homozygous minor	Study population		RR 1.28 (0.40 to 4.11)	44 (2 RCTs)	⊕⊕⊕⊕ VERY LOW ^{a,b,c}	For participants with homozygous minor genotype, very low-quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.
	167 per 1000	213 per 1000 (67 to 685)				
End of treatment	Study population		RR 1.20 (0.88 to 1.63)	900 (2 RCTs)	⊕⊕⊕⊕ LOW ^{a,b}	Pooled result across studies, including all genotypes. Between-genotype group heterogeneity P value = 0.78 (see results for individual subgroups in below rows)
	271 per 1000	325 per 1000 (238 to 441)				
End of treatment - homozygous major	Study population		RR 1.22 (0.59 to 2.51)	566 (2 RCTs)	⊕⊕⊕⊕ VERY LOW ^{a,b,c}	For participants with homozygous major genotype, very low-quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.
	273 per 1000	334 per 1000 (161 to 686)				
End of treatment - heterozygous	Study population		RR 1.40 (0.57 to 3.39)	290 (2 RCTs)	⊕⊕⊕⊕ VERY LOW ^{a,b,c}	For participants with heterozygous genotype, very low-quality evidence suggests that point estimate favours intervention, but 95% CI crosses null effect.
	258 per 1000	362 per 1000				

	(147 to 876)					
End of treatment - homozygous minor	Study population		RR 1.02 (0.65 to 1.58)	44 (2 RCTs)	⊕⊕⊕⊕ LOW ^{a,b}	For participants with homozygous minor genotype, low-quality evidence suggests no effect.
	333 per 1000	340 per 1000 (217 to 527)				

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; NRT: nicotine replacement therapy; RCT: randomised controlled trial; RR: risk ratio.

GRADE Working Group grades of evidence.

High quality: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

^aDowngraded one level owing to high risk of bias: high risk of selection bias in GRPG 1993 due to low fraction of genotyped participants.

^bDowngraded one level owing to imprecision: low number of events; optimal information size criterion not met.

^cDowngraded one level owing to imprecision: 95% CIs include the null effect and fail to exclude important benefit or important harm.

Summary of findings 7. Active NRT compared with placebo - NMR - non-Hispanic black and white for smoking cessation

Active NRT compared with placebo - NMR - non-Hispanic black and white for smoking cessation

Patient or population: people who smoke

Setting: community and healthcare settings

Intervention: active NRT

Comparison: placebo

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo - NMR - non-Hispanic black and white	Risk with active NRT				
6-Month abstinence	Study population		RR 1.51 (1.08 to 2.10)	1417 (2 RCTs)	⊕⊕⊕⊕ MODERATE ^a	Pooled result across studies, including all genotypes. Between-genotype group heterogeneity: P value =

	99 per 1000	149 per 1000 (107 to 207)				0.29 (see results for individual subgroups in below rows)
6-Month abstinence - slow NMR	Study population		RR 1.82 (1.12 to 2.94)	628 (2 RCTs)	⊕⊕⊕⊖ MODERATE ^a	For participants with slow NMR genotype, moderate-quality evidence favours intervention.
	116 per 1000	211 per 1000 (130 to 341)				
6-Month abstinence - normal NMR	Study population		RR 1.21 (0.78 to 1.87)	789 (2 RCTs)	⊕⊕⊕⊖ LOW ^b	For participants with normal NMR genotype, point estimate favours intervention, but 95% CI crosses null effect.
	85 per 1000	103 per 1000 (66 to 159)				
End of treatment	Study population		RR 1.51 (1.19 to 1.90)	1417 (2 RCTs)	⊕⊕⊕⊖ MODERATE ^a	Pooled result across studies, including all genotypes. Between-genotype group heterogeneity: P value = 0.52 (see results for individual subgroups in below rows)
	136 per 1000	205 per 1000 (162 to 258)				
End of treatment - slow NMR	Study population		RR 1.61 (1.18 to 2.20)	847 (2 RCTs)	⊕⊕⊕⊖ MODERATE ^a	For participants with slow NMR genotype, moderate-quality evidence favours intervention.
	127 per 1000	204 per 1000 (149 to 278)				
End of treatment - normal NMR	Study population		RR 1.49 (0.85 to 2.60)	570 (2 RCTs)	⊕⊕⊕⊖ LOW ^{a,b}	For participants with normal NMR genotype, point estimate favours intervention, but 95% CI crosses null effect.
	149 per 1000	222 per 1000 (127 to 388)				

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; NMR: nicotine metabolite ratio; NRT: nicotine replacement therapy; RCT: randomised controlled trial; RR: risk ratio.

GRADE Working Group grades of evidence.

High quality: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

^aDowngraded one level owing to risk of bias: 755/1532 (49%) participants from Patch Trial (GPRG 1993) were genotyped, which could contribute to selection bias.

^bDowngraded one level owing to imprecision: optimal information size criterion is met, but 95% CIs include the null effect and fail to exclude important benefit or important harm.

BACKGROUND

Table 1 presents a glossary of genetic terms.

Description of the condition

Tobacco smoking continues to be the leading cause of preventable death in the world, and yet the most efficacious behavioural and pharmacological treatments are ineffective for most treatment-seeking smokers (Cahill 2012; Giovino 2012; Hughes 2014; Stead 2012a; Stead 2012b). Although social and other environmental determinants are major contributors to tobacco use, twin and family studies over decades have confirmed that genetic factors contribute substantially to smoking behavior and to disease that can be attributed to smoking (Bidwell 2016; Broms 2006; Carmelli 1992; Fisher 1958; Heath 2002; Li 2003; McCaffery 2008; True 1997; Xian 2008).

Given the low cessation success rate of the most efficacious smoking cessation treatments and the observation of substantial heritability for tobacco dependence, investigators have explored the association between polymorphisms among genes involved in tobacco dependence and genes for smoking cessation drug targets (many of which overlap), to better identify individuals who are more or less likely to successfully quit and abstain from smoking in response to specific medications (Mamoun 2015). It has been postulated that hundreds of genes contribute and may interact with each other and with the environment (e.g. via epigenetic processes) to affect the many dimensions of tobacco dependence through altered neuro-adaptations, metabolism, and conditioned behaviour (Agrawal 2012; Sullivan 2004). Genomic analyses have the potential to improve the efficacy of smoking cessation treatment if meta-analyses can identify polymorphisms associated with response to a given pharmacotherapy, and if this is followed by validation of the finding in independent clinical trials and treatment cohorts.

In this review, we used the term 'genomic' to describe both single-gene (traditionally described as 'genetic') and whole-genome ('genomic') analyses. We did this because translational research will continue to test more genetic loci of interest; genome-wide analyses of clinical trials will be performed eventually; and future reviews of more and more complex genetic data are better described as genomic or pharmacogenomic analyses. Our review assesses heterogeneity in treatment effects across genotype groups or nicotine metabolite ratio (NMR) status, and heterogeneity in treatment effects by genotype group or NMR status within treatment arms. These analyses are motivated by specific hypotheses that are pharmacogenomic (i.e. based on which genetic loci in the genome have the greatest effect on nicotine dependence) or pharmacometabolomic (i.e. based on the metabolite ratio of two stable nicotine metabolites that represent the nicotine metabolism rate of the enzyme with the greatest contribution to nicotine metabolism among all protein-coding genes) in nature.

Description of the intervention

The US Food and Drug Administration (FDA) has approved pharmacotherapies as aids to smoking cessation including five forms of nicotine replacement therapy (NRT), bupropion SR (Zyban), and varenicline (Chantix). NRT forms include gum, lozenge, transdermal patch, nasal spray, and oral inhaler (numerous brands, over-the-counter) (Pharmacologic

Product Guide). Different NRT therapies offer distinct benefits and limitations with regard to mode of administration and ease of titration; bupropion and varenicline offer alternative mechanisms of action to those offered by NRT, and varenicline offers greater efficacy than NRT monotherapy (Cahill 2013). Pharmacotherapies not approved by the FDA for use in smoking cessation as monotherapy or combination therapy include adrenergics, monoamine oxidase (MAO) inhibitors, selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs), as well as other drugs and preparations.

Meta-analyses of the primary literature have identified significant effects of monotherapy and combination therapy versus control therapy on abstinence at six-month follow-up (Cochrane Tobacco Addiction Group). In a sample of 117 clinical trials of NRT versus placebo or non-NRT control, data show a risk ratio (RR) of 1.60-fold (95% confidence interval (CI) 1.53 to 1.68) (Stead 2012a); in a sample of trials of the antidepressant bupropion (44 trials) or nortriptyline (six trials) versus placebo, or of bupropion versus nortriptyline (three trials), results include significant RRs of 1.62 (95% CI 1.49 to 1.76) and 2.03 (95% CI 1.48 to 2.78) (Hughes 2014); and in a sample of trials comparing the cholinergic partial agonists varenicline (at standard dosage; 27 trials) and cytisine (two trials) versus placebo, investigators reported significant RRs of 2.24 (95% CI 2.06 to 2.43) and 3.98 (95% CI 2.01 to 7.87) (Cahill 2016). Multiple additional meta-analytical comparisons provide evidence suggesting that varenicline is more effective than bupropion or NRT monotherapy (Mills 2012).

How the intervention might work

Research on the molecular genetics of smoking has pointed to at least two biologically plausible genetic loci contributing to nicotine dependence, cigarette consumption, and smoking cessation. The $\alpha 5$ - $\alpha 3$ - $\beta 4$ nicotinic acetylcholine receptor gene cluster on chromosome 15q25.1 (*CHRNA5-CHRNA3-CHRNA4*) has been associated with cigarettes smoked per day in genome-wide association studies; with lung cancer and chronic obstructive pulmonary disease; and with smoking cessation in retrospective pharmacogenetic analyses of clinical trials (Bergen 2013; Chen 2012; Chen 2014; David 2012; King 2012; Liu 2010; Munafò 2011; Saccone 2010; Thorgeirsson 2008; Thorgeirsson 2010; Tobacco and Genetics Consortium 2010; Zhu 2014). The cytochrome p450 2A6 enzyme inactivates approximately 80% of nicotine to cotinine and other metabolites through oxidative hepatic metabolism; extensive functional variation influencing the speed of nicotine metabolism is found at *CYP2A6* (Benowitz 2006; Benowitz 2009; McDonagh 2012; Murphy 2014). The NMR 3-hydroxycotinine/cotinine has been associated with cigarettes smoked per day, lung and other aerodigestive cancers, and smoking cessation (Bloom 2012; Canova 2009; Chen 2014; Dempsey 2004; Fujieda 2004; Gemignani 2007; Ho 2009; Lerman 2006; Lerman 2010; Liu 2011; Patterson 2008; Rotunno 2009; Schnoll 2009; Schnoll 2010; Schoedel 2004; Tamaki 2011; Thorgeirsson 2010; Tobacco and Genetics Consortium 2010; Topcu 2002). Variation in the *CHRNA3-A5-B4* genetic locus is associated with functional changes in key nicotinic acetylcholine receptors in the brain, which in turn are related to behaviour (i.e. nicotine self-administration and smoking quantity) (Fowler 2011; Scherf 2012; Ware 2012). Variation in the *CYP2A6* genetic locus affects the rate of nicotine metabolism and is associated with smoking quantity (McDonagh 2012). Therefore, biologic

plausibility underlies the relationship between these genetic loci and smoking-related behaviour. Consistent with preclinical studies of nicotine reinforcement and conditioned place preference, genes in the dopamine pathway have been linked to smoking cessation (Balfour 2009; Herman 2014; Leventhal 2014; Tobacco and Genetics Consortium 2010). Many other candidate genes and pathways have been explored for association with smoking cessation in relation to the pharmacology of nicotine and tobacco dependence treatment. Bupropion and to a lesser degree nicotine are metabolised by cytochrome 2B6, which converts bupropion to the more pharmacologically active hydroxybupropion, which in turn has been associated with smoking cessation (Benowitz 2013; Zhu 2012). A low-affinity organic cation transporter gene (*SLC22A2*) has been associated with varenicline adverse effects and with abstinence outcomes in individuals randomised to NRT or varenicline (Bergen 2014; King 2012). Both the endogenous opioid system and serotonin neuronal pathways are implicated in some dimensions of nicotine dependence, and polymorphisms in mu-opioid receptor 1 (*OPRM1*) and serotonin 5-HT₃ receptor (*HTR3B*) genes, respectively, have been linked to response to smoking cessation drugs; however, results have been inconclusive and mixed or without consistent replication for a variety of polymorphisms across both neurotransmitter systems (Balfour 2009; David 2008; Hadjiconstantinou 2011; King 2012; Marteau 2012; Munafò 2007; Munafò 2013a; Quaak 2012; Ray 2007; Verhagen 2012; Wang 2010).

Current clinical practice guidelines recommend clinician assessment of every patient's smoking behaviour, which is followed by advice to quit, assessment of willingness to quit, assistance in quitting, and arranging follow-up support (5 As) (European Smoking Cessation Guidelines 2012; Fiore 2008; West 2000). Clinical practice guidelines describe in detail aspects of patients, clinicians, clinician engagement, behavioural therapy, and pharmacotherapy that contribute towards abstinence (European Smoking Cessation Guidelines 2012; Fiore 2008; West 2000). Both behavioural therapies and pharmacotherapies are effective aids for patient smoking cessation - therapies combining behavioural therapy and pharmacotherapy are recommended for greatest therapeutic efficacy (Patnode 2015). An intervention that addresses pharmacotherapeutic efficacy by genotype or by metabolic activity offers the prospect of improving therapeutic effectiveness beyond the minority of individuals who remain abstinent at 24 weeks with combination therapies delivered by a clinician (European Smoking Cessation Guidelines 2012; Fiore 2008; Kotz 2014; West 2000). A genotype-based, or metabolism-based, pharmacogenomic assay and associated intervention for smoking cessation might be developed if robust evidence for improved efficacy were to be developed through the established pathway of discovery and translation to clinical practice via retrospective and prospective tests of clinical data, analytical validity, clinical validity, and clinical utility. This review uses data from retrospective analyses of abstinence differences by genotype or metabolism subgroup in nearly all cases (one trial contributed data from a prospective stratification by metabolism); thus analyses of these data do not provide clinical guidance for pharmacogenomic testing and treatment selection. However, they do describe the scope of available data in terms of sample sizes, clinical treatments, and selected available genomic data. An intervention would be expected to be available as a pharmacogenomic test that the physician can order; results of the pharmacogenomic assay with clinical treatment recommendations

based on prior clinical validity and utility analyses would be available to assist the physician in treating individuals for tobacco dependence.

Why it is important to do this review

Smoking cessation clinical trials have provided a growing body of genotype-based subgroup analyses, but replication is rare, and there have been no comprehensive systematic reviews with meta-analyses. This review evaluated the effectiveness of pharmacotherapy for smoking cessation in subgroups of treatment-seeking smokers defined by genotype for genome-wide significant single-nucleotide polymorphisms (SNPs), replicated non-SNP polymorphisms, and/or the NMR. Pharmacotherapies discussed in this review include medications approved to treat symptoms of withdrawal, craving, or other behavioural symptoms that affect the ability of the individual to stop smoking and to remain abstinent; these include all forms of NRT (e.g. patch, gum, lozenge, inhaler, spray) and non-nicotine pharmacotherapies (e.g. bupropion, varenicline, cytisine, nortriptyline). Identifying whether clinically important differences in treatment response between genomically defined groups are likely is an essential first step in moving the field closer to personalised treatments guided by genomic testing.

OBJECTIVES

To assess whether quit rates vary by genetically informed biomarkers within pharmacotherapy treatment arms and as compared with placebo. To assess the effects of pharmacotherapies for smoking cessation in subgroups of smokers defined by genotype for identified genome-wide significant polymorphisms.

METHODS

Criteria for considering studies for this review

Types of studies

All published and unpublished primary and secondary analyses of randomised and quasi-randomised controlled trials (RCTs) in which smoking cessation pharmacotherapies were initiated to enhance abstinence from smoking, and in which trial participants were genotyped for polymorphisms that are genome-wide significant (alpha threshold $< 5 \times 10^{-8}$) SNPs for cigarettes per day, nicotine dependence, or smoking cessation, as well as non-SNP polymorphisms that were not included in genome-wide association studies but have been associated with smoking cessation treatment response in at least two trials; or the NMR, which is highly influenced by the cytochrome p450 2A6 (*CYP2A6*) gene, hereafter collectively described as biomarkers (Chenoweth 2017; David 2012; Saccone 2010; Thorgeirsson 2008; Thorgeirsson 2010; Tobacco and Genetics Consortium 2010). Table 2 presents the polymorphisms of interest and NMR, which two review authors (AWB and SPD) identified via literature review. The comparator could be placebo, or usual/standard care, or a different pharmacotherapy, or a non-pharmacotherapy intervention, or a no-intervention control. We also considered trials comparing different doses or durations or regimens of pharmacotherapy, or comparing different formats of NRT, or comparing combinations of pharmacotherapy versus a single type, or comparing different types or intensities of behavioural support as adjuncts to pharmacotherapy. We applied no language or date restrictions. For inclusion of a study in the review, at least one other trial had to

provide genetic or NMR data for the same type of smoking cessation medication (e.g. if we found only one genotyped venlafaxine or one genotyped nortriptyline trial, we did not perform meta-analysis).

Types of participants

Adult men and women who smoke, regardless of the setting from which they were recruited and/or their initial level of nicotine dependence. Participants could be of any ethnicity, but we analysed outcomes within different ethnic subgroups separately. We did not anticipate a sufficient number of genomic pharmacotherapy studies of minors (aged under 18 years) for inclusion in meta-analyses.

Types of interventions

Smoking cessation pharmacotherapy, which included all forms of NRT (e.g. patch, gum, lozenge, inhaler, spray) and non-nicotine pharmacotherapies (e.g. bupropion, varenicline, cytisine, nortriptyline).

Types of outcome measures

Primary outcomes

- Smoking abstinence at six months from the start of treatment.

Secondary outcomes

- Smoking abstinence at end of treatment defined as abstinence between 7 and 12 weeks after the start of treatment.

We did not collect information about adverse events reported in included trials, because we expected the occurrence of such events to be low, making power for analysis according to genotype insufficient.

Search methods for identification of studies

Electronic searches

On 16 August 2016, we searched the Cochrane Tobacco Addiction Group specialised register for trials of pharmacotherapies for smoking cessation, using the term 'genetic', 'genomic', 'pharmacogenetic', or 'pharmacogenomic' in the title, abstract, or keywords to identify relevant records. This register contains trials identified from:

- MEDLINE.
- Embase.
- PsycINFO.
- Reference lists of previous trials and overviews.

See details of search strategies applied for these databases in the [Tobacco Addiction Group module](#).

Additionally, we searched international online clinical trial registers for ongoing and recently completed trials, including the [WHO portal](#); the [UK clinical trials gateway](#); the [US clinical trials register](#); and the [Australian and New Zealand clinical trials register](#).

In addition to the databases mentioned above, we searched genetics databases, including Pharmacogenomics Knowledgebase (PharmGKB) and Pharmacogenomics of Nicotine Addiction Treatment (PNAT). We considered additional searches of National Institutes of Health (NIH) databases, but at the time of this review, smoking cessation clinical trial data were not yet available on

Genotypes and Phenotypes (dbGaP), a database developed to archive and distribute data and results from studies that have investigated the interaction of genotype and phenotype in humans.

Searching other resources

We checked the reference lists of published papers and consulted with experts in the field to identify any relevant forthcoming or unpublished research, or both. We contacted the authors of ongoing studies when necessary.

Data collection and analysis

Selection of studies

Two review authors (AWB and SPD) and Ms. Lindsey Stead (Cochrane Tobacco Addiction Group, Oxford) conducted database searches and performed initial screening of abstracts and manuscripts. Two review authors (ES and SPD) independently checked the abstracts and, if relevant, retrieved and reviewed the full texts of records for data. We observed that most of the studies eligible for inclusion were secondary analyses of pharmacotherapy trials. For each eligible study, we identified the primary trial report for long-term cessation outcomes.

If a given genome-wide significant SNP or non-SNP polymorphism was not reported in an RCT that reported other genotyping data, we contacted study authors to request these data from unpublished genotyping data.

Data extraction and management

Four review authors (ES, OAP, AWB, and SPD) curated records for extraction of study characteristics of primary trials. We assessed each trial in duplicate. Review authors resolved disagreements by consensus, or by recourse to a third review author, who was not assigned to that particular trial. We recorded the following information in the [Characteristics of included studies](#) tables.

- Methods: study design, study name (if applicable), study recruitment period.
- Participants: number of participants in original trial, study recruitment procedure, country, number of study centres, study setting, inclusion and exclusion criteria.
- Interventions: description of intervention(s) (treatment, dosage, regimen, behavioural support), description of control (treatment, dosage, regimen, behavioural support), number of participants in each treatment arm.
- Outcomes: primary outcome and secondary outcomes of trials.
- Funding source.
- Declaration of interest.
- Notes: information on genomic analyses: whether they were performed within the RCT or as secondary analysis, and the number of participants successfully genotyped.

Outcome data

We contacted trial authors and asked them to supply genotype counts by outcome, by pharmacotherapy arm, and by self-identified race/ethnicity for participants in their study for (a) a group (N = 13) of single-nucleotide polymorphisms (SNPs) with reported genome-wide significance with smoking cessation, cigarettes per day, or nicotine dependence in genome-wide association study (GWAS) investigations; (b) three variable

numbers of tandem repeat polymorphisms (VNTRs); or (c) NMR data (David 2012; Thorgeirsson 2010; Tobacco and Genetics Consortium 2010). Table 2 provides an overview of all genetic polymorphisms and major and minor alleles stratified by race group. We asked trial authors to complete at least two predesigned data extraction forms - one on the numbers of participants of different race/ethnicity groups included in the trial, and another on abstinence rates for each polymorphism, stratified by outcome, treatment arm, race/ethnicity, and genotype. Some identified papers presented data from multiple studies (e.g. from a meta-analysis) (Bergen 2013). From the author of these combined analyses, we requested study level data so we could assess and account for differences across studies in the statistical analysis. We collected genotype information for a given polymorphism in a trichotomised fashion (homozygous major (M/M); heterozygous (M/m); homozygous minor (m/m) alleles), and we gathered NMR information in a dichotomised fashion (normal ($\text{NMR} \geq 0.31$) vs slow ($\text{NMR} < 0.31$) metabolisers). For calculation of abstinence rates, we collected the number of participants who were abstinent at the time point of interest (i.e. at 6 months or at end of treatment) and the total number randomised in that subgroup.

We contacted trial authors twice. When they did not respond to our request, we tried to extract requested data from published reports. If trial authors supplied or if the paper reported genotype data in a dichotomised fashion (i.e. M/M vs M/m + m/m), we used this information to perform analysis in a similar fashion.

Assessment of risk of bias in included studies

Four review authors (ES, OAP, AWB, and SPD) independently assessed included studies for risks of selection bias (randomised sequence generation, allocation concealment), performance and detection bias (presence or absence of blinding), attrition bias (levels and reporting of loss to follow-up), and any other threats to study quality, as recommended in Chapter 8 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). We assessed each trial in duplicate. We also assessed trials for other sources of bias specific to genotype studies: genotype frequencies for each study and polymorphism; potential deviation from Hardy-Weinberg equilibrium; source of DNA (e.g. buccal swab, blood, saliva); genotyping protocol; and any quality control (QC) methods described. Review authors resolved disagreements by consensus, or by recourse to a third review author, who was not assigned to that particular trial.

Measures of treatment effect

We calculated the cessation rate as the number of people abstinent at six months and at end of treatment, based on point prevalence abstinence (preferably biochemically verified but otherwise self-reported), divided by the total number of participants in that subgroup, separately in each genotype/treatment subgroup. We assessed treatment effects by meta-analysing active versus placebo effects on abstinence separately in M/M, M/m, and m/m genotype strata; we then generated separate RRs and 95% CIs for active versus placebo for each genotype stratum for each biomarker. Afterwards, we assessed heterogeneity in treatment effect across genotype strata.

For analyses in which we found statistically significant heterogeneity in treatment effects across genotype subgroups, we estimated the difference in treatment effects in M/M versus m/m and in M/m versus m/m to capture the interaction effects of

genotype x treatment. Because estimates of treatment effects were expressed in the log-scale (i.e. logRR), we expressed the genotype x treatment interaction as the ratio of risk ratios (RRR) for treatment effect in one genotype group over treatment effect in the other genotype group. An $\text{RRR} > 1$ means that the treatment effect is greater in individuals with the M/M versus non-M/M genotype.

Initially, we planned to address the potential effect of methodological heterogeneity in behavioural interventions across studies for those analyses in which we found statistically significant heterogeneity in treatment effects across genotype subgroups. However, because the number of included studies in these analyses was small, we deemed that such analysis was not reliable.

Dealing with missing data

We contacted investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data when possible (e.g. when a study was reported as abstract only). In cases for which we received individual participant data, we treated participants lost to follow-up as continuing smokers, which yields conservative absolute quit rates and makes little difference to the risk ratio unless dropout rates differ substantially between groups. For aggregate data, we relied on the decision of investigators of the primary trial, which conventionally reports smokers who are lost to follow-up as smoking, in keeping with intention-to-treat analyses.

We noted in the 'Risk of bias' tables whether results showed high or differential loss to follow-up between treatment groups.

Assessment of heterogeneity

We evaluated levels of clinical heterogeneity between included studies to decide whether it would be appropriate to pool data in planned subgroups. We analysed different pharmacotherapies separately but pooled studies using different types of NRT.

We assessed statistical heterogeneity in each meta-analysis using T^2 , I^2 , and Chi^2 statistics (Higgins 2003). We regarded statistical heterogeneity as substantial if I^2 was greater than 50% and either T^2 was greater than zero, or the P value was low (< 0.10) in the Chi^2 test for heterogeneity.

Assessment of reporting biases

We decided that if 10 or more studies contributed data to the meta-analysis for either outcome, we would investigate reporting biases (such as publication bias) using funnel plots, so as to assess possible asymmetry visually. If asymmetry was suggested by visual assessment, we planned to perform exploratory analyses to investigate this using more formal tests, such as Egger's and Begg's tests (Begg 1994; Egger 1997). This version of the review included too few studies in each of the meta-analyses performed to allow assessment of reporting bias.

Data synthesis

For each polymorphism, we undertook two types of analysis.

- Comparisons of relative treatment effect by genotype. We grouped studies based on the characteristics of intervention and control arms.
 - * Each individual pharmacotherapy or combination compared with placebo/no pharmacotherapy control.
 - * Comparisons between different pharmacotherapies.
 - * Combinations of pharmacotherapy compared with a single pharmacotherapy.

We tested for heterogeneity in relative effects between genotype subgroups.

- Comparisons of treatment effects between genotype groups, within pharmacotherapy randomisation arms. Some clinical trials included only one pharmacotherapy arm but more than one behavioural support arm, but we did not stratify analyses by behavioural support arm. Analyses of genotype effects within drug groups separately compared abstinence outcomes between 1 to 0 risk alleles and 2 to 0 risk alleles. If possible, we compared risk allele heterozygotes and homozygotes versus reference alleles in separate analyses (e.g. rs1051730 CT vs CC, or TT vs CC rather than CT/TT vs CC).

Differences in genetic architecture (allele frequencies and/or linkage disequilibrium) between ancestral groups may result in population structure, which may lead to confounding if smoking behaviour-related outcomes are associated with both ancestry and genetic architecture. Conditions for population stratification are met for comparisons between African Americans and European Americans owing to differences in smoking behaviours (e.g. African Americans smoke fewer cigarettes per day than European Americans and in genetic architecture at relevant loci; we conducted separate analyses for white and black or African American study populations at genotype-based biomarkers (Beirut 2008; Cardon 2003; Trinidad 2015; Wang 2013). We also considered other ancestries (e.g. Asian), but data were not sufficient to allow separate meta-analyses in these populations. We did analyse the NMR across ancestry groups rather than separately by ancestry group because the NMR is a metabolic marker (not a genotype). The NMR is genetically informed by prior knowledge about the CYP2A6 genotype, but other genes and environmental factors affect NMR; because it is not a genotype, the same concerns about population stratification do not apply to the NMR.

We pooled risk ratios (RRs) using a Mantel-Haenszel random-effects model with a 95% confidence interval (CI) for our meta-analysis, so as to account for statistical heterogeneity across included studies. When the event is defined as smoking cessation, an RR greater than one indicates that more people in the treatment group than in the control group successfully quit. We carried out statistical analysis using RevMan (Review Manager 5.3).

Subgroup analysis and investigation of heterogeneity

In the event of evidence of heterogeneity within planned subgroups based on genotype and type of pharmacotherapy, we planned to explore the impact of the following possible factors.

- Different comparators.
- Levels of behavioural support.
- Dose or duration of treatment.
- Gender differences.

- Motivation to quit.
- Level of nicotine dependence.

However, because heterogeneity within genotype groups was generally low and available data within genotype groups were generally sparse, we refrained from performing any such subgroup analyses.

Sensitivity analysis

We planned to conduct sensitivity analyses to determine whether inclusion of quasi-RCTs and risk of bias made a difference in our findings. However, we did not identify any quasi-RCTs, and we did not find enough studies at this time to undertake sensitivity analyses.

'Summary of findings' table

In keeping with standard Cochrane methods, we created a 'Summary of findings' table for comparisons between active NRT and placebo (because it is the most commonly administered intervention of those included in the review) for the genotypes most frequently studied. As part of this process, we used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of the body of evidence for each outcome. This assessment of the quality of evidence within the review informs the confidence with which we view our conclusions.

RESULTS

Description of studies

Results of the search

Through our search strategy, we identified a total of 479 unique papers, of which 94 were eligible for inclusion in our review (Figure 1). These corresponded to 35 primary randomised clinical trials of pharmacotherapies that compared two or more smoking cessation intervention arms that met the inclusion criteria stated (Ahluwalia 2006; Aveyard 2007; Bloch 2010; Brown 2007; Cinciripini 2005; Cox 2012; Gilbert 2009; Gonzales 2006; GPRG 1993; Hall 2008; Hall 2009; Jorenby 2006; Kalman 2011; Killen 2006; Killen 2008; Killen 2010; King 2012; Lerman 2002; Lerman 2004; Lerman 2015; Marteau 2012; McCarthy 2008; McClure 2013; Oncken 2006; Piper 2007; Piper 2009; Rose 2010; Schnoll 2010; Sun 2012; Swan 2003; Swan 2010; Verde 2014; Wagena 2005; Wilcox 2011; Winst 2006). We excluded three of these studies (Bloch 2010; King 2012; McClure 2013; see Excluded studies). Of the remaining 33 studies, we were able to obtain data from 14 studies by contacting the principal investigator and for four studies by extracting data from published reports (Ahluwalia 2006; Aveyard 2007; Brown 2007; Cox 2012; Gilbert 2009; GPRG 1993; Hall 2008; Hall 2009; Lerman 2002; Lerman 2004; Lerman 2015; Marteau 2012; McCarthy 2008; Piper 2007; Piper 2009; Swan 2010; Wagena 2005; Winst 2006). In total, we included 18 randomised clinical trials in the quantitative analysis (Ahluwalia 2006; Aveyard 2007; Brown 2007; Cox 2012; Gilbert 2009; GPRG 1993; Hall 2008; Hall 2009; Lerman 2002; Lerman 2004; Lerman 2015; Marteau 2012; McCarthy 2008; Piper 2007; Piper 2009; Swan 2010; Wagena 2005; Winst 2006). We did not consider 14 trials in the quantitative analysis because we obtained no relevant data via contact with the principal investigator or through review of published reports (Cinciripini 2005; Gonzales 2006; Jorenby 2006; Kalman 2011; Killen 2006; Killen 2008; Killen 2010; Oncken 2006; Rose 2010; Schnoll 2010; Sun 2012; Swan 2003;

Verde 2014; Wilcox 2011). For the remainder of this report, we will focus only on those studies that contributed to the quantitative analysis.

Figure 1. Flow diagram of the search and study selection.

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

Figure 1. (Continued)

Included studies

Refer to the [Characteristics of included studies](#) table for details.

We retrieved data (genotype counts by abstinence status, treatment arm, and race/ethnicity) from 18 randomised clinical trials including 9017 participants, of whom 6924 were non-Hispanic whites (NHWs) and 2093 were non-Hispanic black or African American (NHB) participants.

Data were available for 13 biomarkers: nine SNPs (rs1051730 (*CHRNA3*) (n = 13: [Aveyard 2007](#); [Becker 2008](#); [Brown 2007](#); [GPRG 1993](#); [Hall 2008](#); [Hall 2009](#); [Lerman 2002](#); [Lerman 2004](#); [Marteau 2012](#); [McCarthy 2008](#); [Piper 2007](#); [Piper 2009](#); [Swan 2010](#); [Winst 2006](#)), rs16969968 (n = 7: [Ahluwalia 2006](#); [Cox 2012](#); [Lerman 2015](#); [McCarthy 2008](#); [Piper 2007](#); [Piper 2009](#)), rs588765 (n = 10: [Ahluwalia 2006](#); [Brown 2007](#); [Cox 2012](#); [Hall 2008](#); [Hall 2009](#); [Lerman 2002](#); [Lerman 2004](#); [Lerman 2015](#); [Piper 2009](#); [Swan 2010](#)), rs2036527 (*CHRNA5*) (n = 7: [Ahluwalia 2006](#); [Cox 2012](#); [Lerman 2002](#); [Lerman 2004](#); [McCarthy 2008](#); [Piper 2007](#); [Piper 2009](#)), rs3733829 (n = 4: [Brown 2007](#); [McCarthy 2008](#); [Piper 2007](#); [Piper 2009](#)), rs7937 (*EGLN2*) (n = 3: [McCarthy 2008](#); [Piper 2007](#); [Piper 2009](#)), rs1329650 (n = 3: [McCarthy 2008](#); [Piper 2007](#); [Piper 2009](#)), rs1028936 (*LOC100188947*) (n = 3: [McCarthy 2008](#); [Piper 2007](#); [Piper 2009](#)), and rs215605 (*PDE1C*) (n = 3: [McCarthy 2008](#); [Piper 2007](#); [Piper 2009](#))); two VNTRs (*DRD4*) (n = 4: [Aveyard 2007](#); [Brown 2007](#); [Gilbert 2009](#); [GPRG 1993](#)) and *SLC6A4* (n = 3: [Aveyard 2007](#); [Gilbert 2009](#); [Wagena 2005](#)); and the NMR (n = 3: [Ahluwalia 2006](#); [GPRG 1993](#); [Lerman 2015](#)).

Data were insufficient to allow analysis for five additional biomarkers: four SNPs: rs13280604 (no trials), rs4105144 (no trials), rs6474412 (n = 1: [Brown 2007](#)), and rs3025343 (n = 1: [Brown 2007](#)); and one VNTR: *SLC6A3* (3' 40 bp) (n = 1: [Brown 2007](#)), which were identified initially as relevant to investigate.

We identified placebo-controlled trials of NRT (n = 4: [Ahluwalia 2006](#); [Gilbert 2009](#); [GPRG 1993](#); [Winst 2006](#)); bupropion (n = 6: [Brown 2007](#); [Cox 2012](#); [Hall 2008](#); [Lerman 2002](#); [McCarthy 2008](#); [Wagena 2005](#)); NRT, bupropion, and NRT + bupropion (n = 1: [Piper 2009](#)); NRT and varenicline (n = 1: [Lerman 2015](#)); and bupropion and NRT + bupropion (n = 1: [Piper 2007](#)). In the other trials, all participants received NRT (n = 4: [Aveyard 2007](#); [Hall 2009](#); [Lerman 2004](#); [Marteau 2012](#)) or varenicline (n = 1: [Swan 2010](#)). NRT trials included gum ([Ahluwalia 2006](#); [Hall 2009](#); [Piper 2007](#)), lozenge ([Piper 2009](#)), patch ([Aveyard 2007](#); [Cinciripini 2005](#); [Gilbert 2009](#); [GPRG 1993](#); [Hall 2008](#); [Kalman 2011](#); [Killen 2006](#); [Killen 2008](#); [Killen 2010](#); [Lerman 2004](#); [Lerman 2015](#); [Marteau 2012](#); [Piper 2009](#); [Rose 2010](#); [Schnoll 2010](#); [Verde 2014](#); [Winst 2006](#)), and spray ([Lerman 2004](#)) NRT interventions. [Piper et al](#) included NRT lozenge and

transdermal patch intervention arms in this five-arm trial ([Piper 2009](#)).

Trials contained at least one arm of NRT (n = 10: [Ahluwalia 2006](#); [Aveyard 2007](#); [Gilbert 2009](#); [GPRG 1993](#); [Hall 2009](#); [Lerman 2004](#); [Lerman 2015](#); [Marteau 2012](#); [Piper 2009](#); [Winst 2006](#)), bupropion (n = 7: [Brown 2007](#); [Cox 2012](#); [Hall 2008](#); [Lerman 2002](#); [McCarthy 2008](#); [Piper 2007](#); [Piper 2009](#); [Wagena 2005](#)), varenicline (n = 2: [Lerman 2015](#); [Swan 2010](#)), NRT + bupropion (n = 2: [Piper 2007](#); [Piper 2009](#)), or placebo (n = 13: [Ahluwalia 2006](#); [Brown 2007](#); [Cox 2012](#); [Gilbert 2009](#); [GPRG 1993](#); [Hall 2008](#); [Lerman 2002](#); [Lerman 2015](#); [McCarthy 2008](#); [Piper 2007](#); [Piper 2009](#); [Wagena 2005](#); [Winst 2006](#)), resulting in a total of 40 active versus placebo, 16 active versus active, and 64 between-genotype comparisons.

Data on the primary outcome - abstinence at six months - were available from 16 trials ([Ahluwalia 2006](#); [Aveyard 2007](#); [Brown 2007](#); [Cox 2012](#); [Gilbert 2009](#); [GPRG 1993](#); [Hall 2008](#); [Hall 2009](#); [Lerman 2002](#); [Lerman 2004](#); [Lerman 2015](#); [Marteau 2012](#); [Piper 2009](#); [Swan 2010](#); [Wagena 2005](#); [Winst 2006](#)). Data on abstinence at end of treatment were available from 17 trials ([Ahluwalia 2006](#); [Aveyard 2007](#); [Brown 2007](#); [Cox 2012](#); [Gilbert 2009](#); [GPRG 1993](#); [Hall 2008](#); [Hall 2009](#); [Lerman 2002](#); [Lerman 2004](#); [Lerman 2015](#); [McCarthy 2008](#); [Piper 2007](#); [Piper 2009](#); [Swan 2010](#); [Wagena 2005](#); [Winst 2006](#)). Eleven trials included mostly NHW participants ([Aveyard 2007](#); [Brown 2007](#); [Gilbert 2009](#); [GPRG 1993](#); [Hall 2008](#); [Hall 2009](#); [Marteau 2012](#); [McCarthy 2008](#); [Swan 2010](#); [Wagena 2005](#); [Winst 2006](#)). Five trials included NHW and NHB participants ([Lerman 2002](#); [Lerman 2004](#); [Lerman 2015](#); [Piper 2007](#); [Piper 2009](#)). Two trials included NHB participants only ([Ahluwalia 2006](#); [Cox 2012](#)). Available data were insufficient to allow meta-analyses for Hispanic or Latino race or for non-Hispanic or non-Latino ethnic groups other than NHW or NHB.

Excluded studies

In total, we excluded three of the 36 identified randomised clinical trials - one because researchers performed no individual genotyping, and two because investigators reported no genotypes of interest and/or made none available ([Becker 2008](#); [King 2012](#); [McClure 2013](#)). Additional information on these studies can be found in the [Characteristics of excluded studies](#) tables.

Risk of bias in included studies

Overall risk of bias of randomised clinical trials included in the quantitative analysis varied from low to high. Refer to the [Characteristics of included studies](#) table for details, and to [Figure 2](#) and [Figure 3](#) for a summary of 'Risk of bias' assessments. For one trial, we had only a protocol available, and this made it difficult to assess risk of bias of this study as actually performed ([Winst 2006](#)).

Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each study.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Ahluwalia 2006	+	+	+	+	+	+	+
Aveyard 2007	+	+	-	+	+	+	+
Brown 2007	+	?	+	?	+	+	-
Cox 2012	+	+	+	+	+	+	+
Gilbert 2009	+	?	+	?	?	-	-
GPRG 1993	+	+	+	+	?	+	-
Hall 2008	+	+	?	+	+	+	+
Hall 2009	+	+	?	+	+	+	+
Lerman 2002	+	+	+	+	-	+	+
Lerman 2004	+	-	-	+	-	?	+
Lerman 2015	+	+	+	+	+	+	+
Marteau 2012	+	+	-	+	+	+	+
McCarthy 2008	+	?	?	+	+	+	-
Piper 2007	?	?	+	+	+	+	?
Piper 2009	?	+	+	+	+	+	+
Swan 2010	+	?	+	+	?	+	?
Wagena 2005	+	+	+	+	+	+	+
WINST 2006	+	?	?	?	?	?	?

Figure 3. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Allocation

We assessed random sequence generation as having low risk of bias for 16 studies (Ahluwalia 2006; Aveyard 2007; Brown 2007; Cox 2012; Gilbert 2009; GPRG 1993; Hall 2008; Hall 2009; Lerman 2002; Lerman 2004; Lerman 2015; Marteau 2012; McCarthy 2008; Swan 2010; Wagena 2005; Winst 2006). We assessed two studies as having unclear risk (Piper 2007; Piper 2009). We considered allocation concealment as having low risk of bias for 10 studies (Ahluwalia 2006; Aveyard 2007; GPRG 1993; Hall 2008; Hall 2009; Lerman 2002; Lerman 2015; Marteau 2012; Piper 2009; Wagena 2005). We found unclear risk for seven studies (Brown 2007; Cox 2012; Gilbert 2009; McCarthy 2008; Piper 2007; Swan 2010; Winst 2006). We determined that one study was at high risk (Lerman 2004).

Blinding

We considered blinding of participants and personnel as having low risk of bias for 11 studies (Ahluwalia 2006; Brown 2007; Cox 2012; Gilbert 2009; GPRG 1993; Lerman 2002; Lerman 2015; Piper 2007; Piper 2009; Swan 2010; Wagena 2005). We judged four studies as having unclear risk (Hall 2008; Hall 2009; McCarthy 2008; Winst 2006). We found that three studies were at high risk (Aveyard 2007; Lerman 2004; Marteau 2012). We considered blinding of outcome assessment as having low risk of bias for 13 studies (Aveyard 2007; GPRG 1993; Hall 2008; Hall 2009; Lerman 2002; Lerman 2004; Lerman 2015; Marteau 2012; McCarthy 2008; Piper 2007; Piper 2009; Swan 2010; Wagena 2005). We determined that five studies were at unclear risk (Ahluwalia 2006; Brown 2007; Cox 2012; Gilbert 2009; Winst 2006).

Incomplete outcome data

We considered incomplete outcome data as having low risk of bias for 12 studies (Ahluwalia 2006; Aveyard 2007; Brown 2007; Cox 2012; Hall 2008; Hall 2009; Lerman 2015; Marteau 2012; McCarthy 2008; Piper 2007; Piper 2009; Wagena 2005). We deemed that four studies had unclear risk (Gilbert 2009; GPRG 1993; Swan 2010; Winst 2006). We found high risk for two studies (Lerman 2002; Lerman 2004).

Selective reporting

We considered selective reporting as having low risk of bias for 15 studies (Ahluwalia 2006; Aveyard 2007; Brown 2007; Cox 2012; GPRG 1993; Hall 2008; Hall 2009; Lerman 2002; Lerman 2015; Marteau 2012; McCarthy 2008; Piper 2007; Piper 2009; Swan 2010; Wagena 2005). We determined that two studies were at unclear risk (Lerman 2004; Winst 2006). We found that one study was at high risk (Gilbert 2009).

Other potential sources of bias

We assessed 11 studies as having low risk of bias for other potential sources of bias based on genotype frequencies (in study and polymorphism), potential deviation from Hardy-Weinberg equilibrium, source of DNA (e.g. buccal swab, blood, saliva), genotyping protocol, and QC methods (Ahluwalia 2006; Aveyard 2007; Cox 2012; Hall 2008; Hall 2009; Lerman 2002; Lerman 2004; Lerman 2015; Marteau 2012; Piper 2009; Wagena 2005). For three studies, we were unable to assess the risk of other biases (Piper 2007; Swan 2010; Winst 2006). For four studies, we considered the risk of other bias to be high because a large proportion of original trial participants were not genotyped, thereby opening the possibility of selection bias, or because relapsers were excluded from analyses, which may have created study population imbalance for genetic predisposition to successfully quit smoking (Brown 2007; Gilbert 2009; GPRG 1993; McCarthy 2008).

Effects of interventions

See: [Summary of findings for the main comparison](#) Active NRT compared with placebo - rs1051730 - non-Hispanic white for smoking cessation; [Summary of findings 2](#) Active NRT compared with placebo - rs16969968 - non-Hispanic white for smoking cessation; [Summary of findings 3](#) Active NRT compared with placebo - rs16969968 - non-Hispanic black or African American for smoking cessation; [Summary of findings 4](#) Active NRT compared with placebo - rs 588765 - non-Hispanic white for smoking cessation; [Summary of findings 5](#) Active NRT compared with placebo - rs2036527 - non-Hispanic black or African American for smoking cessation; [Summary of findings 6](#) Active NRT compared

with placebo - DRD4 (exon 3 48 bp) - non-Hispanic white for smoking cessation; **Summary of findings 7** Active NRT compared with placebo - NMR - non-Hispanic black and white for smoking cessation

Results are presented according to type of analysis (comparisons of relative treatment effect by genotype, or comparisons of treatment effect between genotype groups, within pharmacotherapy randomisation arms) and type of treatment (comparison). [Table 3](#), [Table 4](#), [Table 5](#), and [Table 6](#) show the summary results for each type of analysis with separate tables for six-month abstinence and abstinence at the end of treatment.

Comparisons of relative treatment effects by genotype

Active NRT versus placebo

Six-month abstinence

Data were available for the following SNPs: rs1051730 (n = 3, 1597 participants, NHW; [Analysis 1.1](#)), rs16969968 (n = 2, 709 participants, NHB; [Analysis 3.1](#)), rs2036527 (n = 2, 709 participants, NHB; [Analysis 5.1](#)), DRD4 (exon 3 48 bp) (n = 2, 900 participants, NHW; [Analysis 6.1](#)), and NMR (n = 2, 1418 participants, NHW or NHB; [Analysis 7.1](#)).

Results showed statistically significant heterogeneity between genotype groups in the analysis of NHB for rs16969968 (P = 0.03; [Analysis 3.1](#); [Summary of findings 3](#)). Six-month abstinence was increased in the active NRT group as compared with the placebo group among participants with a GG genotype (RR 1.47, 95% CI 1.07 to 2.03), but not in the combined group of those with a GA or AA genotype (RR 0.43, 95% CI 0.15 to 1.26; [Analysis 3.1](#); [Summary of findings 3](#); RRR GG vs GA or AA 3.51, 95% CI 1.19 to 10.3). We found no such heterogeneity for any of the other biomarkers.

End-of-treatment abstinence

Data were available for the following SNPs: rs1051730 (n = 2, 1391 participants, NHW; [Analysis 1.2](#)), rs16969968 (n = 2, 1127 participants, NHW; [Analysis 2.1](#); n = 2, 709 participants, NHB; [Analysis 3.2](#)), rs588765 (n = 2, 923 participants, NHW; [Analysis 4.1](#)), rs2036527 (n = 2, 708 participants, NHB; [Analysis 5.2](#)), DRD4 (exon 3 48 bp) (n = 2, 900 participants, NHW; [Analysis 6.2](#)), and NMR (n = 2, 1417 participants, NHW or NHB; [Analysis 7.2](#)).

We found statistically significant heterogeneity between genotype groups in the analysis of NHW for rs1051730 (heterogeneity P = 0.004; [Analysis 1.2](#); [Summary of findings for the main comparison](#)) and rs16969968 (heterogeneity P = 0.02; [Analysis 2.1](#); [Summary of findings for the main comparison](#)), and of NHB for rs16969968 (heterogeneity P = 0.003; [Analysis 3.2](#); [Summary of findings 3](#)). For the rs1051730 analysis in NHW, abstinence at end of treatment was comparable between the active NRT group and the placebo group among participants with a GG genotype (RR 1.09, 95% CI 0.85 to 1.41), but was increased in those with GA or AA genotype (RR 2.13, 95% CI 1.52 to 2.97; and RR 2.18, 95% CI 1.04 to 4.58, respectively; [Analysis 1.2](#); [Summary of findings for the main comparison](#); RRR GG vs AA and GA vs AA genotype of 0.54, 95% CI 0.26 to 1.14; and 0.96, 95% CI 0.44 to 2.11, respectively). For the rs16969968 analysis in NHW, end-of-treatment abstinence increased with active NRT as compared with placebo among individuals with GA genotype (RR 1.85, 95% CI 1.33 to 2.59), but was comparable among those with GG or AA (RR 1.01, 95% CI 0.77 to 1.33; and RR 1.80, 95% CI 0.45 to 7.23, respectively; [Analysis 2.1](#); [Summary of findings for the](#)

[main comparison](#); RRR GG vs AA and GA vs AA genotype of 0.78, 95% CI 0.33 to 1.47; and 1.04, 95% CI 0.45 to 2.41, respectively). For rs16969968 in NHB, active NRT increased end-of-treatment abstinence compared with placebo among those with GG genotype (RR 1.57, 95% CI 1.15 to 2.15), and it decreased end-of-treatment abstinence among those with GA or AA phenotype (RR 0.29, 95% CI 0.10 to 0.86; [Analysis 3.2](#); [Summary of findings 3](#); RRR GG vs GA or AA genotype of 5.84, 95% CI 1.89 to 18.1). We found no such heterogeneity for any of the other biomarkers.

Bupropion versus placebo

Six-month abstinence

Data were available for the following SNPs: rs1051730 (n = 4, 1329 participants, NHW; [Analysis 8.1](#); n = 3, 126 participants, NHB; [Analysis 9.1](#)), rs16969968 (n = 2, 578 participants, NHB; [Analysis 11.1](#)), rs588765 (n = 4, 1108 participants, NHW; [Analysis 12.1](#)), rs2036527 (n = 2, 738 participants, NHW; [Analysis 13.1](#); n = 3, 660 participants, NHB; [Analysis 14.1](#)), and rs3733829 (n = 2, 571 participants, NHW; [Analysis 15.1](#)).

We found no heterogeneity between genotype groups when comparing bupropion versus placebo for any of the biomarkers.

End-of-treatment abstinence

Data were available for the following SNPs: rs1051730 (n = 6, 1379 participants, NHW; [Analysis 8.2](#); n = 3, 159 participants, NHB; [Analysis 9.2](#)), rs16969968 (n = 3, 557 participants, NHW; [Analysis 10.1](#); n = 3, 611 participants, NHB; [Analysis 11.2](#)), rs588765 (n = 4, 1107 participants, NHW; [Analysis 12.2](#)), rs2036527 (n = 4, 975 participants, NHW; [Analysis 13.2](#); n = 4, 693 participants, NHB; [Analysis 14.2](#)), rs3733829 (n = 4, 807 participants, NHW; [Analysis 15.2](#); n = 2, 75 participants, NHB; [Analysis 16.1](#)), rs7937 (n = 3, 557 participants, NHW; [Analysis 17.1](#); n = 2, 76 participants, NHB; [Analysis 18.1](#)), rs1329650 (n = 3, 559 participants, NHW; [Analysis 19.1](#); n = 2, 76 participants, NHB; [Analysis 20.1](#)), rs1028936 (n = 3, 559 participants, NHW; [Analysis 21.1](#); n = 2, 76 participants, NHB; [Analysis 22.1](#)), and rs215605 (n = 3, 558 participants, NHW; [Analysis 23.1](#); n = 2, 76 participants, NHB; [Analysis 24.1](#)).

We found no heterogeneity between genotype groups when comparing bupropion versus placebo for any of the biomarkers.

Bupropion + any NRT versus placebo

Six-month abstinence

No data were available for this outcome.

End-of-treatment abstinence

Data were available for the following SNPs: rs1051730 (n = 2, 444 participants, NHW; [Analysis 25.1](#); n = 2, 69 participants, NHB; [Analysis 26.1](#)), rs16969968 (n = 2, 441 participants, NHW; [Analysis 27.1](#); n = 2, 69 participants, NHB; [Analysis 28.1](#)), rs2036527 (n = 2, 443 participants, NHW; [Analysis 29.1](#); n = 2, 69 participants, NHB; [Analysis 30.1](#)), rs3733829 (n = 2, 441 participants, NHW; [Analysis 31.1](#); n = 2, 69 participants, NHB; [Analysis 32.1](#)), rs7937 (n = 2, 442 participants, NHW; [Analysis 33.1](#); n = 2, 69 participants, NHB; [Analysis 34.1](#)), rs1329650 (n = 2, 442 participants, NHW; [Analysis 35.1](#); n = 2, 69 participants, NHB; [Analysis 36.1](#)), rs1028936 (n = 2, 444 participants, NHW; [Analysis 37.1](#); n = 2, 69 participants, NHB; [Analysis 38.1](#)), and rs215605 (n = 2, 442 participants, NHW; [Analysis 39.1](#); n = 2, 68 participants, NHB; [Analysis 40.1](#)).

We found no heterogeneity between genotype groups when comparing bupropion + any NRT versus placebo for any of the biomarkers.

Bupropion + any NRT versus bupropion alone

Six-month abstinence

No data were available for this outcome.

End-of-treatment abstinence

Data were available for the following SNPs: rs1051730 (n = 2, 533 participants, NHW; [Analysis 41.1](#); n = 2, 87 participants, NHB; [Analysis 42.1](#)), rs16969968 (n = 2, 531 participants, NHW; [Analysis 43.1](#); n = 2, 87 participants, NHB; [Analysis 44.1](#)), rs2036527 (n = 2, 532 participants, NHW; [Analysis 45.1](#); n = 2, 87 participants, NHB; [Analysis 46.1](#)), rs3733829 (n = 2, 531 participants, NHW; [Analysis 47.1](#); n = 2, 94 participants, NHB; [Analysis 48.1](#)), rs7937 (n = 2, 533 participants, NHW; [Analysis 49.1](#); n = 2, 87 participants, NHB; [Analysis 50.1](#)), rs1329650 (n = 2, 531 participants, NHW; [Analysis 51.1](#); n = 2, 87 participants, NHB; [Analysis 52.1](#)), rs1028936 (n = 2, 533 participants, NHW; [Analysis 53.1](#); n = 2, 87 participants, NHB; [Analysis 54.1](#)), and rs215605 (n = 2, 532 participants, NHW; [Analysis 55.1](#); n = 2, 87 participants, NHB; [Analysis 56.1](#)).

We found no heterogeneity between genotype groups when comparing bupropion + any NRT versus bupropion for any of the biomarkers.

Comparisons of treatment effects between genotype groups within pharmacotherapy randomisation arms

Active NRT

Six-month abstinence

Data were available for the following SNPs: rs1051730 (n = 7, 2687 participants, NHW; [Analysis 57.1](#); n = 2, 237 participants, NHB; [Analysis 58.1](#)), rs16969968 (n = 2, 392 participants, NHB; [Analysis 59.1](#)), rs588765 (n = 3, 832 participants, NHW; [Analysis 60.1](#)), rs2036527 (n = 2, 948 participants, NHW; [Analysis 61.1](#); n = 2, 391 participants, NHB; [Analysis 62.1](#)), DRD4 (exon 3 48 bp) (n = 3, 1119 participants, NHW; [Analysis 63.1](#)), SLC6A4 (Promoter) (n = 2, 926 participants, NHW; [Analysis 64.1](#)), and NMR (n = 2, 718 participants, NHW and NHB; [Analysis 65.1](#)).

Among those receiving active NRT, individuals with a slow NMR were more successful in achieving six-month abstinence as compared with those with a normal NMR among NHW and NHB participants (normal NMR vs slow NMR: RR 0.54, 95% CI 0.37 to 0.78; [Analysis 65.1](#)).

We found no heterogeneity between genotype group comparisons (homozygous major vs homozygous minor compared with heterozygous vs homozygous minor, or slow vs normal) among individuals randomised to active NRT for any of the other biomarkers.

End-of-treatment abstinence

Data were available for the following SNPs: rs1051730 (n = 5, 2208 participants, NHW; [Analysis 57.2](#)), rs16969968 (n = 2, 392 participants, NHB; [Analysis 59.2](#)), rs588765 (n = 3, 832 participants, NHW; [Analysis 60.2](#)), rs2036527 (n = 2, 948 participants, NHW; [Analysis 61.2](#); n = 2, 391 participants, NHB; [Analysis 62.2](#)), DRD4 (exon 3 48 bp) (n = 3, 1119 participants, NHW; [Analysis 63.2](#)), SLC6A4

(Promoter) (n = 2, 926 participants, NHW; [Analysis 64.2](#)), and NMR (n = 2, 718 participants, NHW and NHB; [Analysis 65.2](#)).

Among those receiving active NRT, GG genotype individuals more often achieved end-of-treatment abstinence as compared with individuals with a combination of GA and AA genotypes for rs16969968 and rs2036527 in NHB (RR 2.75, 95% CI 1.08 to 7.02; [Analysis 59.2](#); RR 1.73, 95% CI 1.20 to 2.49; [Analysis 62.2](#); respectively).

We found no heterogeneity between genotype group comparisons (homozygous major vs homozygous minor compared with heterozygous vs homozygous minor, or slow vs normal) among individuals randomised to active NRT for any of the other biomarkers.

Bupropion

Six-month abstinence

Data were available for the following SNPs: rs1051730 (n = 4, 610 participants, NHW; [Analysis 66.1](#); n = 2, 63 participants, NHB; [Analysis 67.1](#)), rs16969968 (n = 2, 294 participants, NHB; [Analysis 69.1](#)), rs588765 (n = 4, 596 participants, NHW; [Analysis 70.1](#)), rs2036527 (n = 2, 412 participants, NHW; [Analysis 71.1](#); n = 3, 331 participants, NHB; [Analysis 72.1](#)), and rs3733829 (n = 2, 307 participants, NHW; [Analysis 73.1](#)).

Among those receiving bupropion, we identified no specific genotype groups that were more successful in achieving six-month abstinence than other groups. Additionally, we found no heterogeneity between genotype group comparisons (homozygous major vs homozygous minor compared with heterozygous vs homozygous minor, or slow vs normal) among individuals randomised to bupropion for any of the biomarkers.

End-of-treatment abstinence

Data were available for the following SNPs: rs1051730 (n = 6, 743 participants, NHW; [Analysis 66.2](#); n = 3, 84 participants, NHB; [Analysis 67.2](#)), rs16969968 (n = 3, 324 participants, NHW; [Analysis 68.1](#); n = 3, 315 participants, NHB; [Analysis 69.2](#)), rs588765 (n = 4, 596 participants, NHW; [Analysis 70.2](#)), rs2036527 (n = 4, 546 participants, NHW; [Analysis 71.2](#); n = 4, 352 participants, NHB; [Analysis 72.2](#)), rs3733829 (n = 4, 440 participants, NHW; [Analysis 73.2](#); n = 2, 46 participants, NHB; [Analysis 74.1](#)), rs7937 (n = 3, 324 participants, NHW; [Analysis 75.1](#); n = 2, 47 participants, NHB; [Analysis 76.1](#)), rs1329650 (n = 3, 324 participants, NHW; [Analysis 77.1](#); n = 2, 47 participants, NHB; [Analysis 78.1](#)), rs1028936 (n = 3, 324 participants, NHW; [Analysis 79.1](#); n = 2, 47 participants, NHB; [Analysis 80.1](#)), and rs215605 (n = 3, 324 participants, NHW; [Analysis 81.1](#); n = 2, 47 participants, NHB; [Analysis 82.1](#)).

Among those receiving bupropion, we identified no specific genotype groups that were more successful in achieving end-of-treatment abstinence than other groups. Additionally, we found no heterogeneity between genotype group comparisons (homozygous major vs homozygous minor compared with heterozygous vs homozygous minor, or slow vs normal) among individuals randomised to bupropion for any of the biomarkers.

Varenicline

Six-month abstinence

Data were available for the following SNPs: rs16969968 (n = 2, 707 participants, NHW; [Analysis 83.1](#)) and rs588765 (n = 2, 699 participants; [Analysis 84.1](#)).

Among those receiving varenicline, we identified no specific genotype groups that were more successful than other groups in achieving six-month abstinence. Additionally, we found no heterogeneity between genotype group comparisons (homozygous major vs homozygous minor compared with heterozygous vs homozygous minor, or slow vs normal) among individuals randomised to varenicline for any of the biomarkers.

End-of-treatment abstinence

Data were available for the following SNPs: rs16969968 (n = 2, 707 participants, NHW; [Analysis 83.2](#)) and rs588765 (n = 2, 699 participants, NHW; [Analysis 84.2](#)).

Among those receiving varenicline, we identified no specific genotype groups that were more successful than other groups in achieving end-of-therapy abstinence. Additionally, we found no heterogeneity between genotype group comparisons (homozygous major vs homozygous minor compared with heterozygous vs homozygous minor, or slow vs normal) among individuals randomised to varenicline for any of the biomarkers.

Bupropion + any NRT

Six-month abstinence

No data were available for this outcome.

End-of-treatment abstinence

Data were available for the following SNPs: rs1051730 (n = 2, 268 participants, NHW; [Analysis 85.1](#); n = 2, 40 participants, NHB; [Analysis 86.1](#)), rs16969968 (n = 2, 266 participants, NHW; [Analysis 87.1](#); n = 2, 40 participants, NHB; [Analysis 88.1](#)), rs2036527 (n = 2, 267 participants, NHW; [Analysis 89.1](#); n = 2, 40 participants, NHB; [Analysis 90.1](#)), rs3733829 (n = 2, 267 participants, NHW; [Analysis 91.1](#); n = 2, 40 participants, NHB; [Analysis 92.1](#)), rs7937 (n = 2, 268 participants, NHW; [Analysis 93.1](#); n = 2, 40 participants, NHB; [Analysis 94.1](#)), rs1329650 (n = 2, 266 participants, NHW; [Analysis 95.1](#); n = 2, 40 participants, NHB; [Analysis 96.1](#)), rs1028936 (n = 2, 268 participants, NHW; [Analysis 97.1](#); n = 2, 40 participants, NHB; [Analysis 98.1](#)), and rs215605 (n = 2, 267 participants, NHW; [Analysis 99.1](#); n = 2, 40 participants, NHB; [Analysis 100.1](#)).

Among those receiving bupropion + any NRT, GG genotype individuals more often achieved six-month abstinence as compared with AA genotype individuals for rs1329650 in NHW (AA vs GG, RR 0.64, 95% CI 0.43 to 0.94; [Analysis 95.1](#)), as did individuals with GG or AG genotype compared with AA genotype individuals for rs3733829 in NHB (AA vs AG or GG RR 0.36, 95% CI 0.13 to 0.99; [Analysis 92.1](#)).

We found no heterogeneity between genotype group comparisons (homozygous major vs homozygous minor compared with heterozygous vs homozygous minor, or slow vs normal) among individuals randomised to bupropion + any NRT for any of the other biomarkers.

Placebo

Six-month abstinence

Data were available for the following SNPs: rs1051730 (n = 6, 974 participants, NHW; [Analysis 101.1](#); n = 2, 63 participants, NHB; [Analysis 102.1](#)), rs16969968 (n = 2, 343 participants, NHW; [Analysis 103.1](#); n = 3, 584 participants, NHB; [Analysis 104.1](#)), rs588765 (n = 5, 723 participants, NHW; [Analysis 105.1](#); n = 2, 566 participants, NHB; [Analysis 106.1](#)), rs2036527 (n = 2, 326 participants, NHW; [Analysis 107.1](#); n = 4, 629 participants, NHB; [Analysis 108.1](#)), DRD4 (exon 3 48 bp) (n = 3, 573 participants, NHW; [Analysis 109.1](#)), rs3733829 (n = 2, 264 participants, NHW; [Analysis 110.1](#)), SLC6A4 (Promoter) (n = 2, 151 participants, NHW; [Analysis 119.1](#)), and NMR (n = 2, 699 participants, NHW and NHB; [Analysis 120.1](#)).

Among those receiving placebo, abstinence rates were not statistically significantly different between specific genotype groups. Additionally, we found no heterogeneity between genotype group comparisons (homozygous major vs homozygous minor compared with heterozygous vs homozygous minor, or slow vs normal) among individuals randomised to placebo for any of the biomarkers.

End-of-treatment abstinence

Data were available for the following SNPs: rs1051730 (n = 7, 983 participants, NHW; [Analysis 101.2](#); n = 3, 83 participants, NHB; [Analysis 102.2](#)), rs16969968 (n = 4, 445 participants, NHW; [Analysis 103.2](#); n = 4, 596 participants, NHB; [Analysis 104.2](#)), rs588765 (n = 5, 658 participants, NHW; [Analysis 105.2](#); n = 2, 566 participants, NHB; [Analysis 106.2](#)), rs2036527 (n = 4, 429 participants, NHW; [Analysis 107.2](#); n = 5, 641 participants, NHB; [Analysis 108.2](#)), DRD4 (exon 3 48 bp) (n = 3, 573 participants, NHW; [Analysis 109.2](#)), rs3733829 (n = 4, 367 participants, NHW; [Analysis 110.2](#)), rs7937 (n = 3, 233 participants, NHW; [Analysis 111.1](#); n = 2, 29 participants, NHB; [Analysis 112.1](#)), rs1329650 (n = 3, 235 participants, NHW; [Analysis 113.1](#); n = 2, 29 participants, NHB; [Analysis 114.1](#)), rs1028936 (n = 3, 235 participants, NHW; [Analysis 115.1](#); n = 2, 29 participants, NHB; [Analysis 116.1](#)), rs215605 (n = 3, 234 participants, NHW; [Analysis 117.1](#); n = 2, 29 participants, NHB; [Analysis 118.1](#)), SLC6A4 (Promoter) (n = 2, 151 participants, NHW; [Analysis 119.2](#)), and NMR (n = 2, 718 participants, NHW and NHB; [Analysis 120.2](#)).

Abstinence at the end of treatment among those receiving placebo was greater among individuals with AA or GA genotype than among those with GG genotype for rs16969968 in NHB (GG vs GA or AA, RR 0.55, 95% CI 0.35 to 0.86; [Analysis 104.2](#)).

We found no heterogeneity between genotype group comparisons (homozygous major vs homozygous minor compared with heterozygous vs homozygous minor, or slow vs normal) among individuals randomised to placebo for any of the other biomarkers.

DISCUSSION

Summary of main results

Using data from 18 randomised controlled trials (RCTs), we investigated whether a total of 13 biomarkers, including nine single-nucleotide polymorphisms (SNPs), two variable number tandem repeats (VNTRs) (*DRD4* and *SLC6A4*), and the nicotine metabolite ratio (NMR) modify the effects of different smoking cessation pharmacotherapies (nicotine replacement therapy (NRT), bupropion, varenicline, and combination therapy) on

abstinence from smoking at six months and at end of treatment. We carried out analyses separately in non-Hispanic whites (NHWs) and non-Hispanic blacks (NHBs). Results showed statistical heterogeneity between genotypes for only NRT versus placebo in NHWs for rs1051730 and rs16969968 at end of treatment. In addition, rs16969968 showed evidence of heterogeneity in NHBs at six months, as well as at end of treatment, but sample sizes for some genotype subgroups were small, rendering these results unreliable. Results at rs16969968 for NRT versus placebo in NHWs and in NHBs reflect opposite directions. For the other seven SNPs evaluated in clinical trials, we found no evidence of SNP $\times$ treatment interaction. Within-treatment arm analyses indicated that six-month abstinence was less often achieved in NHW normal metabolisers and more often among NHB individuals with rs16969968 GG and rs2036527 GG genotype who received NRT, and that end-of-treatment abstinence was less often achieved among NHWs with rs1329650 TT genotype and NHBs with rs3733829 GG or AG genotype who received bupropion + any NRT, and among NHBs with rs16969968 AA or GA genotype who received placebo. Trial results revealed no such differences for other treatments or biomarkers. In conclusion, although these findings suggest superior short-term efficacy of NRT in specific rs1051730 and rs16969968 genotype subgroups among NHWs, lack of significant genotype differences within treatment arms limits confidence in the validity of these findings. The same holds true for results of within-treatment analyses.

Overall completeness and applicability of evidence

For the vast majority of biomarkers for which we had data, we found no evidence that they may modify the effects of smoking cessation interventions, although evidence showed nominally significant treatment effects in specific genotype groups. Various reasons may explain this. First, identification of biomarker $\times$ treatment interactions may require large sample sizes (Cardon 2000), which were not available for the current RCTs. Traditionally, RCTs are designed to address comparative effectiveness questions regarding one or more active drugs. Genomic analyses are usually conducted retrospectively after trial completion and are rarely taken into account at design stages. Although we aimed to overcome sample size limitations of individual studies by combining data through meta-analysis, for most comparisons we were not able to obtain summary level data that would allow us to quantitatively synthesise all available information. Second, RCTs that were included in our analyses used genotype information for a few preselected SNPs that were chosen on the basis of biological plausibility and prior genome-wide significance with regards to smoking phenotypes. However, treatment response is likely to be under polygenic influences of biomarkers with small and large effects. Therefore, additional biomarkers across the genome may confer useful predictive information from which to identify individuals who will benefit from a particular smoking cessation intervention. To achieve this, RCTs should routinely collect and analyse DNA samples at the genome-wide level. We refer readers to our recent reviews of progress of and recommendations for genomic studies of clinical trials of smoking cessation therapies (Chen 2017; Saccone 2017).

Quality of the evidence

Our analysis constitutes a synthesis of evidence from RCTs retrospectively evaluated for effects of smoking cessation treatments according to specific genotypes. Therefore, our results

should be interpreted as evidence of heterogeneity of treatment effects (Varadhan 2013) according to specific biomarkers. Given the large number of analyses performed and assessment of the quality of evidence (GRADE) as moderate, one should interpret the results of this review with caution.

Although treatment effect heterogeneity is critical for making clinical and policy decisions, it provides only indirect evidence of the clinical utility of these genetic markers (i.e. whether measuring a particular biomarker will result in better or worse clinical outcomes).

The chr15q25.1 SNPs rs2036527, rs16969968, and rs1051730 are highly correlated ($r^2 = 0.90$ for rs2036527 vs the latter two SNPs, and $r^2 = 1$ vs the latter two SNPs) in individuals of European ancestry (Utah residents from North and West Europe), but are less highly correlated in African American individuals ($r^2 = 0.28$, 0.38 , and 0.46 for rs2036527 vs rs16969968, rs2036527 vs rs1051730, and rs16969968 vs rs1051730; Americans of African Ancestry in SW USA). In addition, the minor allele frequency of all three SNPs is lower among individuals of African American ancestry (from 0.40 to 0.22 for rs2036527, from 0.38 to 0.07 for rs16969968, and from 0.38 to 0.15 for rs1051730). In particular, the minor allele frequency of rs16969968 is much lower among those of African ancestry (means are < 0.01 in sub-Saharan Africans, 0.027 in East Asians, 0.21 in Amerindians, 0.37 in Europeans, and 0.18 in South Asians; 1000 Genomes Project Consortium 2015). Therefore, one should use caution when comparing results at these chr15q25.1 SNPs between NHWs and NHBs owing to differences in linkage disequilibrium (LD) and power (due to differences in allele frequency). All three variants constitute susceptibility loci for lung cancer and are associated with measures of nicotine dependence (David 2012; Landi 2009; Liu 2010; McKay 2008; Thorgeirsson 2008; Thorgeirsson 2010; Tobacco and Genetics Consortium 2010; Zanetti 2016). rs16969968 (NM_000745.3:c.1192G>A) is a missense variant (Asp398Asn) of the nicotinic acetylcholine receptor alpha 5 subunit gene (CHRNA5); African American individuals who are homozygous for the major allele have a higher probability of smoking abstinence with NRT than with placebo, but individuals of European ancestry who are heterozygous for rs16969968 (A/G genotype) have a higher probability of smoking abstinence with NRT than with placebo (see Results). Similarly, rs1051730 (NM_000743.4:c.645C>T) is a synonymous substitution in the nicotinic acetylcholine receptor alpha 3 subunit gene (CHRNA3) that confers higher probability of abstinence among individuals of European ancestry who are heterozygous or homozygous for the minor allele (AA genotype) (see Results). rs2036527, found proximal to CHRNA5, is associated with nicotine dependence and with lung cancer in African Americans, but has much lower LD with the two other chr15q25.1 SNPs in African Americans than in European Americans. We did observe that NHB with GG genotype may benefit more from NRT than from placebo (see Results). Differences in SNP allele frequencies and in LD between NHW and NHB populations at chr15q25.1 (above) and differences in allele frequencies between NHW and NHB at chr19q13.2 (rs3733829) and chr10q23.32 (rs1329650), together with known differences in LD, suggest caution when results are compared between NHWs and NHBs. Given the small number of trials with available data for these and other comparisons, review findings should be interpreted with caution and should be revisited when results of future trials become available.

Potential biases in the review process

We should acknowledge that owing to the numbers of biomarkers, interventions, endpoints, and ancestry subgroups, our systematic review includes a large number of analyses. However, we did not correct for the multiplicity of comparisons because our aim was to synthesise existing evidence rather than focus on hypothesis testing. Therefore, we put greater emphasis on the estimation of effects of smoking cessation interventions than on testing for these effects (Higgins 2011). Moreover, in our review, we report all performed analyses regardless of whether they achieved statistical significance at the nominal $P = 0.05$ threshold; hence, we are not selectively reporting nominally significant results. Another issue of multiple comparisons relates to the selection of particular SNP $\times$ treatment interactions among many in the primary RCTs. Although most trials report only one or a few SNPs, we cannot exclude the possibility that these associations may have been selected among a number of analyses. Formally controlling for this type of multiplicity (e.g. using the approach proposed by Benjamini and Bogomolov) is difficult in the absence of detailed reporting in primary studies (Benjamini 2014). However, most RCTs had low risk of selective reporting and had specified a priori the SNPs of interest used in analyses of pharmacogenomics.

Agreements and disagreements with other studies or reviews

In European ancestry samples, minor alleles of both variants (rs1051730 and rs16969968) have been associated with increased abstinence (Bergen 2013; Chen 2012) and with decreased abstinence after NRT (Munafò 2011). Others have not been associated with abstinence (Tyndale 2015). In addition, a recent meta-analysis revealed that neither of these SNPs was associated with smoking cessation among individuals randomised to NRT (Leung 2015). In contrast to our meta-analysis, the studies of Leung et al evaluated only the per-allele effect for each SNP among those randomised to NRT; these investigators did not examine effect modification, as we did in our analysis. In other words, they did not address the comparative effectiveness of NRT relative to placebo or some other smoking cessation intervention. On the other hand, in our meta-analysis, we performed both within- and across-treatment arms comparisons of effects of biomarkers to evaluate the efficacy of smoking cessation interventions in specific genotype groups. Hence, the fact that we did find evidence of treatment effect heterogeneity for both rs16969968 and rs1051730 suggests a likely gene $\times$ treatment interaction.

AUTHORS' CONCLUSIONS

Implications for practice

These data suggest that response to nicotine replacement therapy (NRT) may be greater for non-Hispanic black (NHB) individuals at six months with rs16969968 GG genotype than for those with GA or AA genotype; among individuals treated with active NRT, nicotine metabolite ratio (NMR) slow metaboliser status predicts higher six-month abstinence outcomes than among those with normal metaboliser status. For NHBs and NHBs, rs1051730 GA and AA genotypes were associated with higher NRT response at end of treatment, and rs16969968 GG genotypes were associated with greater NRT response for abstinence at end of therapy.

Genotype comparisons within treatment arms were notable for higher abstinence rates on NRT among NHBs for rs2036527 GG (vs AA or AG) genotypes, and lower abstinence rates among NHBs treated with combination bupropion with NRT for rs1329650 TT (vs GG), and among NHBs for rs3733829 AG or GG (vs AA).

Although we did identify some genotype-treatment interactions and genotype effects within treatment arms, the vast majority of analyses indicated no such results. Significant results should be considered preliminary and interpreted with caution because none of the statistically significant meta-analyses included more than two trials per genotype comparison, many confidence intervals were wide, and the quality of evidence (GRADE) was generally moderate. In addition, our analyses could not adjust for ancestry informative markers; thus, these findings have the potential to be confounded by population stratification.

Implications for research

We observed that smokers with slow NMR on NRT patch demonstrated higher abstinence rates than smokers with normal NMR on NRT patch. Our meta-analyses did not detect heterogeneity in NRT patch efficacy (active vs placebo patch) between NMR groups, which could be a function of statistical power or lack of superior efficacy for slow metabolisers. Data provided by extant trials would increase the reliability of effect estimates and confidence in determining the potential clinical utility of NMR to guide selection of NRT versus an alternative treatment. In particular, access to individual participant data (IPD) would be desirable, as this may help to improve the quantity and quality of data, while standardising outcomes across included trials and enabling detailed data checking (Debray 2015; Tierney 2015). IPD offer greater flexibility in investigating effect modifiers and appear to be particularly useful for addressing genotype-treatment interactions. Increases in data sharing by randomised controlled trials (RCTs) reporting response to treatment GWAS summary statistics (e.g. as exemplified by sharing of the response to treatment summary result from the Clinical Antipsychotic Trials of Intervention Effectiveness) may provide the catalyst to encourage future replications and meta-analyses (McClay 2011).

Recent methodological advances may facilitate the design and analysis of such predictive trials (e.g. the adaptive signature design and the cross-validated adaptive signature design are clinical trial designs used for development and validation of high-dimensional biosignatures within single trials) (Freidlin 2005; Freidlin 2010). In a setting with SNP markers routinely available for patients, and with genomic architecture and genome-wide significant single-nucleotide polymorphisms (SNPs) known for nicotine dependence behavioural components, development and validation of predictive genomic signatures for response to smoking cessation therapies might begin (Sun 2015; Weiss 2016). Additionally, polygenic risk scores could be helpful, as even if many individual markers produce no detected effect on their own, combined scores could serve as a strong predictor of outcomes (Dudbridge 2013).

Prediction of response to smoking cessation pharmacotherapies based on genomic information is a complex issue that poses challenges for the design and analysis of clinical trials. As genotyping costs continue to fall, it is important that existing and future pharmacotherapy trials interrogate genome-wide variation to identify biomarkers that predict treatment response for future

assessment of clinical utility. Availability of genome-wide data enables correction of population genetic variation in genome-wide association studies, as exemplified in Pharmacogenomics of Nicotine Addiction Treatment (PNAT) Consortium Group RCT analyses, as well as examination of effects of genetic ancestry on treatment efficacy, as observed in analyses of response to treatment for tobacco dependence, major depression, and schizophrenia (Adkins 2013; Bress 2015; Murphy 2013). Genome-wide genotype data will permit examination of multiple a priori SNPs in risk score format for treatment response, along with novel searches for SNPs associated with response to treatment at

genome-wide significance, as has recently been accomplished in relatively modest samples for lithium and bipolar disorder (Hou 2016; Uhl 2014).

ACKNOWLEDGEMENTS

We acknowledge all principal investigators who provided their study data to us. Furthermore, we acknowledge the assistance of Alexandros Christodoulou-Rubalcava in drafting the protocol of this review, and the support of Lindsay Stead in identifying relevant literature.

REFERENCES

References to studies included in this review

Ahluwalia 2006 {published data only}

- * Ahluwalia JS, Okuyemi K, Nollen N, Choi WS, Kaur H, Pulvers K, et al. The effects of nicotine gum and counseling among African American light smokers: a 2 × 2 factorial design. *Addiction* 2006;**101**(6):883-91.

Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. *Clinical Pharmacology & Therapeutics* 2009;**85**(6):635-43.

Zhu AZ, Zhou Q, Cox LS, David SP, Ahluwalia JS, Benowitz NL, et al. Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers. *Clinical Pharmacology & Therapy* 2014;**96**(2):256-65.

Aveyard 2007 {published and unpublished data}

- * Aveyard P, Brown K, Saunders C, Alexander A, Johnstone E, Munafò MR, et al. Weekly versus basic smoking cessation support in primary care: a randomised controlled trial. *Thorax* 2007;**62**(10):898-903. [PUBMED: 17483139]

David SP, Johnstone EC, Churchman M, Aveyard P, Murphy MF, Munafò MR. Pharmacogenetics of smoking cessation in general practice: results from the Patch II and Patch in Practice trials. *Nicotine & Tobacco Research* 2011;**13**(3):157-67.

David SP, Johnstone EC, Murphy MF, Aveyard P, Guo B, Lerman C, et al. Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses. *Drug and Alcohol Dependence* 2008;**98**(1-2):77-85.

Munafò MR, Johnstone EC, Guo B, Murphy MF, Aveyard P. Association of COMT Val108/158Met genotype with smoking cessation. *Pharmacogenetics and Genomics* 2008;**18**(2):121-8.

Munafò MR, Johnstone EC, Murphy MF, Aveyard P. Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. *Nicotine & Tobacco Research* 2009;**11**(4):404-7.

Munafò MR, Johnstone EC, Walther D, Uhl GR, Murphy MF, Aveyard P. CHRNA3 rs1051730 genotype and short-term smoking cessation. *Nicotine & Tobacco Research* 2011;**13**(10):982-8.

Spruelli T, Colavita G, Donegan T, Egawhary M, Hurley M, Aveyard P, et al. Association between nicotinic acetylcholine receptor single nucleotide polymorphisms and smoking cessation. *Nicotine & Tobacco Research* 2012;**14**(8):993-7.

Uhl GR, Drgon T, Johnson C, Walther D, David SP, Aveyard P, et al. Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement. *Pharmacogenomics* 2010;**11**(3):357-67.

Bloch 2010 {published data only}

- * Bloch B, Reshef A, Cohen T, Tafla A, Gathas S, Israel S, et al. Preliminary effects of bupropion and the promoter region (HTTLPR) serotonin transporter (SLC6A4) polymorphism on smoking behavior in schizophrenia. *Psychiatry Research* 2010;**175**(1-2):38-42.

Brown 2007 {published and unpublished data}

- * Brown RA, Niaura R, Lloyd-Richardson EE, Strong DR, Kahler CW, Abrantes AM, et al. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. *Nicotine & Tobacco Research* 2007;**9**(7):721-30.

David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafò MR, et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. *Nicotine & Tobacco Research* 2007;**9**(8):821-33.

David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafò MR, et al. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. *Addiction* 2013;**108**(12):2202-11.

David SP, Strong DR, Munafò MR, Brown RA, Lloyd-Richardson EE, Wileyto PE, et al. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. *Nicotine & Tobacco Research* 2007;**9**(12):1251-7.

Leventhal AM, David SP, Brightman M, Strong D, McGeary JE, Brown RA, et al. Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. *Pharmacogenomics Journal* 2012;**12**(1):86-92.

Cinciripini 2005 {published data only}

Cinciripini P, Wetter D, Tomlinson G, Tsoh J, De Moor C, Cinciripini L, et al. The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. *Nicotine & Tobacco Research* 2004;**6**(2):229-39.

- * Cinciripini PM, Tsoh JY, Wetter DW, Lam C, de Moor C, Cinciripini L, et al. Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. *Experimental & Clinical Psychopharmacology* 2005;**13**(4):282-92.

Cox 2012 {published data only}

- * Cox LS, Nollen NL, Mayo MS, Choi WS, Faseru B, Benowitz NL, et al. Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. *Journal of the National Cancer Institute* 2012;**104**(4):290-8.

Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, et al. CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. *Clinical Pharmacology & Therapeutics* 2012;**92**(6):771-7.

Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, Tyndale RF. Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted

smoking cessation outcomes. *Drug Metabolism & Disposition* 2014;**42**(11):1971-7.

Zhu AZ, Zhou Q, Cox LS, David SP, Ahluwalia JS, Benowitz NL, et al. Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers. *Clinical Pharmacology & Therapeutics* 2014;**96**(2):256-65.

Gilbert 2009 {published and unpublished data}

* Gilbert DG, Zuo Y, Rabinovich NE, Riise H, Needham R, Huggenvik JI. Neurotransmission-related genetic polymorphisms, negative affectivity traits, and gender predict tobacco abstinence symptoms across 44 days with and without nicotine patch. *Journal of Abnormal Psychology* 2009;**118**(2):322-34.

Gonzales 2006 {published data only}

* Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA* 2006;**296**(1):47-55.

King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. *Neuropsychopharmacology* 2012;**37**(3):641-50.

GPRG 1993 {published and unpublished data}

David SP, Johnstone EC, Churchman M, Aveyard P, Murphy MF, Munafò MR. Pharmacogenetics of smoking cessation in general practice: results from the Patch II and Patch in Practice trials. *Nicotine & Tobacco Research* 2011;**13**(3):157-67.

David SP, Munafò MR, Murphy MF, Proctor M, Walton RT, Johnstone EC. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. *Pharmacogenomics Journal* 2008;**8**(2):122-8.

David SP, Munafò MR, Murphy MF, Walton RT, Johnstone EC. The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. *Nicotine & Tobacco Research* 2007;**9**(2):225-31.

* Imperial Cancer Research Fund General Practice Research Group. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice.. *BMJ* 1993;**306**(6888):1304-8.

Johnstone EC, Elliot KM, David SP, Murphy MF, Walton RT, Munafò MR. Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. *Cancer Epidemiology Biomarkers & Prevention* 2007;**16**(6):1065-9.

Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. *Pharmacogenetics* 2004;**14**(2):83-90.

Munafò MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC. Association of the mu-opioid receptor gene with smoking cessation. *Pharmacogenomics Journal* 2007;**7**(5):353-61.

Munafò MR, Johnstone EC, Walther D, Uhl GR, Murphy MF, Aveyard P. CHRNA3 rs1051730 genotype and short-term smoking cessation. *Nicotine & Tobacco Research* 2011;**13**(10):982-8.

Hall 2008 {published and unpublished data}

Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. *Nicotine & Tobacco Research* 2014;**16**(12):1638-46.

Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. *Pharmacogenetics and Genomics* 2013;**23**(2):94-103.

* Hall SM, Humfleet GL, Gorecki JA, Muñoz RF, Reus VI, Prochaska JJ. Older versus younger treatment-seeking smokers: differences in smoking behavior, drug and alcohol use, and psychosocial and physical functioning. *Nicotine & Tobacco Research* 2008;**10**(3):463-70.

Hall 2009 {published and unpublished data}

Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. *Nicotine & Tobacco Research* 2014;**16**(12):1638-46.

Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. *Pharmacogenetics and Genomics* 2013;**23**(2):94-103.

* Hall SM, Humfleet GL, Muñoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. *Addiction* 2009;**104**(6):1043-52.

Jorenby 2006 {published data only}

* Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.. *JAMA* 2006;**296**(1):56-63.

King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. *Neuropsychopharmacology* 2012;**37**(3):641-50.

Kalman 2011 {published data only}

* Kalman D, Herz L, Monti P, Kahler CW, Mooney M, Rodrigues S, et al. Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study. *Drug and Alcohol Dependence* 2011;**118**(2-3):111-8.

McGeary JE, Knopik VS, Hayes JE, Palmer RH, Monti PM, Kalman D. Predictors of relapse in a bupropion trial for smoking cessation in recently-abstinent alcoholics: preliminary results using an aggregate genetic risk score. *Substance Abuse* 2012;**6**:107-14.

Killen 2006 {published data only}

* Killen JD, Fortmann SP, Murphy GM Jr, Hayward C, Arredondo C, Cromp D, et al. Extended treatment with bupropion SR for cigarette smoking cessation. *Journal of Consulting and Clinical Psychology* 2006;**74**(2):286-94.

Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Schatzberg AF, et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. *American Journal of Medical Genetics B Neuropsychiatric Genetics* 2011;**156B**(3):275-84.

Killen 2008 {published data only}

* Killen JD, Fortmann SP, Schatzberg AF, Arredondo C, Murphy G, Hayward C, et al. Extended cognitive behavior therapy for cigarette smoking cessation. *Addiction* 2008;**103**(8):1381-90.

Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Schatzberg AF, et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics* 2011;**156B**(3):275-84.

Killen 2010 {published data only}

* Killen JD, Fortmann SP, Murphy GM Jr, Hayward C, Fong D, Lowenthal K, et al. Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. *Addiction* 2010;**105**(9):1660-8.

Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Ameli N, et al. Response to transdermal selegiline smoking cessation therapy and markers in the 15q24 chromosomal region. *Nicotine & Tobacco Research* 2015;**17**(9):1126-33.

Lerman 2002 {published and unpublished data}

Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. *Nicotine & Tobacco Research* 2014;**16**(12):1638-46.

Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. *Pharmacogenetics and Genomics* 2013;**23**(2):94-103.

Bergen AW, Javitz HS, Su L, He Y, Conti DV, Benowitz NL, et al. The DRD4 exon III VNTR, bupropion, and associations with prospective abstinence. *Nicotine & Tobacco Research* 2013;**15**(7):1190-200.

Berrettini WH, Wileyto EP, Epstein L, Restine S, Hawk L, Shields P, et al. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. *Biological Psychiatry* 2007;**61**(1):111-8.

Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD, et al. Pharmacogenetics of Nicotine Addiction and Treatment Consortium. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. *Human Molecular Genetics* 2008;**17**(18):2834-48.

David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafò MR, et al. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. *Addiction* 2013;**108**(12):2202-11.

Gold AB, Wileyto EP, Lori A, Conti D, Cubells JF, Lerman C. Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation. *Neuropsychopharmacology* 2012;**37**(7):1683-8.

Heitjan DF, Guo M, Ray R, Wileyto EP, Epstein LH, Lerman C. Identification of pharmacogenetic markers in smoking cessation therapy. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics* 2008;**147B**(6):712-9.

Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, et al. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. *Biological Psychiatry* 2007;**62**(6):635-41.

Lee W, Bergen AW, Swan GE, Li D, Liu J, Thomas P, et al. Gender-stratified gene and gene-treatment interactions in smoking cessation. *Pharmacogenomics Journal* 2012;**12**(6):521-32.

Lee W, Ray R, Bergen AW, Swan GE, Thomas P, Tyndale RF, et al. DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers. *Pharmacogenetics and Genomics* 2012;**22**(7):551-4.

* Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, et al. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. *Drug and Alcohol Dependence* 2002;**67**(2):219-23.

Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr, Pinto A, et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. *Health Psychology* 2003;**22**(5):541-8.

Leventhal AM, Lee W, Bergen AW, Swan GE, Tyndale RF, Lerman C, et al. Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. *Drug and Alcohol Dependence* 2014;**138**:109-17.

Lerman 2004 {published and unpublished data}

Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. *Pharmacogenetics and Genomics* 2013;**23**(2):94-103.

Gold AB, Wileyto EP, Lori A, Conti D, Cubells JF, Lerman C. Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation. *Neuropsychopharmacology* 2012;**37**(7):1683-8.

Hutchison KE, Allen DL, Filbey FM, Jepson C, Lerman C, Benowitz NL, et al. CHRNA4 and tobacco dependence: from

gene regulation to treatment outcome. *Archives of General Psychiatry* 2007;**64**(9):1078-86.

Lee AM, Jepson C, Shields PG, Benowitz N, Lerman C, Tyndale RF. CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. *Cancer Epidemiology Biomarkers & Prevention* 2007;**16**(6):1312-4.

Lee W, Bergen AW, Swan GE, Li D, Liu J, Thomas P, et al. Gender-stratified gene and gene-treatment interactions in smoking cessation. *Pharmacogenomics Journal* 2012;**12**(6):521-32.

Lee W, Ray R, Bergen AW, Swan GE, Thomas P, Tyndale RF, et al. DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers. *Pharmacogenetics and Genomics* 2012;**22**(7):551-4.

* Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. *Annals of Internal Medicine* 2004;**140**(6):426-33.

Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. *Pharmacogenomics Journal* 2004;**4**(3):184-92.

Leventhal AM, Lee W, Bergen AW, Swan GE, Tyndale RF, Lerman C, et al. Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. *Drug and Alcohol Dependence* 2014;**138**:109-17.

Ray R, Jepson C, Wileyto EP, Dahl JP, Patterson F, Rukstalis M, et al. Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial. *Nicotine & Tobacco Research* 2007;**9**(11):1237-41.

Ray R, Mitra N, Baldwin D, Guo M, Patterson F, Heitjan DF, et al. Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. *Neuropsychopharmacology* 2010;**35**(6):1374-82.

Lerman 2015 {published data only}

* Lerman C, Schnoll RA, Hawk LW Jr, Cinciripini P, George TP, Wileyto EP, et al. PGRN-PNAT Research Group. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. *Lancet Respiratory Medicine* 2015;**3**(2):131-8.

Tyndale RF, Zhu AZ, George TP, Cinciripini P, Hawk LW Jr, Schnoll RA, et al. PGRN-PNAT Research Group. Lack of associations of CHRNA5-A3-B4 genetic variants with smoking cessation treatment outcomes in Caucasian smokers despite associations with baseline smoking. *PLoS One* 2015;**10**(5):e0128109.

Marteau 2012 {published and unpublished data}

* Marteau TM, Aveyard P, Munafò MR, Prevost AT, Hollands GJ, Armstrong D, et al. Effect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: a randomised controlled trial. *PLoS One* 2014;**7**(4):e35249.

Munafò MR, Johnstone EC, Aveyard P, Marteau T. Lack of association of OPRM1 genotype and smoking cessation. *Nicotine & Tobacco Research* 2013;**15**(3):739-44.

McCarthy 2008 {published and unpublished data}

Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. *Nicotine & Tobacco Research* 2014;**16**(12):1638-46.

Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. *Pharmacogenetics and Genomics* 2013;**23**(2):94-103.

* McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC, et al. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. *Nicotine & Tobacco Research* 2008;**10**(4):717-29.

Oncken 2006 {published data only}

* Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. *Archives of Internal Medicine* 2006;**166**(15):151-7.

Piper 2007 {published and unpublished data}

Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. *Nicotine & Tobacco Research* 2014;**16**(12):1638-46.

Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. *Pharmacogenetics and Genomics* 2013;**23**(2):94-103.

* Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, et al. Efficacy of bupropion alone and in combination with nicotine gum. *Nicotine & Tobacco Research* 2007;**9**(9):947-54.

Piper 2009 {published and unpublished data}

Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. *Nicotine & Tobacco Research* 2014;**16**(12):1638-46.

Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. *Pharmacogenetics and Genomics* 2013;**23**(2):94-103.

Chen LS, Baker TB, Piper ME, Breslau N, Cannon DS, Doheny KF, et al. Interplay of genetic risk factors (CHRNA5-CHRNA3-

CHRNA4) and cessation treatments in smoking cessation success. *American Journal of Psychiatry* 2012;**169**(7):735-42.

Chen LS, Bloom AJ, Baker TB, Smith SS, Piper ME, Martinez M, et al. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). *Addiction* 2014;**109**(1):128-37.

* Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. *Archives of General Psychiatry* 2009;**66**(11):1253-62.

Rose 2010 {published data only}

* Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. *Molecular Medicine* 2010;**16**(7-8):247-53.

Schnoll 2010 {published data only}

Gold AB, Wileyto EP, Lori A, Conti D, Cubells JF, Lerman C. Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation. *Neuropsychopharmacology* 2012;**37**(7):1683-8.

Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. *Clinical Pharmacology & Therapeutics* 2010;**87**(5):553-7.

* Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. *Annals of Internal Medicine* 2010;**152**(3):144-51.

Sun 2012 {published data only}

* Sun H, Guo S, Chen D, Yang F, Zou Y, Di X, et al. Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy. *Journal of Neural Transmission (Vienna)* 2012;**119**(12):1491-8.

Swan 2003 {published data only}

Swan GE, Jack LM, Valdes AM, Ring HZ, Ton CC, Curry SJ, et al. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. *Health Psychology* 2007;**26**(3):361-8.

* Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. *Archives of Internal Medicine* 2003;**163**(19):2337-44.

Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, Ton CC, et al. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. *Pharmacogenomics Journal* 2005;**5**(1):21-9.

Swan 2010 {published and unpublished data}

Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. *Nicotine & Tobacco Research* 2014;**16**(12):1638-46.

Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. *Pharmacogenetics and Genomics* 2013;**23**(2):94-103.

* Swan GE, McClure JB, Jack LM, Zbikowski SM, Javitz HS, Catz SL, et al. Behavioral counseling and varenicline treatment for smoking cessation. *American Journal of Preventive Medicine* 2010;**38**(5):482-90.

Verde 2014 {published data only}

Verde Z, Santiago C, Rodríguez González-Moro JM, de Lucas Ramos P, López Martín S, Bandrés F, et al. Are serotonergic system genes associated to smoking cessation therapy success in addition to CYP2A6? *Pharmacopsychiatry* 2014;**47**(1):33-6. [PUBMED: 24127329]

Wagena 2005 {published data only}

Quaak M, van Schayck CP, Postma DS, Wagena EJ, van Schooten FJ. Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation. *Addiction* 2012;**107**(1):178-87.

* Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayck CP. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. *Archives of Internal Medicine* 2005;**165**(19):2286-92.

Wilcox 2011 {published data only}

* Wilcox CS, Noble EP, Oskooilar N. ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data. *Journal of Investigative Medicine* 2011;**59**(8):1280-3.

Winst 2006 {published and unpublished data}

De Ruyck K, Nackaerts K, Beels L, Werbruggen J, De Volder A, Meysman M, et al. Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. *Pharmacogenomics* 2010;**11**(8):1053-63.

References to studies excluded from this review

Baker 2009 {published data only}

* Baker TB, Weiss RB, Bolt D, von Niederhausen A, Fiore MC, Dunn DM, et al. Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. *Nicotine & Tobacco Research* 2009;**11**(7):785-96.

Becker 2008 {published data only}

* Becker KM, Rose JE, Albino AP. A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation. *Nicotine & Tobacco Research* 2008;**10**(7):1139-48.

Uhl 2007 {published data only}

* Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE. Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs. *BMC Genetics* 2007;**8**:10.

Additional references

1000 Genomes Project Consortium 2015

1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for human genetic variation. *Nature* 2015;**526**(7571):68-74. [PUBMED: 26432245]

Adkins 2013

Adkins DE, Souza RP, Aberg K, Clark SL, McClay JL, Sullivan PF, et al. Genotype-based ancestral background consistently predicts efficacy and side effects across treatments in CATIE and STAR*D. *PLoS One* 2013;**8**(2):e55239. [PUBMED: 23405125]

Agrawal 2012

Agrawal A, Verweij KJ, Gillespie NA, Heath AC, Lessov-Schlaggar CN, Martin NG, et al. The genetics of addiction - a translational perspective. *Translational Psychiatry* 2012;**2**(e140):1-14. [PUBMED: 22806211]

Aguirre-Samudio 2014

Aguirre-Samudio AJ, Cruz-Fuentes CS, González-Sobrino BZ, Gutiérrez-Pérez V, Medrano-González L. Haplotype and nucleotide variation in the exon 3-VNTR of the DRD4 gene from indigenous and urban populations of Mexico. *Am J Hum Biol* 2014;**26**(5):682-9. [PUBMED: 24979719]

Attia 2009

Attia J, Ioannidis JP, Thakkinstian A, McEvoy M, Scott RJ, Minelli C, et al. How to use an article about genetic association: A: background concepts. *JAMA* 2009;**301**(1):74-81. [PUBMED: 19126812]

Balfour 2009

Balfour DJ. The neuronal pathways mediating the behavioral and addictive properties of nicotine. *Handbook of Experimental Pharmacology* 2009;**192**:209-33. [PUBMED: 19184651]

Begg 1994

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;**50**(4):1088-101. [PUBMED: 7786990]

Beirut 2008

Beirut LJ, Stitzel JA, Wang JC, Hinrichs AL, Gruzca RA, Xuei X, et al. Variants in nicotinic receptors and risk for nicotine dependence. *American Journal of Psychiatry* 2008;**165**(9):1163-71. [PUBMED: 18519524]

Benjamini 2014

Benjamini Y, Bogomolov M. Selective inference on multiple families of hypotheses. *Journal of the Royal Statistical Society Series B* 2014;**76**(1):297-318.

Benowitz 2006

Benowitz NL, Swan GE, Jacob P 3rd, Lessov-Schlaggar CN, Tyndale RF. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. *Clinical Pharmacology and Therapeutics* 2006;**80**(5):457-67. [PUBMED: 17112802]

Benowitz 2009

Benowitz NL, Hukkanen J, Jacob P 3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. *Handbook of Experimental Pharmacology* 2009;**192**:29-60. [PUBMED: 19184645]

Benowitz 2013

Benowitz NL, Zhu AZ, Tyndale RF, Dempsey D, Jacob P 3rd. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. *Pharmacogenetics and Genomics* 2013;**23**(3):135-41. [PUBMED: 23344581]

Bergen 2013

Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. *Pharmacogenetics and Genomics* 2013;**23**(2):94-103. [PUBMED: 23249876]

Bergen 2014

Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. *Nicotine & Tobacco Research* 2014;**16**(12):1638-46. [PUBMED: 25143296]

Bidwell 2016

Bidwell LC, Palmer RH, Brick L, McGeary JE, Knopik VS. Genome-wide single nucleotide polymorphism heritability of nicotine dependence as a multidimensional phenotype. *Psychological Medicine* 2016;**46**(10):2059-69. [PUBMED: 27052577]

Bloom 2012

Bloom AJ, Harari O, Martinez M, Madden PA, Martin NG, Montgomery GW, et al. Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. *Human Molecular Genetics* 2012;**21**(13):3050-62. [PUBMED: 22451501]

Bress 2015

Bress A, Kittles R, Wing C, Hooker SE Jr, King A. Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial. *Pharmacogenetics and Genomics* 2015;**25**(6):305-12. [PUBMED: 25918964]

Broms 2006

Broms U, Silventoinen K, Madden PA, Heath AC, Kaprio J. Genetic architecture of smoking behavior: a study of Finnish adult twins. *Twin Research and Human Genetics* 2006;**9**(1):64-72. [PUBMED: 16611469]

Cahill 2012

Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database of Systematic Reviews* 2012, Issue 4. [DOI: [10.1002/14651858.CD006103.pub6](https://doi.org/10.1002/14651858.CD006103.pub6); PUBMED: 22513936]

Cahill 2013

Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network

meta-analysis. *Cochrane Database of Systematic Reviews* 2013;**5**:CD009329. [PUBMED: 23728690]

Cahill 2016

Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database of Systematic Reviews* 2016;**9**(5):CD006103.

Canova 2009

Canova C, Hashibe M, Simonato L, Nelis M, Metspalu A, Lagiou P, et al. Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. *Cancer Research* 2009;**69**(7):2956-65. [PUBMED: 19339270]

Cardon 2000

Cardon LR, Idury RM, Harris TJ, Witte JS, Elston RC. Testing drug response in the presence of genetic information: sampling issues for clinical trials. *Pharmacogenetics* 2000;**10**(6):503-10. [PUBMED: 10975604]

Cardon 2003

Cardon LR, Palmer LJ. Population stratification and spurious allelic association. *Lancet* 2003;**361**(9357):598-604. [PUBMED: 12598158]

Carmelli 1992

Carmelli D, Swan GE. Genetic influence on smoking - a study of male twins. *New England Journal of Medicine* 1992;**327**(12):829-33. [PUBMED: 1508241]

Chen 2012

Chen LS, Baker TB, Piper ME, Breslau N, Cannon DS, Doheny KF, et al. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNA4) and cessation treatments in smoking cessation success. *American Journal of Psychiatry* 2012;**169**(7):735-42. [PUBMED: 22648373]

Chen 2014

Chen LS, Bloom AJ, Baker TB, Smith SS, Piper ME, Martinez M, et al. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). *Addiction* 2014;**109**(1):128-37. [PUBMED: 24033696]

Chen 2017

Chen LS, Zawertailo L, Piasecki T, Kaprio J, Foreman M, Elliott H, et al. Genetics and Treatment Workgroup of the Society for Research on Nicotine and Tobacco (SRNT). Leveraging genomic data in smoking cessation trials in the era of Precision Medicine: why and how. *Nicotine & Tobacco Research* 2017 May 12;(manuscript in press). [PUBMED: 28498934]

Chenoweth 2017

Chenoweth MJ, Tyndale RF. Pharmacogenetic optimization of smoking cessation treatment. *Trends in Pharmacological Science* 2017;**38**(1):55-66. [PUBMED: 27712845]

David 2007

David SP, Munafò MR, Murphy MF, Walton RT, Johnstone EC. The serotonin transporter 5-HTTLPR polymorphism and treatment

response to nicotine patch: follow-up of a randomized controlled trial. *Nicotine & Tobacco Research* 2007;**9**(2):225-31.

David 2008

David SP, Johnstone EC, Murphy MF, Aveyard P, Guo B, Lerman C, et al. Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses. *Drug and Alcohol Dependence* 2008;**98**(1-2):77-85. [PUBMED: 18562131]

David 2008a

David SP, Munafò MR, Murphy MF, Proctor M, Walton RT, Johnstone EC. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. *Pharmacogenomics Journal* 2008;**8**(2):122-8.

David 2011

David SP, Johnstone EC, Churchman M, Aveyard P, Murphy MF, Munafò MR. Pharmacogenetics of smoking cessation in general practice: results from the Patch II and Patch in Practice trials. *Nicotine & Tobacco Research* 2011;**13**(3):157-67. [PUBMED: 21330274]

David 2012

David SP, Hamidovic A, Chen GK, Bergen AW, Wessel J, Kasberger JL, et al. Genome-wide meta-analyses of smoking behaviors in African Americans. *Translational Psychiatry* 2012;**2**:e119. [PUBMED: 22832964]

David 2013a

David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafò MR, et al. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. *Addiction* 2013;**108**(12):2202-11.

De Ruyck 2010

De Ruyck K, Nackaerts K, Beels L, Werbrouck J, De Volder A, Meysman M, et al. Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. *Pharmacogenomics* 2010;**11**(8):1053-63.

Debray 2015

Debray TP, Moons KG, van Valkenhoef G, Efthimiou O, Hummel N, Groenwold RH, et al. GetReal Methods Review Group. Get real in individual participant data (IPD) meta-analysis: a review of the methodology. *Research Synthesis Methods* 2015;**6**:293-309. [PUBMED: 26287812]

Dempsey 2004

Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, Tyndale RF, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. *Clinical Pharmacology & Therapeutics* 2004;**76**(1):64-72. [PUBMED: 15229465]

Drgon 2009

Drgon T, Johnson C, Walther D, Albino AP, Rose JE, Uhl GR. Genome-wide association for smoking cessation success: participants in a trial with adjunctive denicotinized cigarettes. *Molecular Medicine* 2009;**15**(7-8):268-74. [PUBMED: 19593411]

Dudbridge 2013

Dudbridge F. Power and predictive accuracy of polygenic risk scores. *PLoS Genetics* 2013;**9**(3):e1003348. [PUBMED: 23555274]

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**(7109):629-34. [PUBMED: 9310563]

European Smoking Cessation Guidelines 2012

Behrakis PK, Bilir N, Clancy L, Dautzenberg B, Demin AK, Gilljam H, et al. for the European Network for Smoking and Tobacco Prevention (ENSP). European Smoking Cessation Guidelines: The authoritative guide to a comprehensive understanding of the implications and implementation of treatments and strategies to treat tobacco dependence. http://ensp.org/wp-content/uploads/2016/12/ENSP-ESCG_FINAL.pdf 2012.

Fiore 2008

Fiore MC, Jaen CR, Baker TB. Clinical practice guideline - treating tobacco use and dependence: 2008 update. Rockville, MD: US Department of Health and Human Services, 2008; US Preventive Services Task Force. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: recommendation statement. *American Family Physician* 2016;**93**:860A-G.

Fisher 1958

Fisher RA. Lung cancer and cigarettes?. *Nature* 1958;**182**(4628):108. [PUBMED: 13566198]

Fowler 2011

Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ. Habenular $\alpha 5$ nicotinic receptor subunit signalling controls nicotine intake. *Nature* 2011;**471**(7340):597-601. [PUBMED: 21278726]

Freathy 2009

Freathy RM, Ring SM, Shields B, Galobardes B, Knight B, Weedon MN, et al. A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNA4) is associated with a reduced ability of women to quit smoking in pregnancy. *Human Molecular Genetics* 2009;**18**(15):2922-7. [PUBMED: 19429911]

Freidlin 2005

Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. *Clinical Cancer Research* 2005;**11**(21):7872-8. [PUBMED: 16278411]

Freidlin 2010

Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design. *Clinical Cancer Research* 2010;**16**(2):691-8. [PUBMED: 20068112]

Fujieda 2004

Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M, et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related

lung cancer risk in male Japanese smokers. *Carcinogenesis* 2004;**25**(12):2451-8. [PUBMED: 15308589]

Gemignani 2007

Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, et al. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. *Carcinogenesis* 2007;**28**(6):1287-93. [PUBMED: 17259654]

Giovino 2012

Giovino GA, Mirza SA, Samet JM, Gupta PC, Jarvis MJ, Bhala N, et al. GATS Collaborative Group. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. *Lancet* 2012;**380**(9842):668-79. [PUBMED: 22901888]

Gold 2012

Gold AB, Wileyto EP, Lori A, Conti D, Cubells JF, Lerman C. Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation. *Neuropsychopharmacology* 2012;**37**(7):1683-8.

Hadjiconstantinou 2011

Hadjiconstantinou M, Neff NH. Nicotine and endogenous opioids: neurochemical and pharmacological evidence. *Neuropharmacology* 2011;**60**(7-8):1209-20. [PUBMED: 21108953]

Heath 2002

Heath AC, Martin NG, Lynskey MT, Todorov AA, Madden PA. Estimating two-stage models for genetic influences on alcohol, tobacco or drug use initiation and dependence vulnerability in twin and family data. *Twin Research* 2002;**5**(2):113-24. [PUBMED: 11931689]

Herman 2014

Herman AI, DeVito EE, Jensen KP, Sofuoglu M. Pharmacogenetics of nicotine addiction: role of dopamine. *Pharmacogenomics* 2014;**15**(2):221-34. [PUBMED: 24444411]

Higgins 2003

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**(7414):557-60.

Higgins 2011

Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. www.cochrane-handbook.org.

Ho 2009

Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. *Clinical Pharmacology & Therapeutics* 2009;**85**(6):635-43. [PUBMED: 19279561]

Hou 2016

Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. *Lancet* 2016;**387**(10023):1085-93. [PUBMED: 26806518]

Hughes 2014

Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. *Cochrane Database of Systematic Reviews* 2014, Issue 1. [DOI: [10.1002/14651858.CD000031.pub4](https://doi.org/10.1002/14651858.CD000031.pub4); PUBMED: 24402784]

Johnstone 2004

Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. *Pharmacogenetics* 2004;**14**(2):83-90.

Johnstone 2006

Johnstone E, Benowitz N, Cargill A, Jacob R, Hinks L, Day I, et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior. *Clinical Pharmacology & Therapeutics* 2006;**80**(4):319-30. [PUBMED: 17015050]

Johnstone 2007

Johnstone EC, Elliot KM, David SP, Murphy MF, Walton RT, Munafò MR. Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. *Cancer Epidemiology Biomarkers & Prevention* 2007;**16**(6):1065-9.

King 2012

King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. *Neuropsychopharmacology* 2012;**37**(3):641-50. [PUBMED: 22048466]

Kotz 2014

Kotz D, Brown J, West R. Prospective cohort study of the effectiveness of smoking cessation treatments used in the "real world". *Mayo Clinic Proceedings* 2014;**89**(10):1360-7. [PUBMED: 25282429]

Landi 2009

Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. *American Journal of Human Genetics* 2009;**85**(5):679-91. [PUBMED: 19836008]

Lerman 2006

Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. *Clinical Pharmacology & Therapeutics* 2006;**79**(6):600-8. [PUBMED: 16765148]

Lerman 2010

Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. *Clinical Pharmacology and Therapeutics* 2010;**87**(5):553-7. [PUBMED: 20336063]

Leung 2015

Leung T, Bergen A, Munafò MR, De Ruyck K, Selby P, De Luca V. Effect of the rs1051730-rs16969968 variant and smoking cessation treatment: a meta-analysis. *Pharmacogenomics* 2015;**16**(7):713-20. [PUBMED: 25950378]

Leventhal 2012

Leventhal AM, David SP, Brightman M, Strong D, McGeary JE, Brown RA, et al. Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. *Pharmacogenomics Journal* 2012;**12**(1):86-92. [PUBMED: 20661272]

Leventhal 2014

Leventhal AM, Lee W, Bergen AW, Swan GE, Tyndale RF, Lerman C, et al. Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. *Drug and Alcohol Dependence* 2014;**1**(138):109-17. [PUBMED: 24667010]

Li 2003

Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. *Addiction* 2003;**98**(1):23-31. [PUBMED: 12492752]

Liu 2010

Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. *Nature Genetics* 2010;**42**(5):436-40. [PUBMED: 20418889]

Liu 2011

Liu T, David SP, Tyndale RF, Wang H, Zhou Q, Ding P, et al. Associations of CYP2A6 genotype with smoking behaviors in southern China. *Addiction* 2011;**106**(5):985-94. [PUBMED: 21205058]

Mamoun 2015

Mamoun M, Bergen AW, Shieh J, Wiggins A, Brody AL. Biomarkers of response to smoking cessation pharmacotherapies: progress to date. *CNS Drugs* 2015;**29**(5):359-69. [PUBMED: 25895022]

Matsui 2015

Matsui S, Buyse M, Simon R. Design and Analysis of Clinical Trials for Predictive Medicine. Boca Raton, FL: CRC Press, 2015.

McCaffery 2008

McCaffery JM, Papandonatos GD, Lyons MJ, Koenen KC, Tsuang MT, Niaura R. Educational attainment, smoking initiation and lifetime nicotine dependence among male Vietnam-era twins. *Psychological Medicine* 2008;**38**(9):1287-97. [PUBMED: 17949517]

McClay 2011

McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI, et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. *Molecular Psychiatry* 2011;**16**(1):76-85. [PUBMED: 19721433]

McClure 2013

McClure JB, Swan GE, St John J, Fauver R, Javitz HS, Bergen AW, et al. Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study. *Nicotine & Tobacco Research* 2013;**15**(2):518-26. [PUBMED: 22949583]

McDonagh 2012

McDonagh EM, Wassenaar C, David SP, Tyndale RF, Altman RB, Whirl-Carrillo M, et al. PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. *Pharmacogenetics and Genomics* 2012;**22**(9):695-708. [PUBMED: 22547082]

McGeary 2012

McGeary JE, Knopik VS, Hayes JE, Palmer RH, Monti PM, Kalman D. Predictors of relapse in a bupropion trial for smoking cessation in recently-abstinent alcoholics: preliminary results using an aggregate genetic risk score. *Substance Abuse* 2012;**6**:107-14.

McKay 2008

McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, et al. Lung cancer susceptibility locus at 5p15.33. *Nature Genetics* 2008;**40**(12):1404-6. [PUBMED: 18978790]

Mills 2012

Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. *Annals of Medicine* 2012;**44**(6):588-97. [PUBMED: 22860882]

Munafò 2007

Munafò MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC. Association of the mu-opioid receptor gene with smoking cessation [Association of the mu-opioid receptor gene with smoking cessation]. *Pharmacogenomics Journal* 2007;**7**(5):353-61. [17224915]

Munafò 2008

Munafò MR, Johnstone EC, Guo B, Murphy MF, Aveyard P. Association of COMT Val108/158Met genotype with smoking cessation. *Pharmacogenetics and Genomics* 2008;**18**(2):121-8. [PUBMED: 18192898]

Munafò 2009

Munafò MR, Johnstone EC, Murphy MF, Aveyard P. Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. *Nicotine & Tobacco Research* 2009;**11**(4):404-7. [PUBMED: 19273465]

Munafò 2011

Munafò MR, Johnstone EC, Walther D, Uhl GR, Murphy MF, Aveyard P. CHRNA3 rs1051730 genotype and short-term smoking cessation. *Nicotine & Tobacco Research* 2011;**13**(10):982-8. [PUBMED: 21690317]

Munafò 2012

Munafò MR, Timofeeva MN, Morris RW, Prieto-Merino D, Sattar N, Brennan P, et al. EPIC Study Group, Davey Smith G. Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. *Journal of the National Cancer Institute* 2012;**104**(10):740-8. [PUBMED: 22534784]

Munafò 2013a

Munafò MR, Johnstone EC, Aveyard P, Marteau T. Lack of association of OPRM1 genotype and smoking cessation. *Nicotine & Tobacco Research* 2013;**15**(3):739-44.

Murphy 2013

Murphy E, Hou L, Maher BS, Woldehawariat G, Kassem L, Akula N, et al. Race, genetic ancestry and response to antidepressant treatment for major depression. *Neuropsychopharmacology* 2013;**38**(13):2598-606. [PUBMED: 23827886]

Murphy 2014

Murphy SE, Park SS, Thompson EF, Wilkens LR, Patel Y, Stram DO, et al. Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups. *Carcinogenesis* 2014;**35**(11):2526-33. [PUBMED: 25233931]

Patnode 2015

Patnode CD, Henderson JT, Thompson JH, Senger CA, Fortmann SP, Whitlock EP. Behavioral Counseling and Pharmacotherapy Interventions for Tobacco Cessation in Adults, Including Pregnant Women: A Review of Reviews for the US Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US) 2015 Sep; Vol. Report No.: 14-05200-EF-1. [PUBMED: 26491759]

Patterson 2008

Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. *Clinical Pharmacology & Therapeutics* 2008;**84**(3):320-5. [PUBMED: 18388868]

Pearson 2008

Pearson TA, Manolio TA. How to interpret a genome-wide association study. *JAMA* 2008;**299**(11):1335-44. [PUBMED: 18349094]

Peralta-Leal 2012

Peralta-Leal V, Leal-Ugarte E, Meza-Espinoza JP, Dávalos-Rodríguez IP, Bocanegra-Alonso A, Acosta-González RI, Gonzales E, Nair S, Durán-González J. Association of a serotonin transporter gene (SLC6A4) 5-HTTLPR polymorphism with body mass index categories but not type 2 diabetes mellitus in Mexicans. *Genet Mol Biol* 2012;**35**(3):589-93. [PUBMED: 23055796]

Quaak 2012

Quaak M, Van Schayck CP, Postma DS, Wagena EJ, Van Schooten FJ. Genetic variants in the serotonin transporter

influence the efficacy of bupropion and nortriptyline in smoking cessation. *Addiction* 2012;**107**(1):178-87. [PUBMED: 21658141]

Ray 2007

Ray R, Jepson C, Wileyto EP, Dahl JP, Patterson F, Rukstalis M, et al. Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial. *Nicotine & Tobacco Research* 2007;**9**(11):1237-41. [PUBMED: 17978999]

Review Manager 5.3 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Rotunno 2009

Rotunno M, Yu K, Lubin JH, Consonni D, Pesatori AC, Goldstein AM, et al. Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression. *PLoS One* 2009;**4**(5):e5652. [PUBMED: 19479063]

Saccone 2010

Saccone NL, Culverhouse RC, Schwantes-An TH, Cannon DS, Chen X, Cichon S, et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. *PLoS Genetics* 2010;**6**(8):e1001053. [PUBMED: 20700436]

Saccone 2017

Saccone N, Baurley JW, Bergen AW, David SP, Elliott H, Foreman M, et al. Genetics and Treatment Networks of the Society for Research on Nicotine and Tobacco (SRNT). The value of biosamples in smoking cessation trials: a review of genetic, metabolomic, and epigenetic findings. *Nicotine & Tobacco Research* 2017 May 3;(manuscript in press). [PUBMED: 28472521]

Sarginson 2011

Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Schatzberg AF, et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics* 2011;**156B**(3):275-84.

Sarginson 2015

Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Ameli N, et al. Response to transdermal selegiline smoking cessation therapy and markers in the 15q24 chromosomal region. *Nicotine & Tobacco Research* 2015;**17**(9):1126-33.

Scherf 2012

Scherf DB, Sarkisyan N, Jacobsson H, Claus R, Bermejo JL, Peil B, et al. Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNA4. *Oncogene* 2012;**32**(28):3329-38. [PUBMED: 22945651]

Schnoll 2009

Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study.

Pharmacology, Biochemistry, and Behavior 2009;**92**(1):6-11. [PUBMED: 19000709]

Schoedel 2004

Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult caucasians. *Pharmacogenetics* 2004;**14**(9):615-26. [PUBMED: 15475735]

Spruell 2012

Spruell T, Colavita G, Donegan T, Egawhary M, Hurley M, Aveyard P, et al. Association between nicotinic acetylcholine receptor single nucleotide polymorphisms and smoking cessation. *Nicotine & Tobacco Research* 2012;**14**(8):993-7. [PUBMED: 22180580]

Stead 2012a

Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. *Cochrane Database of Systematic Reviews* 2012, Issue 11. [DOI: [10.1002/14651858.CD000146.pub4](https://doi.org/10.1002/14651858.CD000146.pub4); PUBMED: 23152200]

Stead 2012b

Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. *Cochrane Database of Systematic Reviews* 2012, Issue 12. [DOI: [10.1002/14651858.CD009670.pub2](https://doi.org/10.1002/14651858.CD009670.pub2); PUBMED: 23235680]

Sullivan 2004

Sullivan PF, Neale BM, Van den Oord E, Miles MF, Neale MC, Bulik CM, et al. Candidate genes for nicotine dependence via linkage, epistasis, and bioinformatics. *American Journal of Medical Genetics: Part B Neuropsychiatric Genetics* 2004;**126B**(1):23-36. [PUBMED: 15048644]

Sun 2015

Sun J, Kranzler HR, Bi J. An effective method to identify heritable components from multivariate phenotypes. *PLoS One* 2015;**10**(12):e0144418. [PUBMED: 26658140]

Swan 2005

Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, Ton CC, et al. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. *Pharmacogenomics Journal* 2005;**5**(1):21-9.

Swan 2007

Swan GE, Jack LM, Valdes AM, Ring HZ, Ton CC, Curry SJ, et al. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. *Health Psychology* 2007;**26**(3):361-8.

Tamaki 2011

Tamaki Y, Arai T, Sugimura H, Sasaki T, Honda M, Muroi Y, et al. Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. *Drug Metabolism and Pharmacokinetics* 2011;**26**(5):516-22. [PUBMED: 21791872]

Thorgeirsson 2008

Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. *Nature* 2008;**452**(7187):638-42. [PUBMED: 18385739]

Thorgeirsson 2010

Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, et al. Sequence variants at CHRNA3-CHRNA6 and CYP2A6 affect smoking behavior. *Nature Genetics* 2010;**42**(5):448-53. [PUBMED: 20418888]

Tierney 2015

Tierney JF, Vale C, Riley R, Smith CT, Stewart L, Clarke M, et al. Individual participant data (IPD) meta-analyses of randomised controlled trials: guidance on their use. *PLoS Medicine* 2015;**12**:e1001855. [PUBMED: 26196287]

Tobacco and Genetics Consortium 2010

Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. *Nature Genetics* 2010;**42**(5):441-7. [PUBMED: 20418890]

Topcu 2002

Topcu Z, Chiba I, Fujieda M, Shibata T, Ariyoshi N, Yamazaki H, et al. CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka. *Carcinogenesis* 2002;**23**(4):595-8. [PUBMED: 11960911]

Trinidad 2015

Trinidad DR, Xie B, Fagan P, Pulvers K, Romero DR, Blanco L, et al. Disparities in the population distribution of African American and non-Hispanic white smokers along the quitting continuum. *Health Education & Behavior* 2015;**42**(6):742-51. [PUBMED: 25794519]

True 1997

True WR, Heath AC, Scherrer JF, Waterman B, Goldberg J, Lin N, et al. Genetic and environmental contributions to smoking. *Addiction* 1997;**92**(10):1277-87. [PUBMED: 9489045]

Tyndale 2015

Tyndale RF, Zhu AZ, George TP, Cinciripini P, Hawk LW Jr, Schnoll RA, et al. PGRN-PNAT Research Group. Lack of associations of CHRNA5-A3-B4 genetic variants with smoking cessation outcomes in Caucasian smokers despite associations with baseline smoking. *PLoS One* 2015;**10**(5):e0128109. [PUBMED: 26010901]

Uhl 2008

Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, et al. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. *Archives of General Psychiatry* 2008;**65**(6):683-93. [PUBMED: 18519826]

Uhl 2010

Uhl GR, Drgon T, Johnson C, Walther D, David SP, Aveyard P, et al. Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine

replacement. *Pharmacogenomics* 2011;**11**(3):357-67. [PUBMED: 20235792]

Uhl 2014

Uhl GR, Walther D, Musci R, Fisher C, Anthony JC, Storr CL, et al. Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances. *Molecular Psychiatry* 2014;**19**(1):50-4. [PUBMED: 23128154]

Varadhan 2013

Varadhan R, Segal JB, Boyd CM, Wu AW, Weiss CO. A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. *Journal of Clinical Epidemiology* 2013;**66**(8):818-25. [PUBMED: 23651763]

Verhagen 2012

Verhagen M, Kleinjan M, Engels RC. A systematic review of the A118G (Asn40Asp) variant of OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation. *Pharmacogenomics* 2013;**13**(8):917-33. [PUBMED: 22676196]

Wang 2010

Wang J, Li MD. Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. *Neuropsychopharmacology* 2010;**35**(3):702-19. [PUBMED: 19890259]

Wang 2013

Wang JC, Spiegel N, Bertelsen S, Le N, McKenna N, Budde JP, et al. Cis-regulatory variants affect CHRNA5 mRNA expression in populations of African and European ancestry. *PLoS One* 2013;**8**(11):e80204. [PUBMED: 24303001]

Ware 2012

Ware JJ, Van den Bree M, Munafò MR. From men to mice: CHRNA5/CHRNA3, smoking behavior and disease. *Nicotine & Tobacco Research* 2012;**14**(11):1291-9. [PUBMED: 22544838]

Weiss 2016

Weiss ST. Implementing personalized medicine in the academic health center. *Journal of Personalized Medicine* 2016;**6**(3):E18. [PUBMED: 27657137]

West 2000

West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. *Thorax* 2000;**55**(12):987-99. [PUBMED: 11083883]

Xian 2008

Xian H, Scherrer JF, Grant JD, Eisen SA, True WR, Jacob T, et al. Genetic and environmental contributions to nicotine, alcohol and cannabis dependence in male twins. *Addiction* 2008;**103**(8):1391-8. [PUBMED: 18855830]

Yudkin 2004

Yudkin P, Munafò M, Hey K, Roberts S, Welch S, Johnstone E, et al. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. *BMJ* 2004;**328**(7446):989-90. [PUBMED: 15033882]

Zanetti 2016

Zanetti KA, Wang Z, Aldrich M, Amos CI, Blot WJ, Bowman ED, et al. Genome-wide association study confirms lung cancer susceptibility loci on chromosomes 5p15 and 15q25 in an African-American population. *Lung Cancer* 2016;**98**:33-42. [PUBMED: 27393504]

Zhu 2012

Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, et al. CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. *Clinical Pharmacology & Therapeutics* 2012;**92**(6):771-7. [PUBMED: 23149928]

Zhu 2013

Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, Tyndale RF. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. *PLoS One* 2013;**8**(8):e70938. [PUBMED: 23936477]

Zhu 2014

Zhu AZ, Zhou Q, Cox LS, David SP, Ahluwalia JS, Benowitz NL, et al. Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African American smokers. *Clinical Pharmacology & Therapeutics* 2014;**96**(2):256-65. [PUBMED: 24733007]

References to other published versions of this review

David 2015

Sean P David, Andrew W Bergen, Marcus R Munafò, Ewoud Schuit, Derrick A Bennett, Orestis A. Panagiotou. Genomic analysis to guide choice of treatment for smoking cessation. *Cochrane Database of Systematic Reviews* 3 August 2015. [DOI: [10.1002/14651858.CD011823](https://doi.org/10.1002/14651858.CD011823)]

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Ahluwalia 2006

Methods	2 × 2 factorial randomised clinical trial conducted to evaluate the efficacy of nicotine gum and counseling for African American light smokers (the "Kick It at Swope II Trial" (KIS-II)) Study period: March 2003 to June 2004
Participants	N = 755 Participants were recruited using clinic, media, and community outreach efforts, including radio, television, gas pump, billboard advertising, community health fairs, signs posted in minority-owned businesses, and referral letters mailed from physicians in the Kansas City, KS, USA, area Inclusion criteria: (a) self-identified as 'African American or black', (b) ≥ 18 years, (c) smoked ≤ 10 cigarettes/d for ≥ 6 months, (d) before enrolment, smoked on ≥ 25 of the last 30 days, (e) was interested in quitting in the next 2 weeks, (f) spoke English, and (g) had a permanent home address and working telephone. Only 1 smoker per household was allowed to enrol Exclusion criteria: (a) contraindication for nicotine gum (jaw problems, irregular heartbeat, recent myocardial infarction, or stroke), (b) used other pharmacotherapy for smoking cessation in the last 30 days, (c) used other forms of tobacco within the last 30 days, (d) was pregnant or planning to become pregnant within the next 6 months, (e) was breastfeeding, or (f) was planning to move out of the local area within the next 6 months. Individuals demonstrating marked inappropriate affect or behavior were excluded from the study.
Interventions	Health education plus NRT gum (N = 189) Motivational interviewing plus NRT gum (N = 189) Health education plus placebo gum (N = 189) Motivational interviewing plus placebo gum (N = 188) Participants were assigned randomly to 1 of 4 study arms: 2 mg nicotine gum plus health education (HE); 2 mg nicotine gum plus motivational interviewing (MI); placebo gum plus HE; and placebo gum plus MI

Ahluwalia 2006 (Continued)

Outcomes	<p>Primary outcomes: cotinine-verified 7-day abstinence at week 26, defined as having smoked no cigarettes - not even a puff - on the previous 7 days</p> <p>A salivary cotinine cutoff of ≤ 20 ng/mL was used to verify abstinence at 26 weeks; a cutoff of ≤ 10 ppm was used for CO.</p> <p>Secondary outcomes: Secondary outcome was 7-day abstinence at week 8. Process measures included counseling attendance at randomisation and at weeks 1, 3, 6, and 8; and 16 counseling visits and self-reported gum usage in the past 7 days at weeks 1, 3, and 8 (end of gum treatment).</p>
Funding source	This project was supported by the National Cancer Institute at the National Institutes of Health (R01 CA091912). GlaxoSmithKline provided study medication but played no role in design or conduct of the study nor in interpretation and analysis of data.
Declaration of interest	<p>"NLB serves as a consultant to several pharmaceutical companies that market smoking cessation medications and has been a paid expert witness in litigation against tobacco companies. SPD is a scientific adviser to Genophen. RFT has participated in one-day advisory meetings for Novartis and McNeil. RFT is an Associate Editor for <i>Clinical Pharmacology & Therapeutics</i> but was not involved in the review or decision process for this article. The other authors declared no conflict of interest."</p>
Notes	The present study did not report analyses of pharmacogenetics. However, 608/755 (80%) were successfully genotyped. These results were published in subsequent papers (Ho 2009; Zhu 2014).

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation codes were generated in blocks and were linked to medication distribution and counseling assignment.
Allocation concealment (selection bias)	Low risk	"The Investigative Pharmacy at the University of Kansas Medical Center packaged the study medication using codes to maintain blinding. At the randomization visit, a sealed envelope with pre-assigned randomization numbers was drawn to determine which form of counseling the participant would receive. The envelope and box of gum with matching randomization numbers were given to participants in the order in which they were randomized."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Study staff and participants were blinded to whether participants received active gum or placebo. However, assignment to MI counseling versus HE was not blinded."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Researchers and participants were blinded to active or placebo medication.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All randomised participants were accounted for in the analyses.
Selective reporting (reporting bias)	Low risk	Primary endpoints were reported.

Ahluwalia 2006 (Continued)

Other bias	Low risk	80% of participants were genotyped, which was balanced across drug treatment groups. See 'Notes' above.
------------	----------	---

Aveyard 2007

Methods	Randomised controlled clinical trial of behavioural support for smoking cessation (the "Patch in Practice Study") Study period: July 2002 to March 2005
Participants	N = 925 Recruited from 26 general practice clinics in Buckinghamshire and Oxfordshire, UK Inclusion criteria: current smokers, age ≥ 18 , smoked ≥ 10 cigarettes/d Exclusion criteria: contraindications to nicotine replacement therapy (NRT)
Interventions	Basic support (N = 469) Weekly support (N = 456) Participants were randomised to behavioural support provided by practice nurse before quitting, telephoned around quit day, and seen 1 and 4 weeks after the initial appointment (basic support) vs basic support plus weekly support - additional telephone call at 10 days and 3 weeks after the initial appointment, and an additional visit at 2 weeks to motivate adherence to nicotine replacement and to renew quit attempts. 15 mg/16 h nicotine patches were given to all participants.
Outcomes	Primary outcomes: confirmed sustained abstinence at 1, 4, 12, and 26 weeks from quit day. Sustained abstinence was defined as self-reported total abstinence after a 14-day grace period from quit date confirmed by expired air carbon monoxide (CO) < 10 ppm. Secondary outcomes: not indicated
Funding source	"This study was funded by a programme grant from Cancer Research UK (trial registration ISRCTN 05689186). United Pharmaceuticals supplied the nicotine patches for the study free to be given without charge to the participants."
Declaration of interest	"PA has received free nicotine replacement products from Novartis and nortriptyline from King Pharmaceuticals for distribution to trial participants; personal income for advice to Xenova, a biotechnology company investigating a nicotine vaccine; small gifts and had numerous meals paid for by drug companies, including those producing medications for smoking cessation; and travel grants to attend conferences from the Society for Research in Nicotine and Tobacco. KB, CS, and AA have received small gifts and had meals paid for by drug companies, including those manufacturing medications for smoking cessation. M Munafó has received fees for invited lectures from the National Health Service, GlaxoSmithKline, Novartis, the Moffitt Cancer Research Center, and the Karolinska Institutet; benefits in kind (hospitality, etc.) from various pharmaceutical companies; research and travel support from the European Research Advisory Board, GlaxoSmithKline, Pfizer Consumer Healthcare and Novartis; and has acted as a consultant to the European Commission, The American Institutes for Research, the National Audit Office, and G-Nostics Ltd. EJ has received consultancy income from the European Network for Smoking Prevention. M Murphy has received consultancy income from the European Network for Smoking Prevention and has provided scientific consultancy services through the University of Oxford ISIS Innovation to the National Audit Office and G-Nostics Ltd. The Childhood Cancer Research Group and the Cancer Research UK General Practice Research Group have received unrestricted educational grants, research project grants, and consultancy fees from Ciba Geigy/Novartis, GlaxoSmithKline, Pharmacia/Pfizer, Ares-Serono, Sanofi-Synthelabo, Third Wave Technologies, Astra Zeneca, and G-Nostics."

Aveyard 2007 (Continued)

Notes This paper did not report analyses of pharmacogenetics. However, DNA was collected from all trial participants and analyses of pharmacogenetics were reported in subsequent papers (David 2008; David 2011; Munafò 2008; Munafò 2009; Munafò 2011; Munafò 2012; Spruell 2012; Uhl 2010).

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number sequence generation specified
Allocation concealment (selection bias)	Low risk	Random number sequence sealed in numbered envelopes. Nurses opened sealed envelopes in sequence following eligibility and consent determination.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Participants and nurses were necessarily not blinded to allocation.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Research staff was blinded to allocation.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Loss to follow-up was balanced and transparently reported.
Selective reporting (reporting bias)	Low risk	Primary outcomes were reported.
Other bias	Low risk	DNA samples were collected on all participants at the time of study entry.

Bloch 2010

Methods	Double-blind parallel-group placebo-controlled randomised clinical trial Study period: dates not reported
Participants	N = 61 Participants were schizophrenic patients on stable neuroleptic medication who were recruited by hospital doctors and clinicians from community mental health centres and ambulatory clinics. Inclusion criteria: age between 18 and 70 years, met DSM-IV-TR criteria for schizophrenia or schizoaffective disorder, clinically stable (based on psychotic and affective symptoms) as judged by treatment team and psychiatrists, had a stable dose of antipsychotic drugs for ≥ 1 month before the start date, in stable physical health, stable cigarette smoking habits (not defined), strong desire to quit smoking or at least to reduce significantly the number of cigarettes per day (score > 5 on motivational questionnaire) Exclusion criteria: not reported
Interventions	Sustained-release bupropion + cognitive-behavioural group therapy (n = 45) Placebo + cognitive-behavioural group therapy (n = 16)

Bloch 2010 (Continued)

All participants had 2-week stabilisation period followed by 14 weeks of study medication. Initial dose was 150 mg/d for 3 days, then 300 mg/d. All participants participated in a 14-week, 15-session group cognitive-behavioural therapy. Participants received no additional treatment.

Outcomes	Outcomes: self-reports of daily cigarette consumption and the Fagerstrom Test of Nicotine Dependence (FTND), both measured at baseline, week 7, and week 14
Funding source	This research was supported by a Junior Investigator Award from the National Alliance for Research on Schizophrenia and Depression (NARSAD) (AR) and was partially supported by Phillip Morris USA and Phillip Morris International.
Declaration of interest	Declaration of interest was not reported.
Notes	This paper provided analysis of pharmacogenetics.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Participants were randomly allocated according to order of arrival.
Allocation concealment (selection bias)	High risk	Allocation was based on order of arrival.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	The study was double-blind; however it is unclear who exactly was blinded.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Blinding of participants and personnel was unclear; study outcome is objective and can be influenced by participants.
Incomplete outcome data (attrition bias) All outcomes	High risk	Incomplete outcome data were greater in the bupropion group, potentially influencing the overall treatment effect.
Selective reporting (reporting bias)	Unclear risk	No protocol was found.
Other bias	Low risk	Analysis of pharmacogenetics was performed on the total study population.

Brown 2007

Methods	Randomised double-blind placebo-controlled trial of sustained-release bupropion and behavioural support for smoking cessation (the "Zyban Collaborative Trial") Study period: November 1997 to January 2001
Participants	N = 524 Recruited from the general population and treated at 1 of 3 community-based academic teaching hospitals in Pawtucket and Providence, RI, USA Inclusion criteria: current smokers, age ≥ 18 , smoked ≥ 10 cigarettes/d

Brown 2007 (Continued)

Exclusion criteria: (a) current Axis I disorder according to the *Diagnostic and Statistical Manual of Mental Disorders* (4th edition; DSM-IV; American Psychiatric Association, 1994), (b) DSM-IV diagnosis of past-year psychoactive substance abuse or dependence (other than nicotine), (c) current use of psychotropic medication or medication that may interact adversely with bupropion, (d) current weekly (or more frequent) psychotherapy, or (e) use of other tobacco products. Participants also were screened by a study physician to rule out the following: any unstable medical condition; hypertension; pregnancy, lactation, or refusal to use contraception while on study medication; history of seizure disorder or head injury with loss of consciousness; eating disorder; or panic disorder. Participants agreed to use only study-supplied medication for smoking cessation for the duration of their study participation.

Interventions	<p>Standard treatment + placebo (N = 157)</p> <p>Standard plus depression treatment + placebo (N = 112)</p> <p>Standard treatment + bupropion sustained-release (SR) (N = 147)</p> <p>Standard plus depression treatment + bupropion SR (N = 108)</p> <p>Participants were randomised to 1 of 4 twelve-week treatments: (a) standard, cognitive-behavioural smoking cessation treatment (ST) plus bupropion (BUP), (b) ST plus placebo (PLAC), (c) standard cessation treatment combined with cognitive-behavioural treatment for depression (CBTD) plus BUP, and (d) CBTD plus PLAC. Follow-up assessments were conducted 2, 6, and 12 months after treatment, and self-reported abstinence was verified biochemically. Bupropion was delivered according to the standard therapeutic dose (150 mg/d for the first 3 days, followed by 300 mg/d) for a total of 12 weeks. All participants and study staff were blind to medication condition.</p>
Outcomes	<p>Primary outcomes: biochemically verified point prevalence abstinence at end of treatment and at 2-, 6- and 12-month follow-up. Abstinence was confirmed by a combination of CO $\leq$ 10 ppm and cotinine $\leq$ 15 ng/mL.</p> <p>Secondary outcomes: withdrawal and depression symptoms, craving</p>
Funding source	This study was funded in part by US Public Health Service grants HL32318, DA08511, CA84719, and DA14276, and by GlaxoSmithKline, Inc., which provided study medication.
Declaration of interest	SPD is a scientific advisor with BaseHealth and participated in a 1-day workshop with Pfizer. MRM has received research support from Pfizer and GlaxoSmithKline. CL has served as a consultant and has received research funding from Astra Zeneca, GlaxoSmithKline, and Pfizer.
Notes	DNA was collected after start of trial, resulting in genotyping for 59% of trial participants. Participants contributing DNA were significantly more likely to be female (51% vs 40%) and older (45.4 vs 43.2 years), and had been smoking longer (27.1 vs 24.8 years). Analyses of pharmacogenetics were reported in subsequent papers from the original study sample (PMID: 17654295, PMID: 18058343). An additional 60 participants were recruited, randomised to bupropion vs placebo, and administered the same ST behavioural treatment following completion of the original trial. Analyses of the larger sample were reported in additional publications (David 2013a; Leventhal 2012; Uhl 2008).

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomly assigned to 1 of 2 treatment sites, where they were to receive 1 of 2 manualised group treatments, ST, or CBTD, and were randomly assigned to receive 1 of 2 medication conditions or 1 of 2 behavioural interventions, using the urn randomisation technique.
Allocation concealment (selection bias)	Unclear risk	Behavioural treatment allocation may not have been blinded but did appear to result in balanced pharmacological treatment arms.

Brown 2007 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	All participants and study staff were blind to medication condition.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Blinding of outcome assessment was not described.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Handling of missing data was described. Analyses using intention-to-treat vs only complete data were conducted and demonstrated concordance.
Selective reporting (reporting bias)	Low risk	Primary endpoints were reported.
Other bias	High risk	59% of original trial participants were genotyped, which may not be representative of the original study population. Analyses of pharmacogenetics were reported in multiple subsequent papers. See 'Notes' above.

Cinciripini 2005

Methods	Double-blind parallel-group placebo-controlled randomised clinical trial Study period: February 1996 to April 1997	
Participants	N = 147 Participants were smokers recruited from the Houston, Texas, metropolitan area via newspaper, radio, and TV advertisements and public service announcements. Inclusion criteria: smoking ≥ 10 cigarettes/d at baseline, between 18 and 75 years old Exclusion criteria: taking smoking cessation treatment; taking psychoactive medication; or having any uncontrolled systemic illness, contraindications for taking venlafaxine or the nicotine patch, current substance abuse, or other psychiatric disorders	
Interventions	Venlafaxine (n = 71) Placebo (n = 76) 21 weeks of active venlafaxine or placebo. After a 1-week no-medication baseline (3 weeks before the quit date), participants began antidepressant therapy 2 weeks before quitting at an initial dose of 75 mg/d (37.5 mg/d twice daily). The dose was increased up to 150 mg/d during the week just before participants were to quit. During each subsequent week, the dose was raised in 37.5-mg increments up to a maximum 225 mg/d. Two weeks before the end of treatment, the dose was decreased by 37.5 mg every 2 to 3 days. The medication cycle was completed 18 weeks after quitting. All participants also used the nicotine patch (Prostep, 22 mg) for 6 weeks, beginning on their quit date, and received smoking cessation counseling.	
Outcomes	Outcomes: Abstinence was assessed on the quit date and at post quit weeks 1, 3, 6, 18 (end of treatment), 26, and 52. Abstinence was verified in person by expired air carbon monoxide ≤ 10 ppm or by a saliva cotinine sample of < 15 ng/ μ L at 26 or 52 weeks.	
Funding source	Support for this research was provided by grants from the MD Anderson Cancer Center (PRS), the National Cancer Institute (P50CA70907), and the National Institute on Drug Abuse (R01DA1182-01) to Paul M. Cinciripini. Study medication was provided by Wyeth-Ayerst Laboratories.	

Cinciripini 2005 (Continued)

Declaration of interest	Declaration of interest was not reported.	
Notes	Analysis of pharmacogenetics was reported in Cinciripini 2005 .	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation was performed by the pharmacy, but details are absent.
Allocation concealment (selection bias)	Low risk	Randomisation was centralised and was performed by a third party (pharmacy).
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants, study staff, and study personnel with direct patient contact were blinded to group assignment.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding was appropriate and the outcome of the study was objective.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Incomplete outcome data were similar between groups.
Selective reporting (reporting bias)	Unclear risk	No protocol was found.
Other bias	Low risk	Additional analyses of pharmacogenetics in Cinciripini 2004 were conducted in the large majority of the original randomised trial population, so selection bias seems unlikely.

Cox 2012

Methods	Randomised double-blind placebo-controlled trial of sustained-release bupropion for smoking cessation in African Americans (the "Kick It at Swope III Trial" (KIS-III)) (ClinicalTrials.gov Identifier: NCT00666978) Study period: December 2007 to May 2010	
Participants	N = 540 Participants were recruited through clinic- and community-based efforts. Clinic-based efforts included use of fliers, posters, physician letters, pharmacy inserts, and lobby recruitment at the primary study site, Swope Health Services in Kansas City, 2 Swope affiliate clinics, and 2 regional hospitals (University of Kansas Medical Center and Truman Medical Center) in Kansas City, Kansas, USA. Inclusion criteria: (a) African American, (b) ≥ 18 years, (c) interested in stopping smoking, (d) smoked ≤ 10 cigarettes/d for ≥ 2 years, (e) smoked on ≥ 25 days in the past month, and (f) were willing to attend 4 clinic visits over the course of 6 months; (g) must have smoked ≥ 3 years, and (h) had a home address and (i) a functioning telephone number Exclusion criteria: (a) current use of bupropion; (b) use of psychoactive medications; (c) use of NRT, (d) fluoxetine, (e) clonidine, (f) buspirone, or (g) doxepin in the past 30 days; (h) history of alcohol or (i) substance abuse within the past year; (j) current drinking of 14 or more alcoholic drinks per week and/	

Cox 2012 (Continued)

or binge drinking (≥ 5 drinks on 1 occasion) 2 or more times in the past month; (k) history of seizures or head trauma; (l) history of bulimia or anorexia nervosa; (m) pregnant (verified by over-the-counter pregnancy test kit for women of childbearing age only) or (n) contemplating pregnancy; (o) breastfeeding; (p) myocardial infarction in the past 30 days; (q) use of other forms of tobacco in the past 30 days; (r) reported use of opiates, (s) cocaine, (t) or stimulants; (u) diabetes treated with oral hypoglycaemics or insulin; (v) planning to move from the Kansas City metro area in the next 12 months; and (w) having another smoker in the household enrolled in the study

Interventions	<p>Bupropion SR (N = 270)</p> <p>Placebo (N = 270)</p> <p>Participants were randomly assigned to receive 300 mg bupropion SR (150 mg once daily for 3 days, then 150 mg twice daily) (n = 270 participants) or placebo (n = 270 participants) for 7 weeks, and up to 6 sessions of health education counseling.</p>
Outcomes	<p>Primary outcomes: salivary cotinine-verified 7-day point prevalence smoking abstinence at week 26 (a cut point of 15 ng/mL differentiated smokers from non-smokers)</p> <p>Secondary outcomes: Salivary cotinine-verified smoking abstinence at end of medication treatment at week 7 was also examined.</p>
Funding source	<p>"The Kick It at Swope III (KIS-III) study is a federally funded registered clinical trial (ClinicalTrials.gov identifier: NCT00666978) from the grant "Enhancing Tobacco Use Treatment for African American Light Smokers"."</p>
Declaration of interest	<p>"JSA serves as a consultant to Pfizer Pharmaceuticals, Inc.; NLB serves as a consultant to Pfizer Pharmaceuticals, Inc., and has been a paid expert witness in litigation against tobacco companies; RFT holds shares in Nicogen Research, Inc., a company that is focused on novel smoking cessation treatment approaches; no Pfizer or Nicogen funds were used in this work." "NLB serves as a consultant to several pharmaceutical companies that market smoking cessation medications and has been a paid expert witness in litigation against tobacco companies. SPD is a scientific adviser to Genophen. RFT has participated in one-day advisory meetings for Novartis and McNeil. RFT is an Associate Editor for <i>Clinical Pharmacology & Therapeutics</i> but was not involved in the review or decision process for this article. The other authors declared no conflict of interest."</p>
Notes	<p>The present study did not report analyses of pharmacogenetics. However, 534/540 (~ 90%) were successfully genotyped. These results were published in subsequent papers (Zhu 2013; Zhu 2014).</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	A computer-generated table of random numbers was used to randomise.
Allocation concealment (selection bias)	Low risk	Allocation was concealed before group assignment.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Study staff and participants were blinded to treatment conditions.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding was appropriate, and the outcome of the study was objective.
Incomplete outcome data (attrition bias)	Low risk	Loss to follow-up was ~ 30% in both groups, but all participants were accounted for in intention-to-treat follow-up.

Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)

Cox 2012 (Continued)

All outcomes

Selective reporting (reporting bias)	Low risk	Primary outcomes were reported.
Other bias	Low risk	534/540 (~ 90%) from the original trial were successfully genotyped, and distribution of participants across treatment groups was balanced. See 'Notes' above.

Gilbert 2009

Methods	Randomised parallel-group double-blind placebo-controlled trial of NRT vs placebo patch with non-randomised continuing smoking control arm Study period: 1998 to 2004 (specific months not reported)	
Participants	N = 171 Inclusion criteria: "Smokers wanting to quit" Exclusion criteria: (a) smoking < 7 cigarettes/d for the past 2 years, (b) habitual cigarette nicotine deliveries < 0.6 mg, (c) use of psychoactive drugs or medications other than alcohol and caffeine, (d) alcohol use in excess of 28 alcoholic drinks/week, (e) age < 18 or > 50 years, (f) non-English speaking, (g) atypical sleep cycles, (h) pregnancy, and (i) serious medical or visual problems	
Interventions	Smoke control (N = 38) Nicotine patch (N = 90) Placebo patch (N = 81) Participants were randomly assigned in an 80:20 ratio to a quit group or a group that continued to smoke; those in the quit group were randomised (50:50) to nicotine patch or placebo patch. Participants received an abbreviated form of the American Lung Association smoking cessation programme. Nicotine patches and placebo patches of corresponding size were 21 mg for the first 17 days of abstinence, 14 mg for days 18 to 26, and 7 mg for days 27 to 38.	
Outcomes	Primary outcomes: Implied primary outcomes are symptom trajectories of affect (anger, anxiety, depression). Secondary outcomes: Abstinence was biochemically verified but was not reported as an outcome. Abstinence failure was defined as smoking a total of more than 4 cigarettes after quitting.	
Funding source	Research was supported by National Institute on Drug Abuse Grant R01 DA12289 awarded to David G. Gilbert and by nicotine and placebo patches from GlaxoSmithKline.	
Declaration of interest	None	
Notes	Participants were excluded for abstinence failure. DNA appears to have been collected for all participants.	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation sequence described using an urn technique

Gilbert 2009 (Continued)

Allocation concealment (selection bias)	Unclear risk	Quit group allocation and pharmacological treatment allocation were randomised, but quit group allocation was not blinded.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind design
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	77% in the nicotine patch group correctly guessed treatment assignment, which may have been shared with data collectors.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Treatment dropout high in both groups were reported as "all relapsed to smoking".
Selective reporting (reporting bias)	High risk	Multiple gene x treatment interactions were reported for multiple behavioural phenotypes.
Other bias	High risk	Exclusion of relapsers from analyses may create study population imbalance for genetic predisposition to successfully quit smoking.

Gonzales 2006

Methods	Double-blind parallel-group placebo and active treatment-controlled randomised clinical trial Study period: June 2003 to April 2005
Participants	N = 1025 Participants generally were healthy smokers (≥ 10 cigarettes/d) with < 3 months of smoking abstinence in the past year, 18 to 75 years old, recruited via media advertising. Inclusion criteria: generally healthy, smoking ≥ 10 cigarettes/d, < 3 months of smoking abstinence in the past year, 18 to 75 years old, motivated to stop smoking Exclusion criteria: any serious or unstable disease within past 6 months; seizure risk; diabetes mellitus requiring insulin or oral hypoglycaemic medications; hepatic or renal impairment; clinically significant cardiovascular disease within past 6 months; uncontrolled hypertension; severe chronic obstructive pulmonary disease; history of cancer (except treated basal cell or squamous cell carcinoma of the skin); history of clinically significant allergic reactions; major depressive disorder within past year requiring treatment; history of panic disorder, psychosis, bipolar disorder, or eating disorders; alcohol or drug abuse/dependency within the past year; use of tobacco products other than cigarettes; use of nicotine replacement therapy, clonidine, or nortriptyline within the month before enrolment; body mass index < 15 or > 38 or weight < 45.5 kg; prior exposure to bupropion; and prior varenicline exposure
Interventions	Varenicline (n = 352) Bupropion SR (n = 329) Placebo (n = 344) Study medication was taken orally for 12 weeks. Active drugs were titrated as follows: varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice per day for days 4 to 7, then 1 mg twice per day through week 12; bupropion SR 150 mg/d for days 1 to 3, then 150 mg twice per day through week 12. All participants received brief (≤ 10 -minute), standardised, individual counseling to assist in problem solving and skills training for relapse prevention.

Gonzales 2006 (Continued)

Outcomes	Primary outcome: exhaled carbon monoxide–confirmed 4-week continuous abstinence rate for weeks 9 through 12, defined as the proportion of participants who reported no smoking (not even a puff) or use of any nicotine-containing products confirmed by an exhaled carbon monoxide measurement ≤ 10 ppm Other outcomes: continuous abstinence rates from week 9 through week 24, and from week 9 through week 52; 7-day point prevalence abstinence rates at weeks 12, 24, and 52	
Funding source	This study was supported by Pfizer Inc., which provided funding, study drug and placebo, and monitoring. The database containing findings of the 19 individual investigator sites was maintained by Pfizer Inc., and statistical analyses were performed at Pfizer Inc. by Mr Billing and by Ann Pennington, MS. Independent analysis was performed to verify the findings of Pfizer Inc.	
Declaration of interest	Dr Gonzales reports having received research contracts from Pfizer, Sanofi-Aventis, GlaxoSmithKline, and Nabi Biopharmaceuticals; and consulting fees and honoraria from Pfizer, Sanofi-Aventis, and GlaxoSmithKline; and owning 5 shares of Pfizer stock. Dr Rennard reports having had or currently having a number of relationships with companies who provide products and/or services relevant to outpatient management of chronic obstructive pulmonary disease. These relationships include serving as a consultant for Adams, Almirall, Altana, Array Biopharma, AstraZeneca, Aventis, Biolipox, Centocor, Dey, Critical Therapeutics, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, OnoPharma, Otsuka, RJ Reynolds, Roche, Sankyo, Schering-Plough, Scios, and Wyeth; advising regarding clinical trials for Altana, AstraZeneca, Aventis, Centocor, GlaxoSmithKline, Novartis, Pfizer, and Philip Morris; and speaking at continuing medical education programs and performing funded research at both basic and clinical levels for Altana, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Novartis. Dr Nides reports having received research grants, consulting fees, and honoraria from Pfizer, Sanofi-Aventis, and GlaxoSmithKline. Dr Oncken reports having received research grants, consulting fees, and honoraria from Pfizer; receiving, at no cost, nicotine replacement and placebo products from GlaxoSmithKline for smoking cessation studies; and receiving honoraria from Pri-Med. Drs Azoulay, Watsky, Gong, Williams, and Reeves and Mr Billing report owning Pfizer stock or having stock options in Pfizer.	
Notes	Analysis of pharmacogenetics was reported in King 2012 .	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	A predefined, central, computer-generated randomisation sequence stratified by centre assigned participants to treatment groups using a block size of 6.
Allocation concealment (selection bias)	Low risk	Centralised randomisation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants and investigators were blinded to drug treatment assignments. Participants were not encouraged to guess their treatment assignment.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding was appropriate, and the outcome of the study was objective.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	More refusal to continue participation in the placebo group and more dropout in the bupropion SR group due to adverse effects. Dropouts were assumed to be smoking.
Selective reporting (reporting bias)	Low risk	All outcomes listed on clinicaltrials.gov (NCT00141206) are reported.

Gonzales 2006 (Continued)

Other bias	Low risk	Additional analyses of pharmacogenetics in King 2012 were conducted in a subset of the original randomised trial population, but baseline characteristics were comparable between treatment groups, so selection bias seems unlikely.
------------	----------	---

GPRG 1993

Methods	Randomised double-blind placebo-controlled trial of smoking cessation with a 2 × 2 factorial design (the “Patch Trial”) Study period: June 1991 to March 1992
Participants	N = 1686 Recruited from 19 general practice clinics in Oxfordshire, UK Inclusion criteria: current smokers, age ≥ 18 and ≤ 65 years, smoked ≥ 15 cigarettes/d Exclusion criteria: (a) known skin hypersensitivity to nicotine, (b) severe skin condition likely to make patch use impossible, (c) untreated peptic ulcer, (d) life-threatening arrhythmia, (e) active cancer, (f) cerebrovascular or cardiovascular event within past 6 months, (g) lactation, and (h) existing or planned pregnancy. Patients were warned that they should not use other forms of nicotine, such as cigars, pipes, or nicotine chewing gum, during the trial, and that medication with centrally acting alpha activity (such as clonidine) was contraindicated.
Interventions	16-Page booklet plus nicotine patch (N = 422) 46-Page booklet plus nicotine patch (N = 420) 16-Page booklet plus placebo patch (N = 422) 46-Page booklet plus placebo patch (N = 422) Participants were randomised to 1 of 4 treatment groups: (a) nicotine patch with a standard, 16-page Health Education Authority pamphlet on smoking cessation; (b) nicotine patch with a 46-page booklet giving specific and more detailed information on smoking cessation with the help of patches; (c) placebo patch with a standard, 16-page Health Education Authority pamphlet on smoking cessation; or (d) placebo patch with a 46-page booklet giving specific and more detailed information on smoking cessation with the help of patches. Patches were delivered 21 mg/d × 4 weeks, followed by 14 mg/d × 4 weeks, then 7 mg/d × 4 weeks.
Outcomes	Primary outcomes: biochemically verified point prevalence abstinence at 1 and 4 weeks (CO ≤ 10 ppm), and at 12, 24, and 52 weeks by cotinine ≤ 20 ng/mL or CO ≤ 10 ppm. Non-attenders were assumed to be smoking. Abstinence at follow-up in 1999 to 2000 was confirmed by a plasma cotinine level ≤ 20 ng/mL. Secondary outcomes: withdrawal symptoms
Funding source	The Patch Trial was supported by Ciba-Geigy Pharmaceuticals, which also supplied the nicotine and placebo patches. The Patch II Study was funded by the Imperial Cancer Research Fund and Cancer Research UK. “Personal funding to SPD provided by DA027331; National Institute for Health Research fellowship (to PA); and the UK Centre for Tobacco Control Studies (UKCTCS to P.A. and M.M.). The UKCTCS gratefully acknowledges funding from British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, and the Department of Health, under the auspices of the UK Clinical Research Collaboration.”
Declaration of interest	No conflicts of interest were declared for the original Patch Trial. However, subsequent papers on pharmacogenetics report: “Paul Aveyard has done consultancy for McNeil, Pfizer, and Celtic Biotechnolo-

GPRG 1993 (Continued)

gy and Sean David has done consultancy with Pfizer—both with regard to smoking cessation” (PMID: 21330274).

Notes The “Patch II Study”: 1532 of the original 1686 Patch Trial participants were contacted again between July 1999 and July 2000 and were invited to participate in 8-year follow-up of smoking status and to provide DNA samples, of whom 840 returned questionnaires and 755 were successfully genotyped. These results were published in subsequent papers (David 2007; David 2008; David 2008a; David 2011; Johnstone 2004; Johnstone 2006; Johnstone 2007; Munafò 2007; Munafò 2011; Munafò 2012; Uhl 2010; Yudkin 2004).

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	“Randomisation was carried out by prior random allocation of study numbers to each intervention group and by sequential allocation of a study number to patients on entry.”
Allocation concealment (selection bias)	Low risk	“Prepared precoded packages containing the patches were handed to the patients by the general practitioner.”
Blinding of participants and personnel (performance bias) All outcomes	Low risk	“The packaging and appearance of the two types of patch were identical.”
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Research staff were blinded to randomisation status throughout the trial.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	755/1686 (45%) Patch Trial participants were genotyped and Patch II Study participants were more female, were slightly older, and were more likely to be abstinent than non-genotyped Patch Trial participants. However, Patch II Study participants were balanced to treatment allocation.
Selective reporting (reporting bias)	Low risk	Primary outcome results were published for all candidate genes in comprehensive reviews and subsequent papers.
Other bias	High risk	45% of original trial participants were genotyped, which may not be representative of the original study population. Analyses of pharmacogenetics were reported in multiple subsequent papers. See ‘Notes’ above.

Hall 2008

Methods Randomised parallel-group open-label efficacy clinical trial consisting of 2 phases: phase 1 lasting 12 weeks, during which all participants receive a standard treatment of NRT, bupropion, and 5 group counseling sessions; followed by phase 2, randomisation to 1 of 5 treatments for another 40 weeks.

Outcomes are measured at multiple time points to 104 weeks.

Study period: 2002 to 2004

Participants N = 407

Recruited through multi-media advertising, public service announcements, flyers, and direct mailing

Hall 2008 (Continued)

Inclusion criteria: treatment-seeking smokers 18 years of age or older who currently smoke 10 cigarettes/d, report a regular smoking history ≥ 5 years, and answer "yes" to the question, "Do you smoke within 30 minutes of arising?"

Exclusion criteria: history of seizure or head injury resulting in unconsciousness; any condition that might predispose to seizures (brain tumour or stroke); current or history of anorexia nervosa or bulimia; any disease acutely life-threatening or so severe that the patient is judged unable to comply with the protocol; use of a protease inhibitor or MAO inhibitor within the past 2 weeks; current use of psychiatric drugs that would interfere with interpretation of study results, including antidepressants; treatment for alcohol dependence during the past year, or evidence of alcohol abuse so severe that the patient is judged potentially unable to comply with the protocol; patients who know they are leaving the Bay Area within the study period and non-English speakers; suicidal or homicidal ideation; current major depression; history of bipolar disorder; recent (within 12 months) myocardial infarction; any other medical condition that would contraindicate use of NRT or bupropion; physical limitation so severe that participation in a programme of moderate exercise is not possible; and pregnancy or lactation

Interventions	All participants receive 10 weeks of NRT (patch, tapering from 21 mg to 7 mg over 8 weeks, starting at week 3) and 12 weeks of bupropion treatment and 5 mandatory group counseling sessions. At week 11, subjects are randomly assigned to 1 of 5 treatment groups: (a) no further treatment, with assessments at weeks 12, 24, 36, 52, 64, and 104 weeks (standard assessments for all treatments); (b) extended active medication (bupropion) treatment through week 52 with low-intensity (monthly) counseling with medical staff; (c) extended placebo medication treatment through week 52 with low-intensity counseling with medical staff; (d) extended active medication treatment with high-intensity (session 20 to 40 minutes in duration at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52, and telephone contact at weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, and 48) counseling; and (e) extended placebo medication treatment with high-intensity counseling. High-intensity counseling sessions included additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal.	
Outcomes	Primary outcome: biochemically verified 7-day point prevalence abstinence at weeks 12, 24, 52, 64, and 104	
Funding source	The clinical trial was supported by a grant from the National Institute on Drug Abuse (R01DA015732, Maintaining Abstinence in Chronic Smokers, PI: Sharon M Hall).	
Declaration of interest	Declaration of interest was not reported.	
Notes	Analyses of pharmacogenetics were described in Bergen 2013 .	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computerised allocation was performed by study statistician who did not have contact with participants.
Allocation concealment (selection bias)	Low risk	Assignment for individual participants was transmitted electronically to staff.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	The trial was open-label, but other aspects of the trial suggest rigorous management and lower probability of high performance bias to unclear.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome assessment was done by self-report and by 2 biochemical methods using exhaled breath and urine (i.e. very thorough outcome assessment).

Hall 2008 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition rates were low for the companion trial.
Selective reporting (reporting bias)	Low risk	Outcome assessment was very thorough, with 3 pieces of information required to note an individual as abstinent. In the companion trial, only 17/905 urine determinations had data discordant with outcomes of self-report and CO measurement (< 2%).
Other bias	Low risk	Analyses of pharmacogenetics were performed on ~ 37% of total study, ~ 50% of self-identified "Caucasian". Minimum arm N was 26. Data show no significant differences by arm with respect to proportion of the arm genotyped. Not generalisable to other ancestries

Hall 2009

Methods	<p>Randomised parallel-group open-label efficacy clinical trial consisting of 2 phases: phase 1, lasting 12 weeks during which all participants receive a standard treatment of NRT, bupropion, and 5 group counseling sessions; followed by phase 2, randomization to 1 of 4 treatments for another 40 weeks.</p> <p>Outcomes are measured at multiple time points to 104 weeks.</p> <p>Study period: 2002 to 2004</p>	
Participants	<p>N = 402</p> <p>N = 403 were enrolled, but 1 individual died before randomisation.</p> <p>Recruited through multi-media advertising, public service announcements, flyers, and direct mailing.</p> <p>Inclusion criteria: treatment-seeking smokers 50 years of age or older who currently smoke 10 cigarettes/d</p> <p>Exclusion criteria: history of seizure or head injury resulting in unconsciousness; any condition that might predispose to seizures (brain tumour or stroke); current or history of anorexia nervosa or bulimia; any disease acutely life-threatening or so severe that the patient is judged unable to comply with the protocol; use of a protease inhibitor or MAO inhibitor within the past 2 weeks; current use of psychiatric drugs that would interfere with interpretation of study results, including antidepressants; treatment for alcohol dependence during the past year, or evidence of alcohol abuse so severe that the patient is judged potentially unable to comply with the protocol; patients who know they are leaving the Bay Area within the study period and non-English speakers; suicidal or homicidal ideation; current major depression; history of bipolar disorder; recent (within 12 months) myocardial infarction; any other medical condition that would contraindicate use of NRT or bupropion; physical limitation so severe that participation in a programme of moderate exercise is not possible; and pregnancy or lactation</p>	
Interventions	<p>All participants receive 10 weeks of NRT (gum, 2 mg for those smoking < 25 cigarettes/d, up to 12 pieces a day, or 4 mg for heavier smokers or heavy users of 2-mg gum still reporting withdrawal) and 12 weeks of bupropion treatment (150 mg for a week, then 300 mg the second week and thereafter, with no adverse effects) and 5 mandatory group counseling sessions (90 minutes each). At week 8 (to permit NRT tapering for those assigned to no further treatment), participants are randomly assigned to 1 of 4 treatment groups: (a) no further treatment, with assessments at weeks 12, 24, 36, 52, 64, and 104 (standard assessments for all treatments); (b) extended NRT (to week 52) with no further counseling; (c) extended NRT with extended cognitive-behavioural therapy to prevent relapse and encourage abstinence in case of relapse before week 12, and in case of lapses after week 12, where extended individual (20 to 40 minutes) counseling occurred at week 10, every 2 weeks thereafter, then every 4 weeks, then at weeks 44 and 52, with telephone contact in between clinical visits; and (d) extended NRT and extended counseling. Extended counseling sessions included additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal.</p>	

Hall 2009 (Continued)

Outcomes	Primary outcome: biochemically verified 7-day point prevalence abstinence at weeks 12, 24, 52, 64, and 104
Funding source	Clinical trial and publications (portion related to this trial) were supported by grants from the National Institute on Drug Abuse (R01 DA02538, K05 DA016752, K23 DA018691 and P50 DA 09253, and R01 DA15732).
Declaration of interest	Declarations of interest were not reported.
Notes	Neither this paper nor the clinicaltrials.gov record provided analyses of pharmacogenetics. These were provided in Bergen 2013 .

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computerised allocation performed by study statistician who did not have contact with participants.
Allocation concealment (selection bias)	Low risk	Assignment for individual participants was transmitted electronically to staff.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Trial was open-label, but other aspects of trial suggest rigorous management and lower probability of high performance bias to unclear.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome assessment was done by self-report and by 2 biochemical methods using exhaled breath and urine (i.e. very thorough outcome assessment).
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition rates were low (ranging from 3.2% at week 12 to 13.4% at week 104). Per-arm assessment rates averaged 93%, and abstinence assessments were available for 92% of participants.
Selective reporting (reporting bias)	Low risk	Outcome assessment was very thorough, with 3 pieces of information required to note an individual as abstinent. Only 17/905 urine determinations had data discordant with outcomes of self-report and CO measurement (< 2%).
Other bias	Low risk	Analyses of pharmacogenetics performed on ~ 42% of total study; ~ 55% of self-identified "Caucasian"; minimum arm N was 35; no significant differences by arm with respect to proportion of arm analysed. Not generalisable to other ancestries

Jorenby 2006

Methods	Double-blind parallel-group placebo and active treatment-controlled randomised clinical trial Study period: June 2003 to March 2005
Participants	N = 1027 Participants were generally healthy smokers. Inclusion criteria: smoking ≥ 10 cigarettes/d the previous year, < 3 months of smoking abstinence in the past year, and 18 to 75 years old

Jorenby 2006 (Continued)

Exclusion criteria: previous use of bupropion in any form; contraindications for use of bupropion (e.g. history of seizure, diagnosis of eating disorder, use of a monoamine oxidase inhibitor in the prior 14 days, hepatic or renal impairment, diabetes requiring insulin, oral hypoglycaemics); serious or unstable disease within previous 6 months; clinically significant cardiovascular disease in previous 6 months; uncontrolled hypertension; baseline systolic blood pressure higher than 150 mmHg or diastolic blood pressure higher than 95 mmHg; severe chronic obstructive pulmonary disease; history of cancer; clinically significant allergic reactions; body mass index < 15 or > 38; body weight < 45 kg; history of alcohol or other drug abuse or dependence in the previous 12 months (nicotine excepted); treatment for major depression in the previous 12 months; history of or current panic disorder, psychosis, or bipolar disorder; use of another investigational drug within the past 30 days; intention to donate blood or blood products during treatment phase of the study (12 weeks); previous participation in any varenicline study; use in the previous month or intention to use medications that might interfere with study medication evaluation (e.g. nicotine replacement, nortriptyline, clonidine); use of marijuana or other tobacco products during the study; clinically significant abnormalities in screening laboratory values

Interventions	<p>Varenicline (n = 344)</p> <p>Bupropion SR (n = 342)</p> <p>Placebo (n = 341)</p> <p>Treatment phase doses were 1 mg of varenicline twice daily and 150 mg of bupropion SR twice daily for 12 weeks, with an initial dose titration to full strength during the first week for both drugs.</p> <p>All participants received a folder on the study medication without de-blinding treatment allocation.</p>
Outcomes	<p>Primary outcome: exhaled carbon monoxide–confirmed 4-week continuous abstinence rate for weeks 9 through 12, defined as the proportion of participants who reported no smoking (not even a puff) and no use of nicotine-containing products confirmed by an exhaled carbon monoxide measurement ≤ 10 ppm</p> <p>Other outcomes: continuous abstinence rates from week 9 through week 24, and from week 9 through week 52; 7-day point prevalence abstinence rates at weeks 12, 24, and 52</p>
Funding source	The clinical trial was sponsored by Pfizer Inc., which provided funding, study drug and placebo, and monitoring. Drs Azoulay, Watsky, Williams, Gong, and Reeves, and Mr Billing, employees of Pfizer Inc., were involved in all elements of this study. In addition, the database containing findings of the 14 investigator sites was maintained by Pfizer Inc., and statistical analyses were performed at Pfizer Inc. by Mr Billing and Ann Pennington, MS. Independent analysis was performed to verify the findings of Pfizer Inc.
Declaration of interest	Dr Jorenby reported receiving research support from Pfizer, Nabi Biopharmaceutical, and Sanofi-Aventis, and consulting fees from Nabi Biopharmaceutical. Dr Hays reported receiving a research grant from Pfizer. Dr Rigotti reported receiving research grant funding and consulting fees from GlaxoSmithKline, which markets smoking cessation medications, and from Pfizer and Sanofi-Aventis, which are developing smoking cessation medications. Dr Rigotti also reported receiving consulting fees from Merck, which is developing smoking cessation medications.
Notes	Analysis of pharmacogenetics was reported in King 2012 .

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was completed centrally with the use of a computer-generated list; sites used an electronic system to assign participants to treatment.
Allocation concealment (selection bias)	Low risk	Centralised randomisation

Jorenby 2006 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Blinding of personnel is not explicitly described.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome of the study was objective.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	More refusal to continue participation in the placebo group. Dropouts were assumed to be smoking.
Selective reporting (reporting bias)	Low risk	All outcomes listed on clinicaltrials.gov (NCT00143364) are reported.
Other bias	Low risk	Additional analyses of pharmacogenetics in King 2012 were conducted in a subset of the original randomised trial population, but baseline characteristics were comparable between treatment groups, so selection bias seems unlikely.

Kalman 2011

Methods	Double-blind parallel-group placebo-controlled randomised clinical trial Study period: June 2005 to April 2010
Participants	N = 143 Participants were in recovery from alcohol problems and were recruited from a residential substance abuse treatment programme and from the community. Inclusion criteria: smoked ≥ 10 cigarettes/d, history of alcohol abuse or dependence, and between 2 and 12 months of abstinence from alcohol Exclusion criteria: older than age 70; diagnosis of schizophrenia; current psychotic episode; cardiac problems in the past 3 months; uncontrolled hypertension; history of seizure; history of head injury with neurological sequelae or prolonged loss of consciousness; and use of medications that lower the seizure threshold
Interventions	Bupropion + nicotine patch (n = 73) Placebo + nicotine patch (n = 70) Participants were taking study medication for 8 weeks. They began study medication (bupropion 150 mg SR tablets or placebo) 1 week before their quit day. Participants were instructed to take 1 tablet/d for 3 days, then one 150-mg tablet twice per day for the remainder of the treatment phase of the study. All participants received a nicotine patch for 7 weeks, starting 1 week after starting study medication on their quit day. They received a 21-mg patch for 4 weeks, a 14-mg patch for 2 weeks, and a 7-mg patch for 1 week.
Outcomes	Outcomes: 7-day point prevalence smoking abstinence at week 7 (end of treatment), week 11, and week 24. At week 7, smoking abstinence was defined via self-report (complete abstinence during the 7 days before the time of assessment) and biochemical verification (CO reading < 8 ppm). At week 11 and week 24, smoking abstinence was defined via self-report and biochemical verification (salivary cotinine levels ≤ 15 ng/mL)

Kalman 2011 (Continued)

Funding source	Study was sponsored through personal funding by David Kalman: NIDA R01-DA11713-01; Peter Monti: NIAAA K05 Senior Scientist Award; and Marc Mooney: NIDA K01-DA-019446. NIDA and NIAAA had no further role in study design; in collection, analysis, and interpretation of data; in writing of the report; or in the decision to submit the paper for publication.
Declaration of interest	No conflicts were declared. None of the review authors have any connection with the tobacco, alcohol, pharmaceutical, or gaming industries or with any body substantially funded by 1 of these organizations.
Notes	Analysis of pharmacogenetics was reported in McGeary 2012 .

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Urn randomisation with 4 variables was used to allocate participants.
Allocation concealment (selection bias)	Low risk	Randomisation was based on 4 variables.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Active and placebo medications were identical in appearance. No further details are presented.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome of the study was objective.
Incomplete outcome data (attrition bias) All outcomes	High risk	Excluded from analysis participants who did not receive the study medication; no ITT analysis was performed.
Selective reporting (reporting bias)	High risk	Weeks of abstinence assessment are different from those listed on clinicaltrials.gov (NCT00304707).
Other bias	Unclear risk	Additional analyses of pharmacogenetics were conducted in a subset of the original randomised trial population in McGeary 2012 , but comparability of baseline characteristics between treatment groups is unclear.

Killen 2006

Methods	Open-label cessation and double-blind extended treatment phase Setting: community cessation clinic, USA Recruitment: community volunteers Study period: December 2001 to March 2004
Participants	N = 362 54% males; average age ~ 45; average number of cigarettes/d: ~ 20 Inclusion criteria: smokers; 18 to 65 years of age; smoking at least 10 cigarettes/d or 3.5 packs/week

Killen 2006 (Continued)

Exclusion criteria: pregnancy, current lactation, epilepsy, bipolar disorder, schizophrenia, receiving active treatment for or reporting current depression or substance abuse, current use of bupropion or NRT, use of medication that could interact with bupropion or NRT

Interventions	<p>Open-label phase: All participants received bupropion SR 300 mg/d (Zyban) for 11 weeks and nicotine patch therapy for 10 weeks.</p> <p>Double-blind phase: bupropion SR (150 mg/d) (n = 181) vs placebo (n = 181) for 14 weeks; at week 12, those assigned to placebo had their bupropion SR dose tapered to 150 mg/d for 2 weeks, then were switched to placebo in week 14</p>
Outcomes	<p>Primary outcome: point prevalence abstinence rates at 25-week and 52-week follow-up</p> <p>Secondary outcomes: repeated point prevalence abstinence; continuous abstinence; craving and withdrawal symptoms; physiological measurements; adverse events; medication compliance</p>
Funding source	Support was provided solely by National Cancer Institute Grant CA 090300 awarded to Joel D. Killen. Nicotine patches and bupropion were kindly provided by GlaxoSmithKline.
Declaration of interest	GlaxoSmithKline did not otherwise participate in the design, conduct, analysis, or reporting of this study.
Notes	Analysis of pharmacogenetics was reported in Sarginson 2011 .

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was conducted before study entry by the method of permuted block (block size = 2 to obtain balance between groups) and was stratified on gender in the order of participant ID numbers.
Allocation concealment (selection bias)	Low risk	When a participant was assigned to the next available ID number in the corresponding gender, he or she was associated with that treatment group.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Both participants and researchers were blinded to treatment at extended treatment phases.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Both participants and researchers were blinded to treatment at extended treatment phases.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Lost at 12 months' follow-up: 8% bupropion; 13% placebo
Selective reporting (reporting bias)	Low risk	Study protocol was not available, but detailed reporting of outcomes does not suggest selective reporting.
Other bias	Unclear risk	Of 304 trial participants, 270 provided samples for DNA extraction, but the selection process for those 270 is unclear.

Killen 2008

Methods	<p>Open-label cessation and double-blind extended treatment phase with follow-up conducted at 20 and 52 weeks</p> <p>Setting: community cessation clinic, USA</p> <p>Recruitment: community volunteers</p> <p>Study period: February 2004 to March 2006</p>
Participants	<p>N = 304; 3 were excluded because of wrong treatment</p> <p>40% females; average age: ~ 46; average cigarettes/d: ~ 20</p> <p>Inclusion criteria: smokers, 18 to 65 years of age; smoking ≥ 10 cigarettes/d or 3.5 packs/week</p> <p>Exclusion criteria: pregnancy, current lactation, epilepsy, bipolar disorder, schizophrenia, receiving active treatment for or reporting current depression or substance abuse, history of heart problems in the previous 6 months, head trauma leading to unconsciousness in the past year, history of severe head injury resulting in brain surgery or specific neurological problems, current use of bupropion or nicotine replacement therapy (NRT), or medication that could interact with bupropion or NRT</p>
Interventions	<p>Open-label – pharmacotherapy: bupropion SR for 9 weeks and nicotine patch therapy for 8 weeks. During their first week, participants continued to smoke while taking bupropion SR (150 mg/d on days 1 to 3, then 300 mg/d on days 4 to 7). Nicotine patch (21 mg) was added to treatment with bupropion (300 mg) on the target quit date if the participant succeeded. After 1 month, participants were tapered to 14 mg nicotine patch for 2 weeks, then to 7 mg for 2 weeks.</p> <p>Open-label – common behavioural therapy: 6 clinic sessions, 30 minutes each, at baseline, quit week, and weeks 1, 2, 4, and 6</p> <p>Double-blind – telephone support (control): n = 147 (excluded: n = 1); 5 minutes general support calls at weeks 8, 12, 16, and 20</p> <p>Double-blind – extended cognitive-behavioural therapy: n = 154 (excluded: n = 2); 4 sessions, 30 minutes each, at weeks 8, 12, 16, and 20 and weekly check-in calls to automated system; report of relapse or craving prompted proactive calls</p>
Outcomes	<p>Primary outcomes: expired air CO-confirmed 7-day point prevalence abstinence evaluated at both 20 and 52 weeks</p> <p>Secondary outcomes: nicotine dependence (craving and withdrawal symptoms); major depressive disorder; medication compliance; heart rate and blood pressure; adverse events; medication compliance</p>
Funding source	Support was provided solely by a grant from the National Institute on Drug Abuse.
Declaration of interest	Dr Schatzberg serves as a consultant to GlaxoSmithKline.
Notes	Analysis of pharmacogenetics is reported in Sarginson 2011 .

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation to extended treatment condition was conducted via a permuted block method (block size = 4 to obtain balance between groups) and was stratified by gender.
Allocation concealment (selection bias)	Low risk	Participants were assigned to the next available ID number in the corresponding gender.

Killen 2008 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	Research team and participants were blinded to extended treatment assignment until the end of the open-label phase.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Research team and participants were blinded to extended treatment assignment.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Follow-up: 89% in standard care; 90% in intervention group
Selective reporting (reporting bias)	Low risk	Study protocol was not available but detailed reporting of outcomes does not suggest selective reporting.
Other bias	Unclear risk	Of 304 trial participants, 270 provided samples for DNA extraction, but the selection process for those 270 was unclear.

Killen 2010

Methods	8-Week double-blind randomized placebo-controlled clinical trial Setting: community-based, USA Recruitment: community recruitment through radio, newspapers, community website, and notices distributed via local organisations Study period: May 2006 to July 2008	
Participants	N = 243 Inclusion criteria: 18 to 65 years of age; smoked 10 or more cigarettes a day Males: 70%; average age: 45; average cigarettes/d: 19	
Interventions	Selegiline patch for 8 weeks, 6 mg/24 hours, starting on TQD vs identical placebo patch on same schedule Both groups received 9 sessions of individual cognitive-behavioural therapy.	
Outcomes	Primary outcome: point prevalence abstinence (PPA) at week 25 and week 52 (i.e. report of non-smoking (not even a puff) for 7 consecutive days before contact and an expired air carbon monoxide level < 10 ppm) Secondary outcomes: time to relapse; occurrence, duration, and severity of adverse events	
Funding source	National Institute on Drug Abuse; medication and matching placebo were provided by Somerset Pharmaceuticals, Inc.	
Declaration of interest	Dr Schatzberg served as a consultant for Somerset Pharmaceuticals.	
Notes	Analyses of pharmacogenomics are reported in Sarginson 2015 (N = 231 with DNA samples; 77.1% Caucasian, 9.1% Hispanic, 3.9% Asian, 1.3% black, 0.4% other, and 8.2% mixed ancestry). All analyses of pharmacogenomics were performed in both the full cohort and the Caucasian-only cohort.	

Killen 2010 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Use of random number generator
Allocation concealment (selection bias)	Low risk	Participants were assigned sequential ID numbers corresponding to drugs used. Also: "The drug (active or placebo) associated with each ID was pre-packaged and labelled by ID only at an off-site location by an individual who had no association with the participants."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Treatment assignment was concealed from staff and both research staff and participants were blind to week 52."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"Treatment assignment was concealed from staff and both research staff and participants were blind to week 52."
Incomplete outcome data (attrition bias) All outcomes	Low risk	Follow-up at 12 months: 87% (same in both arms)
Selective reporting (reporting bias)	Low risk	Registered in clinicaltrials.gov under NCT01330030; no deviation from pre-specified outcomes
Other bias	Low risk	12 people did not provide DNA for analyses of pharmacogenomics; use of PCA was included in analyses of pharmacogenomics.

Lerman 2002

Methods	<p>Double-blind randomised placebo-controlled clinical trial of bupropion HCL (brand name Zyban) in adult male and female smokers</p> <p>Study period: June 1999 to March 2002</p>
Participants	<p>N = 555 allocated and received intervention (Lerman 2006). Numbers included in published pharmacogenetic analyses include ~ 414 (Lerman, 2006), ~ 412 (Conti, 2008), and ~ 416 (Bergen, 2013), which refer to European ancestry individuals only, but data made available for this review include non-Hispanic white and non-Hispanic black, total ~ 494.</p> <p>Participants were smokers seeking treatment and were recruited through advertisements for a free smoking cessation programme at Georgetown University and at the State University of New York at Buffalo.</p> <p>Inclusion criteria: age ≥ 18 years, reported smoking ≥ 10 cigarettes/d for the previous 12 months, who provided informed consent for both genotyping and treatment</p> <p>Exclusion criteria: planning a pregnancy, pregnant, lactating; seizure disorder, history of head trauma or prior seizure, family history of a seizure disorder; brain (or CNS) tumour; history of or current diagnosis of bulimia or anorexia nervosa; diabetes treated with oral hypoglycaemics or insulin; excessive use of alcohol or alcoholism; current addiction to opiates, cocaine, or stimulants; use of other drugs containing bupropion (e.g. Wellbutrin, Wellbutrin SR); allergy to bupropion; currently taking particular medications (e.g. monoamine oxidase inhibitor, antipsychotics, antidepressants, theophylline, sys-</p>

Lerman 2002 (Continued)

temic steroids, over-the-counter stimulants and anorectics); recently taking an MAOI (< 14 days); or recent discontinuation of a benzodiazepine

Interventions	<p>Bupropion and 7 sessions of in-person behavioural group counseling (N = 285 allocated, 229 received allocation), and</p> <p>Placebo and 7 sessions of in-person behavioural group counseling (N = 70 allocated, 211 received allocation)</p> <p>Participants received 10 weeks of pills (active or placebo) initiated on the first day of counseling. Bupropion treatment was standard (150 mg/d for 3 days, then 300 mg/d). The target quit day was day of the third counseling session.</p>
Outcomes	<p>Primary outcomes: continuous abstinence measured at end of treatment and at 6 months after cessation</p> <p>Secondary outcomes: short-term quit rates using 7-day and 30-day point prevalence</p> <p>83% and 86% of participants reporting abstinence at end of treatment and at 6 months provided a CO sample for verification.</p>
Funding source	Study medication for the bupropion trial was provided by GlaxoSmithKline. This research was supported by grants from the National Cancer Institute and the National Institutes of Drug Abuse, P50CA/DA84718 and RO1CA 63562.
Declaration of interest	Dr Berrettini has consulted for GlaxoSmithKline.
Notes	Lerman 2002 described an interim analysis of mediators on cessation and was the first published description of this trial. Lerman 2006 is the definitive description of the trial and the first published analysis of pharmacogenetics.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was computer generated by a senior data manager.
Allocation concealment (selection bias)	Low risk	Allocation was concealed from counselors and study assistants.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcomes were assessed via a timeline follow-back method through phone interviews with study assistants.
Incomplete outcome data (attrition bias) All outcomes	High risk	As described in Lerman 2006, 17% withdrew after allocation but before intervention (not included in ITT analysis), and 23% of the remainder were lost to follow-up or discontinued treatment but were included in the ITT analysis. No significant differences in losses were reported at either stage by arm. However, as abstinence outcomes were 27% at EOT and 22% at 6 months, attrition proportion seems high.
Selective reporting (reporting bias)	Low risk	Conti 2008 reported on continuous abstinence.

Lerman 2002 (Continued)

Other bias	Low risk	Genotype completion rate was very high overall, so selection bias by treatment group is low.
------------	----------	--

Lerman 2004

Methods	Open-label randomised clinical trial of transdermal vs spray nicotine replacement therapy (brand names Nicoderm and Nicotrol), with behavioural group counseling provided to all participants Study period: February 2000 to August 2003
Participants	Participants were smokers seeking treatment and were recruited through advertisements for a free smoking cessation programme at Georgetown University and at the University of Pennsylvania. Inclusion criteria: ≥ 18 years of age, reported smoking of ≥ 10 cigarettes/d for the previous 12 months, and provided informed consent for both genotyping and treatment Exclusion criteria: planning a pregnancy, pregnancy or lactation; seizure disorder, history of head trauma or prior seizure; unstable angina, heart attack, or stroke within past 6 months; current treatment for or recent diagnosis of cancer; drug or alcohol dependence; current diagnosis or history of a DSM-IV axis I psychiatric disorder; current use of bupropion or nicotine-containing products other than cigarettes; and skin allergies or chronic dermatitis
Interventions	N = 600 allocated and received intervention (Lerman 2006). Numbers included in published pharmacogenetic analyses include ~ 368 (Lerman 2006) and ~ 378 (Bergen 2013), which refer to European ancestry individuals only. Treatment allocation could not be concealed. Eight weeks of NRT (standard Nicoderm patch, N = 302, or Nicotrol spray, N = 298) was provided to participants on the target quit date after 2 weeks of counseling. A total of 7 sessions of behavioural group counselling was provided.
Outcomes	Primary outcomes: continuous abstinence measured at end of treatment and at 6 months after cessation Secondary outcomes: short-term quit rates using 7-day and 30-day point prevalence 76% and 72% of participants reporting abstinence at end of treatment and at 6 months provided a CO sample for verification.
Funding source	This work was supported by a Transdisciplinary Tobacco Use Research Center Grant from the National Cancer Institute and the National Institute on Drug Abuse P5084718, and the Abramson Cancer Center and Annenberg Public Policy Center (CL), and PHS grants P60DA005186 (WB), DA02277, DA12393, CA078703, and the UCSF Comprehensive Cancer Center (NB), and Public Health Services Research Grant M01-RR0040 from the National Institutes of Health. Nicotine nasal spray was provided by Pharmacia, Helsingborg, Sweden.
Declaration of interest	Dr Berrettini acts as a consultant to GlaxoSmithKline.
Notes	Lerman 2004 described an interim analysis of pharmacogenetics of abstinence and was the first published description of this trial. Lerman 2006 is the definitive description of the trial.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was computer generated by a senior data manager.

Lerman 2004 (Continued)

Allocation concealment (selection bias)	High risk	Allocation could not be concealed from counselors and study assistants.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open-label trial
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcomes were assessed via a timeline follow-back method through phone interviews with study assistants.
Incomplete outcome data (attrition bias) All outcomes	High risk	As described in Lerman 2006 , 11% withdrew after allocation but before intervention (not included in ITT analysis), and 22% of the remainder were lost to follow-up or discontinued treatment but were included in the ITT analysis. No significant differences in losses at either stage by arm. However, as abstinence outcomes were 33% at EOT and 20% at 6 months, attrition proportion seems high.
Selective reporting (reporting bias)	Unclear risk	Lerman et al reported on primary and secondary outcomes; Bergen et al on secondary outcomes.
Other bias	Low risk	Genotype completion rate was very high overall, so selection bias by treatment group is low.

Lerman 2015

Methods	Double-blind parallel-group placebo and active treatment-controlled randomised clinical trial Study period: November 2010 to September 2013
Participants	N = 1246 Participants were smokers seeking treatment and were recruited through advertisements for a free smoking cessation programme. Inclusion criteria: age between 18 and 65 years, reported smoking ≥ 10 cigarettes/d for 6 months or longer (verified by carbon monoxide concentrations > 10 ppm) Exclusion criteria: use of non-cigarette tobacco products, e-cigarettes, or current smoking treatment; history of substance misuse treatment, current use of cocaine or methamphetamine, or more than 25 alcoholic drinks/week; medical contraindications; history of DSM-IV Axis I psychiatric disorder or suicide risk score on the Mini-International Neuropsychiatric Interview (MINI) > 1 , or current major depression; current use of antipsychotics, stimulants, opiate medications, anticoagulants, rescue inhalers, antiarrhythmics, or medications altering CYP2A6 activity (e.g. monoamine oxidase inhibitors, tricyclic antidepressants); and inability to provide informed consent or any condition that could compromise safety
Interventions	Placebo pill + placebo patch (n = 408) Placebo pill + nicotine patch (n = 418) Varenicline + placebo patch (n = 420) Participants received 11 weeks of patches: 21 mg (6 weeks), 14 mg (2 weeks), and 7 mg (3 weeks). Varenicline (or placebo) was delivered for 12 weeks (1 week before the target quit date): days 1 to 3 (0.5 mg once daily); days 4 to 7 (0.5 mg twice daily); and days 8 to 84 (1.0 mg twice daily).

Lerman 2015 (Continued)

Outcomes	<p>Primary outcome: biochemically verified 7-day point prevalence abstinence at end of treatment</p> <p>Secondary outcomes: side effects, withdrawal symptoms, 6-month and 12-month quit rates</p>
Funding source	<p>This work was supported by a grant from the National Institute on Drug Abuse, the National Cancer Institute, the National Human Genome Research Institute, and the National Institute on General Medical Sciences (U01-DA20830) to CL and RFT; funding from the Abramson Cancer Center at the University of Pennsylvania (P30 CA16520) and a grant from the Commonwealth of Pennsylvania Department of Health was provided to CL; a grant from the Canadian Institutes of Health Research (CIHR TMH109787), an endowed Chair in Addiction for the Department of Psychiatry, CAMH Foundation, the Canada Foundation for Innovation (#20289 and #16014), and the Ontario Ministry of Research and Innovation were given to RFT. The Pennsylvania Department of Health disclaims responsibility for analyses, interpretations, or conclusions. Pfizer provided varenicline and placebo pills at no cost.</p>
Declaration of interest	<p>CL received study medication and placebo, and support for medication packaging, from Pfizer; she has also consulted for Gilead, and has been a paid expert witness in litigation against tobacco companies. PC served on the scientific advisory board of Pfizer Pharmaceuticals, presented educational talks sponsored by Pfizer on smoking cessation from 2006 to 2008, and has received grant support from Pfizer.</p> <p>RAS received medication and placebo free of charge from Pfizer for a different project, and has consulted for Pfizer and GlaxoSmithKline.</p> <p>TPG has received both investigator-initiated and industry-sponsored grants from Pfizer in the past 12 months, and serves on a data monitoring committee for Novartis.</p> <p>NIB has served as a consultant to several pharmaceutical companies that market smoking cessation medications and has been a paid expert witness in litigation against tobacco companies.</p> <p>RFT has acted as a consultant to pharmaceutical companies, primarily on smoking cessation.</p> <p>The remaining authors declare no competing interests.</p>
Notes	<p>This paper provided analysis of pharmacogenetics. Additional analyses are reported in Tyndale 2015.</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	A biostatistician, independent of study investigators, developed a randomisation procedure, which was integrated into a centralised data management system.
Allocation concealment (selection bias)	Low risk	Randomisation was centrally organised.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants, study investigators, and personnel were masked to treatment group allocation.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding was appropriate, and the outcome of the study was objective.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Incomplete outcome data are similar in all treatment groups; different validation analyses were performed to deal with missing data.
Selective reporting (reporting bias)	Low risk	All outcomes listed on clinicaltrials.gov (NCT01314001) are reported. However, 12-month quit rates were not listed in the protocol but are presented in the manuscript.

Lerman 2015 (Continued)

Other bias	Low risk	Additional analyses of pharmacogenetics in Tyndale 2015 were conducted in Caucasians only, but these seem to be distributed equally among treatment groups, so selection bias seems unlikely.
------------	----------	---

Marteau 2012

Methods	Open-label parallel-group randomised controlled trial of genotype-based vs dependence score-based oral dose of NRT for smoking cessation (the "Personalised Extra Treatment (PET) Trial") Study period: June 2007 to September 2009
Participants	N = 633 Participants were recruited from 29 primary care practices in Birmingham and Bristol, UK. Inclusion criteria: (a) ≥ 18 years of age, (b) regular cigarette smoker of ≥ 10 cigarettes/d, (c) wants to stop smoking, (d) able to give informed consent to participate, (e) able to complete study questionnaires, alone or with assistance Exclusion criteria: (a) cigar, pipe, and oral tobacco users who do not also smoke ≥ 10 cigarettes/d, (b) contraindications to NRT use, (c) pregnant or lactating women and those who plan to become pregnant during the course of treatment, (d) previous severe adverse reactions to NRT patch or to oral NRT, (e) currently taking medication for smoking cessation that they are unwilling to stop, (f) taking medication with a known influence on smoking cessation that they should not stop (e.g. nortriptyline for depression), (g) non-English speakers, (h) those deemed unsuitable for the study by their primary care physicians
Interventions	DNA-tailored oral NRT dose (N = 315) Nicotine dependence-tailored NRT dose (N = 318) Participants were randomly allocated on a 1:1 basis to 1 of 2 groups: (a) NRT oral dose tailored by DNA analysis (<i>OPRM1</i> gene) (genotype), or (b) NRT oral dose tailored by nicotine dependence questionnaire score (phenotype). All participants were offered behavioural support and an NRT patch, tailored for all participants by phenotype (daily cigarettes smoked). Trial interventions comprised communication that the prescribed dose of oral NRT was based on either genotype (intervention) or phenotype (comparison). Support for behavioural change was based on withdrawal-oriented therapy and was provided for all participants twice before quit day and weekly thereafter until 4 weeks after quitting, then once more 8 weeks after quitting.
Outcomes	Primary outcomes: adherence to prescription of NRT over 28 days, motivation to make further quit attempts Secondary outcomes: adherence to prescription of NRT over 7 days, 6-month abstinence
Funding source	"This study was funded as part of a grant from the Medical Research Council, UK (Risk communication in preventive medicine: Optimising the impact of DNA risk information; G0500274 PI: TMM). The trial protocol was peer reviewed by the Council. PA is funded by a personal award from the National Institute of Health Research (NIHR) and by the UK Centre for Tobacco Control Studies (UKCTCS). PA and MRM are members of UKCTCS, a UKCRC Public Health Research Centre of Excellence. Funding from British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, and National Institute for Health Research, under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged. The sponsors and funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Marteau 2012 (Continued)

Declaration of interest	“PA has done consultancy and research on smoking cessation for pharmaceutical companies. The remaining authors declare that they have no conflicts of interest.”	
Notes	DNA samples were collected at study entry.	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	“The trial statistician generated the sequences and received the stratifier data and participant and family identifier required to randomise participants, and participant date of birth to confirm group allocation at trial closure.”
Allocation concealment (selection bias)	Low risk	Before group assignment, allocation was concealed.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Randomisation sequence was revealed sequentially and was concealed from the study team, nurses, and participants. After assignment to groups, allocation was no longer blinded.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding was appropriate, and the outcome of the study was objective.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Loss to follow-up was modest and balanced, and all participants were analysed by intention-to-treat.
Selective reporting (reporting bias)	Low risk	Trial protocol was pre-registered and was published before the results paper, which reported prespecified outcomes.
Other bias	Low risk	The trial and its outcomes were reported openly.

McCarthy 2008

Methods	Open-label behavioural intervention and placebo-controlled pharmacotherapy intervention randomised clinical trial	
	Study period: January 2001 to October 2003	
Participants	<p>N = 463</p> <p>Participants were smokers seeking treatment recruited through mass media and screened by 3 rounds (telephone, group orientation, office visit).</p> <p>Inclusion criteria: aged 18 years or older who reported smoking ≥ 10 cigarettes/d and whose expired carbon monoxide (CO) levels exceeded 9 ppm. Participants reported being motivated to quit smoking (3 or 4 on a 4-point self-report scale) and being willing to fulfil study requirements.</p> <p>Exclusion criteria: serious psychopathology (bipolar disorder or psychosis), current depression, contraindications to use of bupropion SR (e.g. uncontrolled hypertension, history of seizure disorder, history of eating disorders, current heavy drinking, risk of pregnancy, current breastfeeding). Participants were excluded if their score on the Center for Epidemiologic Studies Depression (CES-D) scale was above 16, except when an interview with a licensed clinician suggested that symptoms were related to a cause other than clinical depression.</p>	

McCarthy 2008 (Continued)

Interventions	<p>Active (bupropion SR) pharmacotherapy and individual targeted counseling (n = 113)</p> <p>Active pharmacotherapy, general counseling (N = 116)</p> <p>Placebo pharmacotherapy, individual targeted counseling (N = 121)</p> <p>Placebo pharmacotherapy, general counseling (N = 113)</p> <p>Participants attended 5 office visits in the 3 weeks before the quit date. Participants received 9 weeks of study pills (active or placebo), to begin 1 week before and to end 8 weeks after the planned quit date. Participants attended another 8 office visits over the 8 weeks following the quit date (provided breath samples at each visit and a blood sample at baseline and at end of treatment), then completed 10 monthly follow-up calls. All participants received education regarding medication use and adherence, quit day information, and general encouragement, and completed electronic diaries for 2 weeks before and 4 weeks after the quit date. Participants randomised to individual targeted counseling received eight 10-minute individual counseling sessions (2 prequit, 1 quit day, 5 postquit over 4 weeks).</p>
Outcomes	<p>Primary outcomes: electronic diary and retrospective report of lapse and of relapse (7 days) with 7-day point prevalence abstinence confirmed via CO at each office visit and cotinine testing at end of treatment; 7-day point prevalence abstinence at 6 and 12 months with CO testing</p> <p>Secondary outcomes: prolonged abstinence outcomes at end of treatment, at 6 and 12 months</p>
Funding source	<p>This work was supported by Transdisciplinary Tobacco Use Research Center grants CA084724 from the National Cancer Institute and DA19706 from the National Institute on Drug Abuse. GlaxoSmithKline provided complimentary active and placebo medication used in this study. GlaxoSmithKline was not involved in the design, data collection, analysis, or reporting of this study.</p>
Declaration of interest	<p>DEJ has received research support from Nabi Biopharmaceutical and Pfizer, Inc., and consulting fees from Nabi Biopharmaceutical. SS serves as consultant to GlaxoSmithKline Consumer Healthcare on an exclusive basis regarding over-the-counter smoking cessation products and is a partner in a company that is developing a new nicotine medication. He is a cofounder of invivodata, Inc., which provides electronic diary services for clinical research. In 1998 the University of Wisconsin appointed MCF to a named Chair made possible by an unrestricted gift to the university from GlaxoWellcome.</p>
Notes	<p>This work did not report analyses of pharmacogenetics, but these were reported in Bergen 2013.</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation via random number list
Allocation concealment (selection bias)	Unclear risk	Study pills did not differ in appearance between active and placebo but were packaged in containers before enrolment of participants. Randomisation was done via a random number list.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Research staff and participants were blind to pharmacotherapy randomisation but were not blind to counseling randomisation.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome assessment was done by electronic diary through end of treatment, and by interview (self-report), performed in office or by phone calls, with biochemical abstinence verified at each office visit (CO) and at 6 and 12 months (cotinine). Discordance between reports or verification methods analysed in multiple ways, but final prevalences highly similar

McCarthy 2008 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition was substantial and did not differ by treatment arm at quit, end of treatment, or any other follow-up point. Attrition was related to various co-variates included in abstinence models in the primary paper.
Selective reporting (reporting bias)	Low risk	Primary and secondary outcomes were reported.
Other bias	High risk	DNA samples were provided for 41% of self-identified whites for analysis of pharmacogenetics. Most (~ 99%) DNA samples were successfully genotyped. Analyses of pharmacogenetics in Bergen 2013 are distributed equally among treatment groups, so selection bias is unlikely in this sample.

Oncken 2006

Methods	Double-blind parallel-group placebo and active treatment-controlled randomised clinical trial Study period: study dates not reported
Participants	N = 647 Participants were healthy cigarette smokers. Recruitment methods not reported Inclusion criteria: 18 to 65 years of age, smoke ≥ 10 cigarettes/d Exclusion criteria: treatment with an investigational drug within the previous month; major depression within the prior year; panic disorder, psychosis, or bipolar disorder; use of nicotine replacement or bupropion within the previous 3 months; cardiovascular disease; clinically significant medical disease; drug or alcohol abuse or dependence within the past year; use of tobacco products other than cigarettes or marijuana within the previous month
Interventions	0.5 mg twice-daily non-titrated varenicline (n = 129) 0.5 mg twice-daily titrated varenicline (n = 130) 1.0 mg twice-daily non-titrated varenicline (n = 129) 1.0 mg twice-daily titrated varenicline (n = 130) Placebo (n = 129) Participants received study medication for 12 weeks. Specifically, participants in each of these groups received the following medication: 0.5 mg twice daily non-titrated (i.e. 0.5 mg twice daily for 12 weeks); 0.5 mg twice daily titrated (i.e. 0.5 mg once daily for 7 days, then 0.5 mg twice daily for 11 weeks); 1.0 mg twice daily non-titrated (i.e. 1.0 mg twice daily for 12 weeks); 1.0 mg twice daily titrated (i.e. 0.5 mg once daily for 3 days, then 0.5 mg twice daily for 4 days, then 1.0 mg twice daily for 11 weeks); or placebo (i.e. 2 placebo tablets twice daily for 12 weeks). All participants received a smoking cessation booklet at the baseline visit and brief smoking cessation counseling (up to 10 minutes) at each visit.
Outcomes	Primary outcomes: carbon monoxide-confirmed 4-week continuous quit rate for weeks 4 through 7 and weeks 9 through 12 during treatment and continuous abstinence rates for weeks 9 through 52 for each dose relative to placebo. Continuous abstinence was defined as self-report of no cigarette use during the specified time period confirmed by an exhaled carbon monoxide measurement ≤ 10 ppm Other outcomes: carbon monoxide-confirmed 7-day point prevalence abstinence, changes in the Minnesota Nicotine Withdrawal Scale and the modified Cigarette Evaluation Questionnaire, carbon monoxide-confirmed 7-day point prevalence abstinence at weeks 24 and 52

Oncken 2006 (Continued)

Funding source	Pfizer Inc. provided funding for this study. Pfizer Inc. was involved in all elements of this study, including, but not limited to, study design and monitoring.
Declaration of interest	Dr Oncken has received research grants, consulting fees, and honoraria from Pfizer; nicotine replacement and placebo products from GlaxoSmithKline at no cost for smoking cessation studies; and honoraria from Pri-Med. Dr Gonzales has received research contracts, consulting fees, and honoraria from Pfizer, Sanofi-Aventis, and GlaxoSmithKline, and owns 5 shares of Pfizer stock that he received as a gift from his parents. Dr Rennard has had or currently has a number of relationships with companies that provide products and/or services relevant to outpatient management of chronic obstructive pulmonary disease. These relationships include serving as a consultant (for Adams, Almirall, Altana, Array Biopharma, AstraZeneca, Aventis, Biolipox, Centocor, Dey, Critical Therapeutics, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Ono Pharma, Otsuka, RJ Reynolds, Roche, Sankyo, Schering-Plough, Scios, and Wyeth), advising regarding clinical trials (Altana, AstraZeneca, Aventis, Centocor, GlaxoSmithKline, Novartis, Pfizer, and Philip Morris), speaking at continuing medical education programs and performing funded research at both basic and clinical levels (Altana, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Novartis). He does not own any stock in any pharmaceutical companies. Dr Nides has received research grants, consulting fees, and honoraria from Pfizer, Sanofi-Avenits, and GlaxoSmithKline. Drs Watsky and Reeves and Messrs Billing and Anziano are employees of Pfizer and own Pfizer stock or hold Pfizer stock options.
Notes	Analysis of pharmacogenetics was reported in King 2012 .

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details reported
Allocation concealment (selection bias)	Unclear risk	No details reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants and investigators were blinded to study drug treatment assignment. Participants were not encouraged to guess their treatment assignment.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding was appropriate, and the outcome of the study was objective.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	More dropout in the placebo group and specific dropout for lack of efficacy occurred more often in the 1.0 mg twice-daily titrated varenicline group. Dropouts were assumed to be smoking.
Selective reporting (reporting bias)	Unclear risk	No protocol was found.
Other bias	Low risk	Additional analyses of pharmacogenetics were conducted in King 2012 in a subset of the original randomised trial population, but baseline characteristics were comparable between treatment groups, so selection bias seems unlikely.

Piper 2007

Methods	Double-blind placebo-controlled combination pharmacotherapy intervention randomised clinical trial. Ten cohorts of participants were randomised in a block manner to 3 intervention arms.
---------	---

Piper 2007 (Continued)

Study period: January 2001 to October 2002

Participants	<p>N = 608</p> <p>Participants were smokers seeking treatment who were recruited through mass media.</p> <p>Inclusion criteria: 18 years of age or older, who reported smoking ≥ 10 cigarettes/d and being motivated to quit (3 or 4 on a 4-point self-report scale).</p> <p>Exclusion criteria: expired carbon monoxide (CO) levels < 10 ppm; CES-D score > 16; suicidality; contraindications to use of bupropion SR (e.g. uncontrolled hypertension, history of seizure disorder, history of eating disorders, current heavy drinking, current breastfeeding). Female participants were not pregnant and agreed to prevent pregnancy during treatment.</p>
Interventions	<p>Active (bupropion SR) pharmacotherapy and active nicotine gum (4 mg as needed up to 12 mg/d) (n = 228)</p> <p>Active bupropion pharmacotherapy and placebo gum (N = 224)</p> <p>Placebo pharmacotherapy and placebo gum (N = 156)</p> <p>Participants attended a baseline screening (physical exam, questionnaires to assess medical/psychological exclusions, and nicotine dependence inventories), were randomised to 1 of 3 intervention arms for 9 weeks of treatment. After the baseline visit, participants attended office visits each week for 4 weeks, then every other week for 4 weeks (through the end of treatment). Participants received three 10-minute counseling sessions (at baseline, quit day, and first post-quit day weeks), providing medication instruction and Public Health Service Guideline elements. At remaining office visits, participants completed questionnaires and vital sign assessment and received medications. Participants completed a daily diary through treatment and used a cell phone for 2 weeks to collect real-time data. Participants were followed monthly by telephone (smoking calendar and symptoms) to 6 months and 12 months.</p>
Outcomes	<p>Primary outcome: 7-day point prevalence abstinence at 6 months confirmed via CO (breath) or cotinine (blood) analysis</p> <p>Secondary outcomes: 7-day point prevalence abstinence at 1 week post quit, at end of treatment, and at 12 months (12-month abstinence confirmed via CO (breath) or cotinine (blood) analysis), continuous abstinence</p>
Funding source	<p>This work was supported by Transdisciplinary Tobacco Use Research Center grants CA084724 from the National Cancer Institute and DA019706 from the National Institute on Drug Abuse.</p>
Declaration of interest	<p>Dr Fiore neither consults for nor accepts honoraria from the pharmaceutical industry, effective 1 January 2006. In 1998 the University of Wisconsin appointed Dr Fiore to a named chair, made possible by an unrestricted gift to the university from GlaxoWellcome. Dr Baker has received monies from pharmaceutical companies (Nabi, Glaxo, Pfizer, Sanofi) to conduct clinical trials; he has received no personal remuneration from these companies.</p>
Notes	<p>This work did not report analyses of pharmacogenetics, but these were reported in Bergen 2013.</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No description
Allocation concealment (selection bias)	Unclear risk	No description

Piper 2007 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	Research staff and participants were blind to pharmacotherapy randomisation.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome assessment was done by daily diary and by self-report through end of treatment, and by self-report through the remaining 12 months, with biochemical abstinence verified at 6 and 12 months.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition was moderate and did not differ by treatment arm at quit, at end of treatment, and at 6 and 12 months.
Selective reporting (reporting bias)	Low risk	Primary and secondary outcomes were reported.
Other bias	Unclear risk	DNA samples were provided for 60% of self-identified white trial participants for analysis of pharmacogenetics. Most (~99%) DNA samples were successfully genotyped. Analyses of pharmacogenetics are distributed equally among treatment groups in Bergen 2013 , so selection bias is unlikely in this sample.

Piper 2009

Methods	Double-blind placebo-controlled single and combination pharmacotherapy intervention randomised clinical trial Study period: September 2004 to August 2010
Participants	N = 1504 Participants were smokers seeking treatment who were recruited through mass media. Inclusion criteria: 18 years of age or older who reported smoking ≥ 10 cigarettes/day for the past 6 months, expired CO > 9 ppm, motivated to quit (3 or 4 on a 4-point self-report scale), able to read and write English, and willing to complete assessments Exclusion criteria: using any form of tobacco other than cigarettes, currently taking bupropion, or having a current psychosis or schizophrenia diagnosis. In addition, participants were excluded if they had medical contraindications for any of the study medications, including high alcohol consumption (6 drinks/day on 6 or 7 days of the week), a history of seizure, high blood pressure ($> 160/100$ mm Hg), bipolar disorder, an eating disorder, a recent cardiac event, or allergies to any of the medications. Only 1 person per household could participate. Finally, pregnant and breastfeeding women were not eligible for participation; eligible female participants had to agree to take steps to prevent pregnancy during the medication treatment phase of the study.
Interventions	Active (bupropion SR) pharmacotherapy for 9 weeks - 1 week prequit, 8 weeks post quit (n = 264) Nicotine lozenge (2 or 4 mg for 12 weeks post quit) (n = 260) Nicotine patch (24-hour patch 21, 14, and 7 mg over 8 weeks post quit) (n = 262) Nicotine patch (8 weeks post quit) plus nicotine lozenge (12 weeks post quit) (n = 267) Active bupropion pharmacotherapy plus nicotine lozenge (n = 262) Placebo pharmacotherapy (placebo bupropion, placebo lozenge, placebo patch, placebo patch plus lozenge, and placebo bupropion plus lozenge) (n = 189)

Piper 2009 (Continued)

Participants attended 5 baseline (prequit) screenings (physical exam, questionnaires to assess medical/psychological exclusions, and nicotine dependence inventories, and cardiovascular assessments). Participants were randomised to 1 of 6 intervention arms for 9 to 12 weeks of treatment at the fifth baseline visit. Participants attended study visits on their quit day and 1, 2, 4, and 8 weeks post quit, and received six 10- to 20-minute counseling sessions at the third and fifth baseline visits, on their quit day, and at weeks 1, 2, and 4.

Outcomes	<p>Primary outcome: 7-day point prevalence abstinence at 1 week post quit, at end of treatment, and at 6 months post quit, confirmed via CO (breath) analysis</p> <p>Secondary outcomes: initial cessation, days to lapse, days to relapse, latency to relapse after lapse</p>
Funding source	This research was conducted at the University of Wisconsin–Madison and was supported by grant P50 DA019706 from the National Institute on Drug Abuse and by grant M01 RR03186 from the General Clinical Research Centers Program of the National Center for Research Resources. Dr Piper was supported by an Institutional Clinical and Translational Science Award, University of Wisconsin–Madison (KL2 grant 1KL2RR025012-01). Medication was provided to participants at no cost under a research agreement with GlaxoSmithKline.
Declaration of interest	Study authors report the following potential conflicts of interest for the past 5 years: Dr Smith has received research support from Elan Corporation. Dr Baker has served as an investigator on research projects sponsored by pharmaceutical companies, including Sanofi-Synthelabo, Pfizer Inc., and Nabi Biopharmaceuticals. Dr Jorenby has received research support from the National Institute on Drug Abuse, the National Cancer Institute, Pfizer Inc., Sanofi-Synthelabo, and Nabi Biopharmaceuticals. He has received support for educational activities from the National Institute on Drug Abuse and the Veterans Administration, and consulting fees from Nabi Biopharmaceuticals. Dr Fiore has received honoraria from Pfizer. He has served as an investigator on research studies at the University of Wisconsin that were funded by Pfizer, Sanofi-Synthelabo, GlaxoSmithKline, and Nabi Biopharmaceuticals. In 1998, the University of Wisconsin appointed Dr Fiore to a named chair funded by an unrestricted gift to University of Wisconsin from Glaxo Wellcome.
Notes	This work did not report analyses of pharmacogenetics, but these were reported in Bergen 2013 .

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Blocked on sex and self-reported race but no other description
Allocation concealment (selection bias)	Low risk	Allocation was concealed until the moment of randomisation (3 different types of pharmacotherapy).
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Research staff and participants were blind to active vs placebo pharmacotherapy randomisation.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome assessment was done by self-report, with biochemical (CO) verification at 6 and 12 months.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition was very modest and did not differ by treatment arm during treatment or follow-up.
Selective reporting (reporting bias)	Low risk	Primary and secondary outcomes were reported.

Piper 2009 (Continued)

Other bias	Low risk	DNA samples were provided for 83% of self-identified white trial participants for analysis of pharmacogenetics. Most (~ 99%) DNA samples were successfully genotyped. Pharmacogenetic analyses are distributed equally amongst treatment groups in Bergen 2013 , so selection bias is unlikely in these arms and subsamples.
------------	----------	--

Rose 2010

Methods	<p>Randomised double-blind parallel-arm placebo-controlled factorial trial with 2 levels of nicotine dependence and 2 nicotine doses</p> <p>Setting: academic centre, USA</p> <p>Recruitment: community volunteers</p> <p>Study period: not reported; August 2007 to May 2009 according to clinicaltrials.gov</p>
Participants	<p>N = 479</p> <p>43.4% males; average age: ~ 44; average cigarettes/d: 24</p> <p>Inclusion criteria (as reported in clinicaltrials.gov): "18-65 years old, smokers of at least 10 cigarettes per day for three cumulative or continuous years of a brand that delivers at least 0.5 mg nicotine, have an expired air carbon monoxide reading of at least 10 ppm, and express a desire to quit smoking. Additionally, subjects must express a willingness to switch to denicotinized cigarettes."</p> <p>Exclusion criteria (as reported in clinicaltrials.gov): "Participants with hypertension or hypotension may, however, be allowed to participate in the study if the study physician or P.A. determines that the condition is stable, controlled by medication, and in no way jeopardizes the individual's safety. Subjects with no previous diagnosis of hypertension may have a screening blood pressure up to 160/100. Potential subjects who report coronary heart disease; heart attack; cardiac rhythm disorder (irregular heart rhythm); chest pains (unless history, exam, and EKG clearly indicate a non-cardiac source); cardiac (heart) disorder (including but not limited to valvular heart disease, heart murmur, heart failure); history of skin allergy; active skin condition (psoriasis) within the last five years; skin disorder except minor skin conditions (including but not limited to facial acne, minor localized infections, and superficial minor wounds.); liver or kidney disorder (except kidney stones, gallstones); gastrointestinal problems or disease other than gastroesophageal reflux or heartburn; ulcers; lung disorder (including but not limited to COPD, emphysema, and asthma); brain abnormality (including but not limited to, stroke, brain tumour, seizure disorder); history of fainting; problems giving blood samples; difficulty passing urine; diabetes treated with insulin, non-insulin treated diabetes (unless glucose is less than 180mg/dcl and HbA1c is less than 7%); current cancer or treatment for cancer in the past 6 months (except basal or squamous cell skin cancer); other major medical condition; current psychiatric disease (with the exception of depression, anxiety disorders, OCD and ADHD) will be excluded from the study. Potential subjects who do not have a self reported diagnosis of the above listed conditions may be excluded if the study physician or P.A. determines that the history, physical findings, EKG, or laboratory studies reveal information that may jeopardize the subject's safe study participation."</p>
Interventions	<p>Nicotine patch 21 mg/24 h vs 42 mg/24 h in low vs high nicotine dependence groups</p> <p>Treatment groups: (a) less dependent/21 mg nicotine patch, (b) less dependent/42 mg nicotine patch, (c) more dependent/21 mg nicotine patch, and (d) more dependent/42 mg nicotine patch</p>
Outcomes	<p>Primary outcome: continuous abstinence from target quit date through end of treatment (10 weeks)</p> <p>Secondary outcomes: 4-week continuous abstinence during weeks 7 to 10 after target quit date; 7-day point abstinence at 6 months</p>

Rose 2010 (Continued)

Funding source	National Institutes of Health (NIH), Intramural Research Program, National Institute on Drug Abuse, Department of Health and Social Services; grant to Duke University from Philip Morris USA, Richmond, VA, USA
Declaration of interest	G.R. Uhl and J.E. Rose are listed as inventors for a patent application filed by Duke University based on genomic markers that distinguishes successful quitters from unsuccessful quitters in data from other clinical trials. Rose is the Principal Investigator for a grant from Philip Morris USA, Richmond, VA, USA, to Duke University; the company had no role in planning or execution of the study, data analysis, or publication of results.
Notes	This study provides analysis of pharmacogenetics.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information
Allocation concealment (selection bias)	Unclear risk	Double-blind design but no further details provided
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind design but no further details provided
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double-blind design but no further details provided
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Reasons for withdrawal not reported
Selective reporting (reporting bias)	Low risk	Protocol available at clinicaltrials.gov (NCT00734617); no deviations from pre-specified endpoints

Schnoll 2010

Methods	Parallel randomised double-blind placebo-controlled trial Setting: academic centre, USA Recruitment: community volunteers Study period: October 2004 to March 2008
Participants	N = 575 44.7% females; average age: 44.8; average cigarettes/d: 21.2 Inclusion criteria: age 18 to 65 years, smoked ≥ 10 cigarettes/d for at least the past year Exclusion criteria: pregnancy or lactation, uncontrolled hypertension, unstable angina, heart attack or stroke within previous 6 months, recent diagnosis of cancer or kidney or liver failure, history of organ

Schnoll 2010 (Continued)

	transplantation, current diabetes, drug or alcohol dependence, history of Axis I psychiatric disorder, current use of a concomitant medication, or current treatment of nicotine addiction
Interventions	Transdermal nicotine (21 mg) for 8 weeks and placebo for 16 weeks (standard therapy) (n = 287) vs transdermal nicotine (21 mg) for 24 weeks (extended therapy) (n = 288) Behavioural counseling was provided to both groups at weeks -2, 0, 1, 4, 8, 12, 16, and 20.
Outcomes	Primary outcome: self-reported and biochemically confirmed 7-day point prevalence abstinence at weeks 24 and 52 Secondary outcomes: self-reported continuous abstinence; prolonged abstinence; time to relapse; incremental cost per additional quitter by treatment group at week 24 Also evaluated: side effects; adherence
Funding source	Transdisciplinary Tobacco Use Research Center Grant from the National Cancer Institute and the National Institute on Drug Abuse at the National Institutes of Health
Declaration of interest	Dr Lerman has served as a consultant to GlaxoSmithKline - one company that manufactures the nicotine patch. She has also served as a consultant for or has received research funding from AstraZeneca, Pfizer, and Novartis. Financial support for this study was not provided by an industry sponsor. Dr Lerman had full access to the data and had full responsibility for the decision to submit for publication.
Notes	Analyses of pharmacogenetics are reported in Gold 2012 and Lerman 2010 .

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-based randomisation; non-stratified randomisation scheme was generated by sampling without replacement and by using small blocks of 20 participants.
Allocation concealment (selection bias)	Low risk	A computer programme linked randomisation to the patch supply, and only the database manager could link identification to treatment allocation.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants and all study personnel, except for the database manager, were blinded to randomisation.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants and all study personnel, except for the database manager, were blinded to randomisation.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Completion rates at 52 weeks: 83% for extended therapy; 79% for standard therapy
Selective reporting (reporting bias)	Low risk	Protocol available at ClinicalTrials.gov (registration number: NCT00364156); no deviations from prespecified outcomes identified
Other bias	Low risk	Analyses of pharmacogenetics were conducted only in Caucasians. Distribution seems balanced between treatment groups because of randomisation.

Sun 2012

Methods	<p>Double-blind randomised clinical trial</p> <p>Setting: community hospital, China</p> <p>Recruitment: community volunteers</p> <p>Study period: March to December 2004</p>
Participants	<p>N = 249</p> <p>93.5% males; average age: 41; average cigarettes/d: 23</p> <p>Inclusion criteria: (a) Han Chinese 20 to 70 years of age who lived in the Haidian District of Beijing; (b) had to be motivated to stop smoking; (c) smoked C10 cigarettes/d and smoked for C3 years; (d) presented with carbon monoxide (CO) level C10 ppm in exhaled air; (e) provided written informed consent and able to take part in assessment</p> <p>Exclusion criteria: psychiatric disorder, alcohol abuse, and other drug abuse (per DSM-IV); pathological changes in the floor of the mouth; cardiovascular disease; taking psychotropic medications; using other forms of tobacco or any other NRT products during the past 6 months; pregnant or breastfeeding</p>
Interventions	<p>Nicotine sublingual tablet (NST) vs placebo</p> <p>“Smokers were recommended to use one or two tablets (4 mg of nicotine) per hour, up to a maximum of 20 tablets per day. Subjects were advised to use the full treatment dose for 4 weeks (minimum of 15 tablets and maximum of 20 tablets per day). After this time-point, treatment could be tapered off up to the 8-week visit. During the next 4-week follow-up phase, no further medication was dispensed.”</p> <p>“In addition, all participants received six sessions of standardized behavioral group counseling focusing on self- monitoring and behavioral modification approaches.”</p>
Outcomes	Continuous, self-reported complete abstinence for ≥ 7 days, verified by exhaled CO level < 10 ppm
Funding source	National Natural Science Foundation of China; Training Program Foundation for Excellent Talents by the Beijing Municipal Government, China; Stanley Medical Research Institute; Department of Veterans Affairs, Mental Illness Research, Education and Clinical Center (MIRECC); US National Institutes of Health
Declaration of interest	Not reported
Notes	This study provides analysis of pharmacogenetics.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Use of a computer-generated randomisation scheme operated by a senior data manager
Allocation concealment (selection bias)	Low risk	“Allocation was concealed from the investigator who delivered the interventions and assessed the outcomes.”
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind design
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Interviewers were blinded.

Sun 2012 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Numbers and reasons for missing participants are not given.
Selective reporting (reporting bias)	Unclear risk	No relevant details on protocol availability

Swan 2003

Methods	Open-label randomised trial Setting: HMO, USA Recruitment: volunteers from Group Health Cooperative (GHC) membership Study duration: April 1998 to May 1999
Participants	N = 1524 57% females; average age: 45; average cigarettes/d: ~ 23 Inclusion criteria: at least 18 years of age, smoked ≥ 10 cigarettes/d, were motivated to stop smoking, were otherwise in good general health, had sufficient verbal and written command of English to provide informed consent and study responses, and were enrolled and planned to stay enrolled in GHC for the next 12 months Exclusion criteria: (1) any predisposition to seizure, as defined by a personal or family history of a seizure disorder, such as epilepsy, or a personal history of febrile seizures; (2) history of stroke or transient ischaemic attack; (3) history of head injury resulting in loss of consciousness for longer than 1 hour; (4) current use of medications contraindicated to bupropion SR or known to lower the seizure threshold (complete list available on request); (5) history of or current diagnosis of anorexia nervosa or bulimia; (6) being of poor general health, as defined by the presence of severe and chronic cardiovascular disease (including myocardial infarction within the previous 3 months), severe and chronic pulmonary disease, renal or hepatic dysfunction, neurological disease, uncontrolled hypertension, or uncontrolled diabetes mellitus; (7) participation in GHC's Free & Clear (FC) smoking cessation programme in the previous 12 months (1 of the treatments included in the present study); (8) current depression; (9) current drinking of 14 or more alcoholic drinks/week and/or binge drinking 2 or more times in the past month; and (10) current pregnancy or plans to become pregnant or current nursing of a child
Interventions	Factorial design crossing 2 drug doses with 2 intensities of behavioural counseling: 150 mg bupropion SR with less intensive counseling (n = 382) or with more intensive counseling (n = 4381); or 300 mg bupropion SR with less intensive counseling (n = 4383) or with more intensive counseling (n = 4378) Free & Clear proactive telephone counseling (4 brief calls), access to quit-line and S-H materials vs Zyban Advantage Program (ZAP) tailored S-H materials, single telephone call after TQD, access to Zyban support line Prescription was mailed. No face-to-face contact during enrolment or Rx
Outcomes	Primary outcomes: self-reported point prevalence 7-day non-smoking status at 3 and 12 months following target quit date Secondary outcomes: adverse and abstinence effects reported since beginning of treatment with bupropion SR
Funding source	US National Cancer Institute

Swan 2003 (Continued)

Declaration of interest	Study authors have no relevant financial interests and have received no financial support or medication from GlaxoSmithKline.	
Notes	Analyses of pharmacogenetics are reported in Swan 2005 and Swan 2007 .	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	“Open-label randomized trial. The computer code for the procedure calculated probabilities of group assignment that were dynamically modified based on the number of members in each group so that final group sizes were equal. No restrictions such as stratification or blocking were used as part of the randomization process.”
Allocation concealment (selection bias)	Low risk	Procedure using a random number generator was built into study database.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Study was not blinded.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Study was not blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Follow-up at 12 months: 83% intervention; 88% control
Selective reporting (reporting bias)	Unclear risk	No relevant information reported
Other bias	High risk	Participants who responded at 12-month follow-up (n = 1299) were invited to participate in the ‘genetic factors’ supplemental study; 496 (50%) actually provided samples.

Swan 2010

Methods	Open-label randomised behavioural intervention clinical trial	
	Study period: October 2005 to June 2008	
Participants	N = 1202	
	Participants were smokers seeking treatment who were recruited through health plan advertisements, physician referrals, and a commercial smoking cessation plan's advertisements.	
	Inclusion criteria: age ≥ 18 years, reported smoking ≥ 10 cigarettes/d for 12 months and ≥ 5 cigarettes/d for the past week, with dependable telephone and Internet access; were financially eligible for smoking cessation services under their health plan and medically eligible for varenicline treatment	
	Exclusion criteria: current pregnancy, plans to become pregnant during the medication treatment period, or breastfeeding; self-report of poor health; severe or chronic heart disease; severe COPD; on dialysis with recent creatinine values > 3; current self-reported diagnosis of or treatment for psychotic disorder; concurrent use of bupropion or nicotine replacement therapy; current use of recreation-	

Swan 2010 (Continued)

al or street drugs; current drinking of ≥ 14 alcoholic drinks/week or binge drinking ≥ 2 times in the past month; current use of cimetidine, metformin, phenformin, pindolol, or procainamide; and recent participation in 2 specific smoking cessation programmes

Interventions	<p>Varenicline and Proactive Telephone Counseling (PTC, n = 402)</p> <p>Varenicline and Web (N = 401)</p> <p>Varenicline, PTC and Web (N = 399)</p> <p>All randomised participants received a prescription for 12 weeks of varenicline, a 5- to 10-minute orientation call, printed Quit Guides including recommended guidelines for varenicline, and access to a toll-free telephone call in line for ad hoc calls.</p> <p>PTC arm participants received up to 5 phone calls. Web arm participants had online access to an interactive online programme modified from PTC content. PTC and Web arm participants received calls that encouraged them to use Web programme tools.</p>
Outcomes	<p>Primary outcome: self-reported 7-day and 30-day point prevalence abstinence at 3 months and at 6 months after the targeted quit day</p> <p>Secondary outcomes: probable side effects (6) and probable abstinence effects (9) at 3 months after the targeted quit day</p>
Funding source	This work was supported by Grant R01CA071358 from the National Cancer Institute. Pfizer provided varenicline and nominal support for recruiting participants.
Declaration of interest	SMZ owns stock in Free & Clear, Inc.; GES received financial support from Pfizer to attend a 1-day advisory meeting in 2008, and a small grant from Pfizer to support recruitment and study intake.
Notes	This paper did not provide analyses of pharmacogenetics, but these were reported in Bergen 2013 .

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Automated algorithm
Allocation concealment (selection bias)	Unclear risk	No data on which to make a judgement (method of concealment not described)
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants and staff were not blinded to treatment assignment. Differences between treatments were obvious to both participants and personnel.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome assessment was done by self-report, which was performed through follow-up calls. Those who could not be contacted were assumed to be smoking.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Although missing outcome data were substantial (~ 25% for 3-month and 6-month follow-up), missing outcome data were balanced in numbers across intervention groups. In this trial, self-report was not biochemically confirmed.
Selective reporting (reporting bias)	Low risk	Primary and secondary outcomes were reported.
Other bias	Unclear risk	Biospecimen collection was done post hoc; 47% of the trial population provided a biospecimen after a multiple-step consent and exclusion process. Da-

Swan 2010 (Continued)

ta show a highly significant difference in abstinence prevalence in the sample available for pharmacogenetic analysis vs the overall trial population (55% vs 44%, $P = 1E-5$ at 3 months; 43% vs 33% at 6 months, $P = 1E-4$). Most (~ 94%) samples collected were genotyped. Pharmacogenetic analyses were conducted in self-identified whites only in [Bergen 2013](#), distributed equally among treatment groups.

Verde 2014

Methods	Randomised open-label trial of bupropion SR or nicotine patch in adult male and female smokers Setting: community hospital, Spain Recruitment period: 2007 to 2010 (months not indicated)
Participants	N = 76 "Heavy smokers" 100% were genotyped Inclusion criteria: (a) to be enrolled in a 'standard' (12-week duration) smoking cessation programme with nicotine substitutive treatment (NST) or bupropion following medical criteria, (b) smoking history > 10 cigarettes/d and > 10 packs/y, and (c) > 3 scores in the Fagerstrom test for nicotine dependence (FTND) Exclusion criteria: not defined
Interventions	Bupropion (N = 34) NRT (N = 36) Doses of bupropion SR provided were 150 mg once per day for days 1 to 6, followed by 150 mg twice per day for days 7 to 84), for 12 weeks For NRT, doses were as follows: (1) for smokers ≥ 20 cigarettes/d, Nicotinell TTS 30 (4 weeks), Nicotinell TTS 20 (4 weeks), and Nicotinell TTS 10 (4 weeks); (2) for smokers < 20 cigarettes/d, Nicotinell TTS 20 (4 weeks), Nicotinell TTS 20 (4 weeks), and Nicotinell TTS 10 (4 weeks)
Outcomes	12-Month post-treatment prolonged abstinence; abstinence rate was measured at 3, 6, 9, and 12 months during follow-up visits. Biochemical verification was not mentioned.
Funding source	Research was supported by the UEM 03-2006 Internal Project of European University of Madrid and by the 035-2006 Project of the Spanish Lung Foundation (SEPAR).
Declaration of interest	No competing interests
Notes	6 candidate polymorphisms in <i>CYP2A6</i> , <i>5-HTT</i> , and <i>HTR2A</i> genes were genotyped.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Random sequence generation was not mentioned in the paper.
Allocation concealment (selection bias)	High risk	Open-label design

Verde 2014 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	High risk	Open-label design
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No mention of blinding of outcomes
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No frequencies of abstinence outcomes reported; thus no way to confirm reporting of outcomes for all participants
Selective reporting (reporting bias)	Unclear risk	Outcomes were not described transparently; thus one cannot confirm whether selective outcome reporting occurred.
Other bias	Unclear risk	Only 3 CYP2A6 alleles were genotyped. Therefore, *1 allele calls are likely over-represented. SLC6A4 5-HTTLPR "L" and "S" are not defined.

Wagena 2005

Methods	Placebo-controlled double-dummy randomised trial of bupropion SR vs nortriptyline or placebo for smoking cessation in patients at risk for chronic obstructive pulmonary disease (COPD) or with COPD Study period: March 2002 to August 2003
Participants	N = 255 Inclusion criteria: (a) current daily smokers at risk for COPD or with COPD, (b) 30 to 70 years of age, (c) smoking history ≥ 5 years, (d) smoked on average ≥ 10 cigarettes/d during the past year, and (e) were motivated to stop smoking Exclusion criteria: (a) having used or were still using bupropion SR or nortriptyline; (b) were using NRT or (c) psychoactive medication at the time of assessment; and (d) had any serious or unstable medical disorders that might affect lung function or for which bupropion SR or nortriptyline was contraindicated
Interventions	Bupropion SR (N = 86) Nortriptyline (N = 80) Placebo (N = 89) Eligible individuals were randomly assigned in a 1:1 ratio to receive the following: (1) bupropion SR, 150 mg once daily, for days 1 through 6, followed by 150 mg twice daily for days 7 through 84; (2) nortriptyline, 25 mg once daily, for days 1 through 3, followed by 50 mg once daily for days 3 through 7, then 75 mg once daily for days 8 through 84; or (3) placebo. At the baseline visit, the target quit date (TQD) was set for the second week, usually day 11 from the start of medication.
Outcomes	Primary outcomes: prolonged abstinence from smoking from week 4 to week 26 after the target quit date. Prolonged abstinence was defined as a participant's report of 0 cigarettes/d (not even a puff) during weeks 4 through 26, confirmed by urinary cotinine values ≤ 60 ng/mL at weeks 4, 12, and 26 after TQD. Participants were allowed to miss 1 in-person visit but not the last follow-up visit. Secondary outcomes: prolonged abstinence during weeks 4 through 12 and 7-day point prevalence abstinence (defined as having smoked 0 cigarettes, not even a puff, for the previous 7 days) at weeks 4, 12, and 26, confirmed by urinary cotinine levels ≤ 60 ng/mL

Wagena 2005 (Continued)

Funding source	This work has been supported by a grant from the Netherlands Organization for Health Research and Development (ZonMW, The Hague; Project no. 50–50101-96–404). The original trial was funded by grants of the Dutch Asthma Foundation (NAF grant no. 3.2.00.21) and the Health Research and Development Council (ZorgOnderzoek Nederland, grant no. 2200.0111), the Netherlands. Lundbeck B.V. provided active nortriptyline free of charge. Lundbeck B.V. as well as GlaxoSmithKline B.V. did not play a role in the design and conduct of the study, nor in interpretation and analysis of the data and the decision to submit for publication.
Declaration of interest	“CPVS has received financing (grants, consultancy and/or travel/accommodation costs) from AstraZeneca, Boehringer Ingelheim, and Pfizer, unrelated to this study. DSP has received financing (grants, consultancy, and/or travel/accommodation costs) from Chiesi, GlaxoSmithKline, AstraZeneca, Nycomed, and Boehringer Ingelheim, unrelated to this study. MQ, EJW, FJVS declare no conflict of interest.”
Notes	The original study did not report pharmacogenetic outcomes. 214/255 (84%) participants in the original clinical trial were genotyped. Results were published in a subsequent pharmacogenetic paper (Quaak 2012).

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was computer generated.
Allocation concealment (selection bias)	Low risk	Randomisation list by a pharmacist, stratified by COPD severity
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants and research staff were blinded to treatment assignment.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	“No patient, research nurse, counselor, investigator, or any other staff member was aware of the treatment assignments for the duration of the study.”
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were included in analyses.
Selective reporting (reporting bias)	Low risk	Primary outcomes were reported.
Other bias	Low risk	214/255 (84%) participants in the original clinical trial were genotyped, with results subsequently published. See ‘Notes’ above.

Wilcox 2011

Methods	Double-blind placebo-controlled trial Pilot study Setting: (not specified), USA Recruitment: community volunteers
---------	--

Wilcox 2011 (Continued)

Study period: not reported

Participants	<p>N = 78</p> <p>Inclusion criteria: male and female white smokers of European descent, at least 18 years of age, who were smoking ≥ 10 cigarettes/d for ≥ 5 years and were in generally good physical and mental health</p> <p>Exclusion criteria: not reported</p>
Interventions	Rimonabant 20 mg/d (n = 48) vs placebo (n = 28) for 10 weeks
Outcomes	Smoking status; exhaled CO level
Funding source	This study reports analysis of pharmacogenetics.
Declaration of interest	Pharmacology Research Institute and laboratory of one of the study authors at the University of California Los Angeles (UCLA)
Notes	Not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No relevant information reported
Allocation concealment (selection bias)	Unclear risk	No relevant information reported
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind design but no other information reported
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double-blind design but no other information reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not reported
Selective reporting (reporting bias)	Unclear risk	No information on protocol availability reported
Other bias	Unclear risk	Distribution of ethnicities between treatment groups unclear

Winst 2006

Methods	<p>Double-blind parallel-group placebo-controlled randomised clinical trial</p> <p>Study period: June 2006 to February 2008</p>
Participants	N = 420

Winst 2006 (Continued)

Participants included hospitalised smokers who needed to stop smoking at admission. Participants were approached by information presented in the general hospital admission leaflet and/or on the intranet and by active recruitment by smoking consults in specific departments of the hospital.

Inclusion criteria: over 18 years of age; daily consumption of ≥ 15 cigarettes in the past 3 years and average daily consumption of 10 cigarettes the week before study inclusion; life expectancy of ≥ 1 year; conscious and approachable; able to read and sign an informed consent form; Dutch- or French-speaking; expected duration of hospitalisation ≥ 72 hours; treating physician and anaesthetist agree on the patient's study inclusion

Exclusion criteria: already using NS within 14 days before study inclusion; use of tobacco products other than cigarettes; alcohol abuse of > 5 U/d; simultaneous use of psychoactive drugs or hallucinogens; referred from other hospitals; existing contraindications for NS use; predicted postoperative ICU stay longer than 48 hours; pregnant or lactating

Interventions	<p>15 minutes counseling + placebo patch (n = 210)</p> <p>15 minutes counseling + nicotine transdermal patch (n = 210)</p> <p>Participants received a nicotine transdermal patch at a 15 mg/16 hours dose, daily, for maximum 7 days after hospital admission (study inclusion), or a placebo patch for the same study duration.</p>
Outcomes	<p>Primary outcome: total addiction score, calculated from the Minnesota questionnaires, taken up at randomisation, after ≥ 72 hours of hospital admission and after a maximum of 7 treatment days</p> <p>Additional outcomes: point prevalence of quit rate at short (7 days) and long term (6 months)</p>
Funding source	Study was conducted through a grant from the Foundation of Scientific Research (FWO number G.0604.06), Vlaamse Liga tegen Kanker, and an independent research grant from McNeil AB, Helsingborg, Sweden.
Declaration of interest	Apart from the funding source, study authors report no other relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript, apart from those disclosed.
Notes	<p>All information from this study is extracted from the study protocol; thus information regarding sample size should be interpreted as the initial target rather than the actual number of recruited participants.</p> <p>Analysis of pharmacogenetics is reported in De Ruyc 2010.</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was performed via an online-available registration and randomisation website.
Allocation concealment (selection bias)	Unclear risk	Randomisation occurred online, but it is unclear whether allocation was properly concealed.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Active and placebo medications were identical in appearance, and the study is labeled as double-blind. No additional details are presented.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Outcome is subjective and can be influenced by study participants.

Winst 2006 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Final study report not available
Selective reporting (reporting bias)	Unclear risk	Final study report not available
Other bias	Unclear risk	Final study report not available

BUP: bupropion; CBTD: cognitive-behavioural treatment for depression; CES-D: Center for Epidemiologic Studies Depression Scale; CO: carbon monoxide; DSM-IV: *Diagnostic and Statistical Manual for Mental Disorders*, Fourth Edition; DSM-IV-TR, *Diagnostic and Statistical Manual for Mental Disorders*, Fourth Edition, Text Revision; EOT: end of therapy; FTND: Fagerstrom Test of Nicotine Dependence; GHC: Group Health Cooperative; HE: health education; ITT: intention-to-treat analysis; MAO: monoamine oxidase; MAOI: monoamine oxidase inhibitor; MI: myocardial infarction; MINI: Mini-International Neuropsychiatric Interview; NARSAD: National Alliance for Research on Schizophrenia and Depression; NIAAA: National Institute on Alcohol Abuse and Alcoholism; NIDA: National Institute on Drug Abuse; NIHR: National Institute on Health Research; NRT: nicotine replacement therapy; NST: nicotine sublingual tablet; PCA: Principal Component Analysis; PLAC: placebo; PPA: point prevalence abstinence; ppm: parts per million; SR: sustained-release; ST: standard treatment; TQD: target quit date; UKCRC: UK Clinical Research Collaboration; UKCTCS: UK Centre for Tobacco Control Studies.

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Baker 2009	Primary paper was not a randomised controlled trial (RCT).
Becker 2008	Pharmacogenetic analyses presented results from pooled (not individual) allelotyping (Drgon 2009). This investigation analysed results from Becker 2008 (no data available).
Uhl 2007	Pharmacogenetic analyses presented results from pooled (not individual) allelotyping (Uhl 2008). This investigation analysed results from Lerman 2002 , Lerman 2004 , David 2007 , and Uhl 2007 (no data available).

DATA AND ANALYSES
Comparison 1. Active NRT vs placebo - rs1051730 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	3	1597	Risk Ratio (M-H, Random, 95% CI)	1.42 [1.16, 1.75]
1.1 Homozygous Major	3	659	Risk Ratio (M-H, Random, 95% CI)	1.27 [0.93, 1.72]
1.2 Heterozygous	3	731	Risk Ratio (M-H, Random, 95% CI)	1.48 [1.08, 2.01]
1.3 Homozygous Minor	3	207	Risk Ratio (M-H, Random, 95% CI)	2.07 [1.06, 4.01]
2 End of Treatment	2	1391	Risk Ratio (M-H, Random, 95% CI)	1.63 [1.14, 2.32]
2.1 Homozygous Major	2	582	Risk Ratio (M-H, Random, 95% CI)	1.09 [0.85, 1.41]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.2 Heterozygous	2	631	Risk Ratio (M-H, Random, 95% CI)	2.13 [1.52, 2.97]
2.3 Homozygous Minor	2	178	Risk Ratio (M-H, Random, 95% CI)	2.18 [1.04, 4.58]

Analysis 1.1. Comparison 1 Active NRT vs placebo - rs1051730 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 1.2. Comparison 1 Active NRT vs placebo - rs1051730 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 2. Active NRT vs placebo - rs16969968 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	1127	Risk Ratio (M-H, Random, 95% CI)	1.38 [0.97, 1.98]
1.1 Homozygous Major	2	449	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.77, 1.33]
1.2 Heterozygous	2	550	Risk Ratio (M-H, Random, 95% CI)	1.85 [1.33, 2.59]
1.3 Homozygous Minor	2	128	Risk Ratio (M-H, Random, 95% CI)	1.80 [0.45, 7.23]

Analysis 2.1. Comparison 2 Active NRT vs placebo - rs16969968 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 3. Active NRT vs placebo - rs16969968 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2	709	Risk Ratio (M-H, Random, 95% CI)	1.11 [0.55, 2.26]
1.1 Homozygous Major	2	637	Risk Ratio (M-H, Random, 95% CI)	1.47 [1.07, 2.03]
1.2 Heterozygous or Homozygous Minor	2	72	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.15, 1.26]
2 End of Treatment	2	709	Risk Ratio (M-H, Random, 95% CI)	1.03 [0.36, 2.94]
2.1 Homozygous Major	2	637	Risk Ratio (M-H, Random, 95% CI)	1.57 [1.15, 2.15]
2.2 Heterozygous or Homozygous Minor	2	72	Risk Ratio (M-H, Random, 95% CI)	0.29 [0.10, 0.86]

Analysis 3.1. Comparison 3 Active NRT vs placebo - rs16969968 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.

Analysis 3.2. Comparison 3 Active NRT vs placebo - rs16969968 - non-Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 4. Active NRT vs placebo - rs 588765 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	923	Risk Ratio (M-H, Random, 95% CI)	1.33 [1.04, 1.71]
1.1 Homozygous Major	2	296	Risk Ratio (M-H, Random, 95% CI)	1.39 [0.89, 2.16]
1.2 Heterozygous	2	469	Risk Ratio (M-H, Random, 95% CI)	1.27 [0.89, 1.79]
1.3 Homozygous Minor	2	158	Risk Ratio (M-H, Random, 95% CI)	1.50 [0.74, 3.06]

Analysis 4.1. Comparison 4 Active NRT vs placebo - rs 588765 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 5. Active NRT vs placebo - rs2036527 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2	708	Risk Ratio (M-H, Random, 95% CI)	1.18 [0.75, 1.87]
1.1 Homozygous Major	2	425	Risk Ratio (M-H, Random, 95% CI)	1.95 [0.46, 8.26]
1.2 Heterozygous or Homozygous Minor	2	283	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.40, 2.03]
2 End of Treatment	2	708	Risk Ratio (M-H, Random, 95% CI)	1.22 [0.77, 1.93]
2.1 Homozygous Major	2	425	Risk Ratio (M-H, Random, 95% CI)	2.39 [0.43, 13.35]
2.2 Heterozygous or Homozygous Minor	2	283	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.55, 1.46]

Analysis 5.1. Comparison 5 Active NRT vs placebo - rs2036527 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.

Analysis 5.2. Comparison 5 Active NRT vs placebo - rs2036527 - non-Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 6. Active NRT vs placebo - DRD4 (exon 3 48 bp) - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2	900	Risk Ratio (M-H, Random, 95% CI)	1.44 [1.08, 1.92]
1.1 Homozygous Major	2	566	Risk Ratio (M-H, Random, 95% CI)	1.34 [0.93, 1.93]
1.2 Heterozygous	2	290	Risk Ratio (M-H, Random, 95% CI)	1.76 [1.00, 3.10]
1.3 Homozygous Minor	2	44	Risk Ratio (M-H, Random, 95% CI)	1.28 [0.40, 4.11]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2 End of Treatment	2	900	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.88, 1.63]
2.1 Homozygous Major	2	566	Risk Ratio (M-H, Random, 95% CI)	1.22 [0.59, 2.51]
2.2 Heterozygous	2	290	Risk Ratio (M-H, Random, 95% CI)	1.40 [0.57, 3.39]
2.3 Homozygous Minor	2	44	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.65, 1.58]

Analysis 6.1. Comparison 6 Active NRT vs placebo - DRD4 (exon 3 48 bp) - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 6.2. Comparison 6 Active NRT vs placebo - DRD4 (exon 3 48 bp) - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 7. Active NRT vs placebo - NMR - non-Hispanic black and white

Outcome or sub-group title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2	1417	Risk Ratio (M-H, Random, 95% CI)	1.51 [1.08, 2.10]
1.1 Slow NMR	2	628	Risk Ratio (M-H, Random, 95% CI)	1.82 [1.12, 2.94]
1.2 Normal NMR	2	789	Risk Ratio (M-H, Random, 95% CI)	1.21 [0.78, 1.87]
2 End of Treatment	2	1417	Risk Ratio (M-H, Random, 95% CI)	1.51 [1.19, 1.90]
2.1 Slow NMR	2	847	Risk Ratio (M-H, Random, 95% CI)	1.61 [1.18, 2.20]
2.2 Normal NMR	2	570	Risk Ratio (M-H, Random, 95% CI)	1.49 [0.85, 2.60]

Analysis 7.1. Comparison 7 Active NRT vs placebo - NMR - non-Hispanic black and white, Outcome 1 Six-Month Abstinence.

Analysis 7.2. Comparison 7 Active NRT vs placebo - NMR - non-Hispanic black and white, Outcome 2 End of Treatment.

Comparison 8. Bupropion vs placebo - rs1051730 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	4	1329	Risk Ratio (M-H, Random, 95% CI)	1.34 [1.11, 1.61]
1.1 Homozygous Major	4	495	Risk Ratio (M-H, Random, 95% CI)	1.24 [0.94, 1.65]
1.2 Heterozygous	4	633	Risk Ratio (M-H, Random, 95% CI)	1.44 [1.09, 1.91]
1.3 Homozygous Minor	4	201	Risk Ratio (M-H, Random, 95% CI)	1.31 [0.57, 2.99]
2 End of Treatment	6	1379	Risk Ratio (M-H, Random, 95% CI)	1.40 [1.19, 1.64]
2.1 Homozygous Major	6	496	Risk Ratio (M-H, Random, 95% CI)	1.32 [1.05, 1.67]
2.2 Heterozygous	6	655	Risk Ratio (M-H, Random, 95% CI)	1.36 [1.03, 1.79]
2.3 Homozygous Minor	6	228	Risk Ratio (M-H, Random, 95% CI)	1.83 [1.20, 2.79]

Analysis 8.1. Comparison 8 Bupropion vs placebo - rs1051730 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 8.2. Comparison 8 Bupropion vs placebo - rs1051730 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 9. Bupropion vs placebo - rs1051730 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2	124	Risk Ratio (M-H, Random, 95% CI)	1.50 [0.75, 3.00]
1.1 Homozygous Major	2	92	Risk Ratio (M-H, Random, 95% CI)	1.61 [0.71, 3.64]
1.2 Heterozygous	2	32	Risk Ratio (M-H, Random, 95% CI)	1.30 [0.32, 5.34]
2 End of Treatment	3	157	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.70, 2.06]
2.1 Homozygous Major	3	117	Risk Ratio (M-H, Random, 95% CI)	1.76 [0.96, 3.23]
2.2 Heterozygous	3	40	Risk Ratio (M-H, Random, 95% CI)	0.68 [0.32, 1.44]

Analysis 9.1. Comparison 9 Bupropion vs placebo - rs1051730 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.

Analysis 9.2. Comparison 9 Bupropion vs placebo - rs1051730 - non-Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 10. Bupropion vs placebo - rs16969968 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	3	557	Risk Ratio (M-H, Random, 95% CI)	1.42 [1.13, 1.77]
1.1 Homozygous Major	3	198	Risk Ratio (M-H, Random, 95% CI)	1.35 [0.92, 1.99]
1.2 Heterozygous	3	276	Risk Ratio (M-H, Random, 95% CI)	1.46 [1.04, 2.04]
1.3 Homozygous Minor	3	83	Risk Ratio (M-H, Random, 95% CI)	2.55 [0.95, 6.85]

Analysis 10.1. Comparison 10 Bupropion vs placebo - rs16969968 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 11. Bupropion vs placebo - rs16969968 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2	578	Risk Ratio (M-H, Random, 95% CI)	1.30 [0.84, 2.00]
1.1 Homozygous Major	2	512	Risk Ratio (M-H, Random, 95% CI)	1.18 [0.75, 1.87]
1.2 Heterozygous or Homozygous Minor	2	66	Risk Ratio (M-H, Random, 95% CI)	2.82 [0.76, 10.45]
2 End of Treatment	3	611	Risk Ratio (M-H, Random, 95% CI)	1.95 [1.23, 3.08]
2.1 Homozygous Major	3	541	Risk Ratio (M-H, Random, 95% CI)	2.12 [1.44, 3.10]
2.2 Heterozygous or Homozygous Minor	3	70	Risk Ratio (M-H, Random, 95% CI)	1.65 [0.33, 8.36]

Analysis 11.1. Comparison 11 Bupropion vs placebo - rs16969968 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.

Analysis 11.2. Comparison 11 Bupropion vs placebo - rs16969968 - non-Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 12. Bupropion vs placebo - rs588765 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	4	1107	Risk Ratio (M-H, Random, 95% CI)	1.37 [1.12, 1.67]
1.1 Homozygous Major	4	384	Risk Ratio (M-H, Random, 95% CI)	1.33 [0.85, 2.08]
1.2 Heterozygous	4	526	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.95, 1.65]
1.3 Homozygous Minor	4	197	Risk Ratio (M-H, Random, 95% CI)	1.95 [1.18, 3.22]
2 End of Treatment	4	1107	Risk Ratio (M-H, Random, 95% CI)	1.36 [1.13, 1.65]
2.1 Homozygous Major	4	385	Risk Ratio (M-H, Random, 95% CI)	1.37 [1.05, 1.79]
2.2 Heterozygous	4	525	Risk Ratio (M-H, Random, 95% CI)	1.31 [0.86, 2.01]
2.3 Homozygous Minor	4	197	Risk Ratio (M-H, Random, 95% CI)	1.43 [0.99, 2.06]

Analysis 12.1. Comparison 12 Bupropion vs placebo - rs588765 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 12.2. Comparison 12 Bupropion vs placebo - rs588765 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 13. Bupropion vs placebo - rs2036527 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2	738	Risk Ratio (M-H, Random, 95% CI)	1.40 [1.05, 1.86]
1.1 Homozygous Major	2	260	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.73, 1.80]
1.2 Heterozygous	2	370	Risk Ratio (M-H, Random, 95% CI)	1.43 [0.99, 2.06]
1.3 Homozygous Minor	2	108	Risk Ratio (M-H, Random, 95% CI)	2.73 [1.02, 7.36]
2 End of Treatment	4	975	Risk Ratio (M-H, Random, 95% CI)	1.43 [1.19, 1.73]
2.1 Homozygous Major	4	339	Risk Ratio (M-H, Random, 95% CI)	1.37 [1.04, 1.80]
2.2 Heterozygous	4	482	Risk Ratio (M-H, Random, 95% CI)	1.36 [1.04, 1.79]
2.3 Homozygous Minor	4	154	Risk Ratio (M-H, Random, 95% CI)	2.64 [1.33, 5.25]

Analysis 13.1. Comparison 13 Bupropion vs placebo - rs2036527 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 13.2. Comparison 13 Bupropion vs placebo - rs2036527 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 14. Bupropion vs placebo - rs2036527 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	3	660	Risk Ratio (M-H, Random, 95% CI)	1.30 [0.88, 1.92]
1.1 Homozygous Major	3	377	Risk Ratio (M-H, Random, 95% CI)	1.17 [0.70, 1.98]
1.2 Heterozygous or Homozygous Minor	3	283	Risk Ratio (M-H, Random, 95% CI)	1.44 [0.71, 2.91]
2 End of Treatment	4	693	Risk Ratio (M-H, Random, 95% CI)	1.87 [1.36, 2.56]
2.1 Homozygous Major	4	395	Risk Ratio (M-H, Random, 95% CI)	2.11 [1.39, 3.22]
2.2 Heterozygous or Homozygous Minor	4	298	Risk Ratio (M-H, Random, 95% CI)	1.57 [0.93, 2.62]

Analysis 14.1. Comparison 14 Bupropion vs placebo - rs2036527 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.

Analysis 14.2. Comparison 14 Bupropion vs placebo - rs2036527 - non-Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 15. Bupropion vs placebo - rs3733829 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2	571	Risk Ratio (M-H, Random, 95% CI)	1.41 [1.07, 1.87]
1.1 Homozygous Major	2	268	Risk Ratio (M-H, Random, 95% CI)	1.21 [0.81, 1.82]
1.2 Heterozygous	2	218	Risk Ratio (M-H, Random, 95% CI)	1.95 [1.22, 3.13]
1.3 Homozygous Minor	2	85	Risk Ratio (M-H, Random, 95% CI)	1.13 [0.58, 2.17]
2 End of Treatment	4	807	Risk Ratio (M-H, Random, 95% CI)	1.55 [1.29, 1.87]
2.1 Homozygous Major	4	367	Risk Ratio (M-H, Random, 95% CI)	1.44 [1.11, 1.86]
2.2 Heterozygous	4	333	Risk Ratio (M-H, Random, 95% CI)	1.69 [1.24, 2.30]
2.3 Homozygous Minor	4	107	Risk Ratio (M-H, Random, 95% CI)	1.69 [0.96, 2.95]

Analysis 15.1. Comparison 15 Bupropion vs placebo - rs3733829 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 15.2. Comparison 15 Bupropion vs placebo - rs3733829 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 16. Bupropion vs placebo - rs3733829 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	61	Risk Ratio (M-H, Random, 95% CI)	1.51 [0.75, 3.04]
1.1 Homozygous Major	2	61	Risk Ratio (M-H, Random, 95% CI)	1.51 [0.75, 3.04]

Analysis 16.1. Comparison 16 Bupropion vs placebo - rs3733829 - non-Hispanic black or African American, Outcome 1 End of Treatment. **Comparison 17. Bupropion vs placebo - rs7937 - non-Hispanic white**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	3	557	Risk Ratio (M-H, Random, 95% CI)	1.42 [1.13, 1.78]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Homozygous Major	3	159	Risk Ratio (M-H, Random, 95% CI)	1.76 [1.13, 2.75]
1.2 Heterozygous	3	285	Risk Ratio (M-H, Random, 95% CI)	1.30 [0.95, 1.76]
1.3 Homozygous Minor	3	113	Risk Ratio (M-H, Random, 95% CI)	1.38 [0.82, 2.31]

Analysis 17.1. Comparison 17 Bupropion vs placebo - rs7937 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 18. Bupropion vs placebo - rs7937 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	76	Risk Ratio (M-H, Random, 95% CI)	1.56 [0.77, 3.18]
1.1 Homozygous Major	2	38	Risk Ratio (M-H, Random, 95% CI)	1.70 [0.57, 5.10]
1.2 Heterozygous or Homozygous Minor	2	38	Risk Ratio (M-H, Random, 95% CI)	1.57 [0.42, 5.84]

Analysis 18.1. Comparison 18 Bupropion vs placebo - rs7937 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 19. Bupropion vs placebo - rs1329650 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	3	559	Risk Ratio (M-H, Random, 95% CI)	1.37 [1.07, 1.74]
1.1 Homozygous Major	3	280	Risk Ratio (M-H, Random, 95% CI)	1.54 [1.07, 2.22]
1.2 Heterozygous	3	244	Risk Ratio (M-H, Random, 95% CI)	1.31 [0.88, 1.96]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.3 Homozygous Minor	3	35	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.33, 4.74]

Analysis 19.1. Comparison 19 Bupropion vs placebo - rs1329650 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 20. Bupropion vs placebo - rs1329650 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	76	Risk Ratio (M-H, Random, 95% CI)	1.44 [0.70, 2.99]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Homozygous Major	2	63	Risk Ratio (M-H, Random, 95% CI)	1.62 [0.67, 3.96]
1.2 Heterozygous or Homozygous Minor	2	13	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.15, 5.70]

Analysis 20.1. Comparison 20 Bupropion vs placebo - rs1329650 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 21. Bupropion vs placebo - rs1028936 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	3	559	Risk Ratio (M-H, Random, 95% CI)	1.39 [1.11, 1.74]
1.1 Homozygous Major	3	370	Risk Ratio (M-H, Random, 95% CI)	1.54 [1.15, 2.06]
1.2 Heterozygous	3	175	Risk Ratio (M-H, Random, 95% CI)	1.33 [0.75, 2.35]
1.3 Homozygous Minor	3	14	Risk Ratio (M-H, Random, 95% CI)	1.60 [0.30, 8.49]

Analysis 21.1. Comparison 21 Bupropion vs placebo - rs1028936 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 22. Bupropion vs placebo - rs1028936 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	76	Risk Ratio (M-H, Random, 95% CI)	1.47 [0.68, 3.21]
1.1 Homozygous Major	2	65	Risk Ratio (M-H, Random, 95% CI)	1.77 [0.74, 4.20]
1.2 Heterozygous or Homozygous Minor	2	11	Risk Ratio (M-H, Random, 95% CI)	0.67 [0.09, 4.77]

Analysis 22.1. Comparison 22 Bupropion vs placebo - rs1028936 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 23. Bupropion vs placebo - rs215605 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	3	558	Risk Ratio (M-H, Random, 95% CI)	1.48 [1.18, 1.87]
1.1 Homozygous Major	3	219	Risk Ratio (M-H, Random, 95% CI)	1.77 [1.23, 2.55]
1.2 Heterozygous	3	259	Risk Ratio (M-H, Random, 95% CI)	1.35 [0.98, 1.87]
1.3 Homozygous Minor	3	80	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.49, 2.55]

Analysis 23.1. Comparison 23 Bupropion vs placebo - rs215605 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 24. Bupropion vs placebo - rs215605 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	76	Risk Ratio (M-H, Random, 95% CI)	1.41 [0.54, 3.69]
1.1 Homozygous Major	2	49	Risk Ratio (M-H, Random, 95% CI)	1.93 [0.15, 24.95]
1.2 Heterozygous or Homozygous Minor	2	27	Risk Ratio (M-H, Random, 95% CI)	1.67 [0.46, 6.13]

Analysis 24.1. Comparison 24 Bupropion vs placebo - rs215605 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Study or subgroup	Bupropion n/N	Placebo n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
24.1.1 Homozygous Major					

Favours Placebo 0.1 0.2 0.5 1 2 5 10 Favours Bupropion

Comparison 25. Bupropion + any NRT vs placebo - rs1051730 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	444	Risk Ratio (M-H, Random, 95% CI)	1.80 [1.07, 3.03]
1.1 Homozygous Major	2	183	Risk Ratio (M-H, Random, 95% CI)	2.11 [0.31, 14.60]
1.2 Heterozygous	2	216	Risk Ratio (M-H, Random, 95% CI)	1.82 [1.23, 2.69]
1.3 Homozygous Minor	2	45	Risk Ratio (M-H, Random, 95% CI)	2.84 [0.90, 8.89]

Analysis 25.1. Comparison 25 Bupropion + any NRT vs placebo - rs1051730 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 26. Bupropion + any NRT vs placebo - rs1051730 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	69	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.27, 3.07]
1.1 Homozygous Major	2	58	Risk Ratio (M-H, Random, 95% CI)	1.64 [0.56, 4.83]
1.2 Heterozygous or Homozygous Minor	2	11	Risk Ratio (M-H, Random, 95% CI)	0.22 [0.03, 1.43]

Analysis 26.1. Comparison 26 Bupropion + any NRT vs placebo - rs1051730 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 27. Bupropion + any NRT vs placebo - rs16969968 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	441	Risk Ratio (M-H, Random, 95% CI)	1.79 [1.07, 2.99]
1.1 Homozygous Major	2	183	Risk Ratio (M-H, Random, 95% CI)	2.11 [0.31, 14.60]
1.2 Heterozygous	2	215	Risk Ratio (M-H, Random, 95% CI)	1.80 [1.22, 2.66]
1.3 Homozygous Minor	2	43	Risk Ratio (M-H, Random, 95% CI)	2.81 [0.89, 8.88]

Analysis 27.1. Comparison 27 Bupropion + any NRT vs placebo - rs16969968 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 28. Bupropion + any NRT vs placebo - rs16969968 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	69	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.46, 2.38]
1.1 Homozygous Major	2	63	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.51, 2.85]
1.2 Heterozygous or Homozygous Minor	2	6	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.03, 4.19]

Analysis 28.1. Comparison 28 Bupropion + any NRT vs placebo - rs16969968 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 29. Bupropion + any NRT vs placebo - rs2036527 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	443	Risk Ratio (M-H, Random, 95% CI)	1.74 [1.09, 2.77]
1.1 Homozygous Major	2	181	Risk Ratio (M-H, Random, 95% CI)	2.20 [0.33, 14.75]
1.2 Heterozygous	2	220	Risk Ratio (M-H, Random, 95% CI)	1.83 [1.23, 2.72]
1.3 Homozygous Minor	2	42	Risk Ratio (M-H, Random, 95% CI)	2.12 [0.79, 5.65]

Analysis 29.1. Comparison 29 Bupropion + any NRT vs placebo - rs2036527 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 30. Bupropion + any NRT vs placebo - rs2036527 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	69	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.52, 1.92]
1.1 Homozygous Major	2	38	Risk Ratio (M-H, Random, 95% CI)	2.03 [0.39, 10.56]
1.2 Heterozygous	2	23	Risk Ratio (M-H, Random, 95% CI)	1.03 [0.38, 2.77]
1.3 Homozygous Minor	2	8	Risk Ratio (M-H, Random, 95% CI)	0.74 [0.26, 2.05]

Analysis 30.1. Comparison 30 Bupropion + any NRT vs placebo - rs2036527 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 31. Bupropion + any NRT vs placebo - rs3733829 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	442	Risk Ratio (M-H, Random, 95% CI)	1.55 [1.20, 2.01]
1.1 Homozygous Major	2	187	Risk Ratio (M-H, Random, 95% CI)	1.48 [0.83, 2.65]
1.2 Heterozygous	2	201	Risk Ratio (M-H, Random, 95% CI)	1.87 [1.04, 3.36]
1.3 Homozygous Minor	2	54	Risk Ratio (M-H, Random, 95% CI)	1.85 [0.91, 3.74]

Analysis 31.1. Comparison 31 Bupropion + any NRT vs placebo - rs3733829 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 32. Bupropion + any NRT vs placebo - rs3733829 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	48	Risk Ratio (M-H, Random, 95% CI)	0.42 [0.14, 1.24]
1.1 Homozygous Major	2	48	Risk Ratio (M-H, Random, 95% CI)	0.42 [0.14, 1.24]

Analysis 32.1. Comparison 32 Bupropion + any NRT vs placebo - rs3733829 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 33. Bupropion + any NRT vs placebo - rs7937 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	442	Risk Ratio (M-H, Random, 95% CI)	1.51 [1.16, 1.97]
1.1 Homozygous Major	2	131	Risk Ratio (M-H, Random, 95% CI)	2.00 [0.84, 4.75]
1.2 Heterozygous	2	229	Risk Ratio (M-H, Random, 95% CI)	1.39 [0.99, 1.94]
1.3 Homozygous Minor	2	82	Risk Ratio (M-H, Random, 95% CI)	2.34 [0.49, 11.08]

Analysis 33.1. Comparison 33 Bupropion + any NRT vs placebo - rs7937 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 34. Bupropion + any NRT vs placebo - rs7937 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	69	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.47, 2.38]
1.1 Homozygous Major	2	31	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.40, 2.73]
1.2 Heterozygous or Homozygous Minor	2	38	Risk Ratio (M-H, Random, 95% CI)	1.08 [0.23, 4.99]

Analysis 34.1. Comparison 34 Bupropion + any NRT vs placebo - rs7937 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 35. Bupropion + any NRT vs placebo - rs1329650 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	442	Risk Ratio (M-H, Random, 95% CI)	1.62 [1.10, 2.39]
1.1 Homozygous Major	2	240	Risk Ratio (M-H, Random, 95% CI)	1.98 [1.31, 3.00]
1.2 Heterozygous	2	172	Risk Ratio (M-H, Random, 95% CI)	1.60 [0.70, 3.67]
1.3 Homozygous Minor	2	30	Risk Ratio (M-H, Random, 95% CI)	2.04 [0.17, 25.25]

Analysis 35.1. Comparison 35 Bupropion + any NRT vs placebo - rs1329650 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 36. Bupropion + any NRT vs placebo - rs1329650 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	69	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.48, 2.41]
1.1 Homozygous Major	2	55	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.40, 2.55]
1.2 Heterozygous or Homozygous Minor	2	14	Risk Ratio (M-H, Random, 95% CI)	1.32 [0.26, 6.80]

Analysis 36.1. Comparison 36 Bupropion + any NRT vs placebo - rs1329650 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 37. Bupropion + any NRT vs placebo - rs1028936 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	444	Risk Ratio (M-H, Random, 95% CI)	1.64 [1.08, 2.49]
1.1 Homozygous Major	2	305	Risk Ratio (M-H, Random, 95% CI)	1.89 [1.34, 2.67]
1.2 Heterozygous	2	125	Risk Ratio (M-H, Random, 95% CI)	1.42 [0.48, 4.20]
1.3 Homozygous Minor	2	14	Risk Ratio (M-H, Random, 95% CI)	1.93 [0.47, 8.02]

Analysis 37.1. Comparison 37 Bupropion + any NRT vs placebo - rs1028936 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 38. Bupropion + any NRT vs placebo - rs1028936 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	69	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.48, 2.41]
1.1 Homozygous Major	2	57	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.43, 2.84]
1.2 Heterozygous or Homozygous Minor	2	12	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.17, 5.39]

Analysis 38.1. Comparison 38 Bupropion + any NRT vs placebo - rs1028936 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 39. Bupropion + any NRT vs placebo - rs215605 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	442	Risk Ratio (M-H, Random, 95% CI)	1.72 [1.16, 2.53]
1.1 Homozygous Major	2	171	Risk Ratio (M-H, Random, 95% CI)	2.00 [1.32, 3.03]
1.2 Heterozygous	2	200	Risk Ratio (M-H, Random, 95% CI)	1.47 [0.60, 3.63]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.3 Homozygous Minor	2	71	Risk Ratio (M-H, Random, 95% CI)	2.29 [0.72, 7.27]

Analysis 39.1. Comparison 39 Bupropion + any NRT vs placebo - rs215605 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 40. Bupropion + any NRT vs placebo - rs215605 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	68	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.41, 1.77]
1.1 Homozygous Major	2	36	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.29, 1.76]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.2 Heterozygous or Homozygous Minor	2	32	Risk Ratio (M-H, Random, 95% CI)	1.19 [0.34, 4.13]

Analysis 40.1. Comparison 40 Bupropion + any NRT vs placebo - rs215605 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 41. Bupropion + any NRT vs bupropion - rs1051730 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	533	Risk Ratio (M-H, Random, 95% CI)	1.18 [0.90, 1.55]
1.1 Homozygous Major	2	206	Risk Ratio (M-H, Random, 95% CI)	1.14 [0.54, 2.42]
1.2 Heterozygous	2	262	Risk Ratio (M-H, Random, 95% CI)	1.22 [0.93, 1.61]
1.3 Homozygous Minor	2	65	Risk Ratio (M-H, Random, 95% CI)	1.28 [0.68, 2.44]

**Analysis 41.1. Comparison 41 Bupropion + any NRT vs bupropion
- rs1051730 - non-Hispanic white, Outcome 1 End of Treatment.** **Comparison 42. Bupropion + any NRT vs bupropion - rs1051730 - non-Hispanic black or African American**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	87	Risk Ratio (M-H, Random, 95% CI)	0.70 [0.37, 1.31]
1.1 Homozygous Major	2	66	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.40, 1.49]
1.2 Heterozygous or Homozygous Minor	2	21	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.05, 2.19]

Analysis 42.1. Comparison 42 Bupropion + any NRT vs bupropion - rs1051730 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 43. Bupropion + any NRT vs bupropion - rs16969968 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	531	Risk Ratio (M-H, Random, 95% CI)	1.18 [0.90, 1.55]
1.1 Homozygous Major	2	206	Risk Ratio (M-H, Random, 95% CI)	1.14 [0.54, 2.42]
1.2 Heterozygous	2	262	Risk Ratio (M-H, Random, 95% CI)	1.22 [0.93, 1.61]
1.3 Homozygous Minor	2	63	Risk Ratio (M-H, Random, 95% CI)	1.27 [0.66, 2.44]

Analysis 43.1. Comparison 43 Bupropion + any NRT vs bupropion - rs16969968 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 44. Bupropion + any NRT vs bupropion - rs16969968 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	87	Risk Ratio (M-H, Random, 95% CI)	0.69 [0.37, 1.27]
1.1 Homozygous Major	2	74	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.38, 1.40]
1.2 Heterozygous or Homozygous Minor	2	13	Risk Ratio (M-H, Random, 95% CI)	0.41 [0.06, 2.76]

Analysis 44.1. Comparison 44 Bupropion + any NRT vs bupropion - rs16969968 - non-Hispanic black or African American, Outcome 1 End of Treatment. **Comparison 45. Bupropion + any NRT vs bupropion - rs2036527 - non-Hispanic white**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	532	Risk Ratio (M-H, Random, 95% CI)	1.18 [0.91, 1.52]
1.1 Homozygous Major	2	204	Risk Ratio (M-H, Random, 95% CI)	1.17 [0.54, 2.52]
1.2 Heterozygous	2	264	Risk Ratio (M-H, Random, 95% CI)	1.21 [0.92, 1.60]
1.3 Homozygous Minor	2	64	Risk Ratio (M-H, Random, 95% CI)	1.24 [0.68, 2.25]

Analysis 45.1. Comparison 45 Bupropion + any NRT vs bupropion - rs2036527 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 46. Bupropion + any NRT vs bupropion - rs2036527 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	87	Risk Ratio (M-H, Random, 95% CI)	0.66 [0.35, 1.23]
1.1 Homozygous Major	2	50	Risk Ratio (M-H, Random, 95% CI)	0.56 [0.23, 1.35]
1.2 Heterozygous or Homozygous Minor	2	37	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.32, 1.90]

**Analysis 46.1. Comparison 46 Bupropion + any NRT vs bupropion - rs2036527
- non-Hispanic black or African American, Outcome 1 End of Treatment.** **Comparison 47. Bupropion + any NRT vs bupropion - rs3733829 - non-Hispanic white**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	531	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.96, 1.39]
1.1 Homozygous Major	2	236	Risk Ratio (M-H, Random, 95% CI)	1.19 [0.77, 1.84]
1.2 Heterozygous	2	229	Risk Ratio (M-H, Random, 95% CI)	1.11 [0.82, 1.51]
1.3 Homozygous Minor	2	66	Risk Ratio (M-H, Random, 95% CI)	1.34 [0.80, 2.25]

**Analysis 47.1. Comparison 47 Bupropion + any NRT vs bupropion
- rs3733829 - non-Hispanic white, Outcome 1 End of Treatment.**

Comparison 48. Bupropion + any NRT vs bupropion - rs3733829 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	94	Risk Ratio (M-H, Random, 95% CI)	0.49 [0.25, 0.99]
1.1 Homozygous Major	2	65	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.18, 1.01]
1.2 Heterozygous or Homozygous Minor	2	29	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.13, 4.20]

**Analysis 48.1. Comparison 48 Bupropion + any NRT vs bupropion - rs3733829
- non-Hispanic black or African American, Outcome 1 End of Treatment.** **Comparison 49. Bupropion + any NRT vs bupropion - rs7937 - non-Hispanic white**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	533	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.95, 1.42]
1.1 Homozygous Major	2	145	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.65, 1.59]
1.2 Heterozygous	2	272	Risk Ratio (M-H, Random, 95% CI)	1.27 [0.81, 2.00]
1.3 Homozygous Minor	2	116	Risk Ratio (M-H, Random, 95% CI)	1.29 [0.90, 1.84]

**Analysis 49.1. Comparison 49 Bupropion + any NRT vs bupropion
- rs7937 - non-Hispanic white, Outcome 1 End of Treatment.**

Comparison 50. Bupropion + any NRT vs bupropion - rs7937 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	87	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.39, 1.43]
1.1 Homozygous Major	2	33	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.13, 2.86]
1.2 Heterozygous or Homozygous Minor	2	54	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.27, 1.93]

**Analysis 50.1. Comparison 50 Bupropion + any NRT vs bupropion - rs7937
- non-Hispanic black or African American, Outcome 1 End of Treatment.** **Comparison 51. Bupropion + any NRT vs bupropion - rs1329650 - non-Hispanic white**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	531	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.97, 1.49]
1.1 Homozygous Major	2	279	Risk Ratio (M-H, Random, 95% CI)	1.22 [0.66, 2.25]
1.2 Heterozygous	2	214	Risk Ratio (M-H, Random, 95% CI)	1.22 [0.92, 1.62]
1.3 Homozygous Minor	2	38	Risk Ratio (M-H, Random, 95% CI)	1.68 [0.89, 3.17]

**Analysis 51.1. Comparison 51 Bupropion + any NRT vs bupropion
- rs1329650 - non-Hispanic white, Outcome 1 End of Treatment.**

Comparison 52. Bupropion + any NRT vs bupropion - rs1329650 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	87	Risk Ratio (M-H, Random, 95% CI)	0.63 [0.33, 1.20]
1.1 Homozygous Major	2	76	Risk Ratio (M-H, Random, 95% CI)	0.59 [0.30, 1.15]
1.2 Heterozygous or Homozygous Minor	2	11	Risk Ratio (M-H, Random, 95% CI)	1.2 [0.17, 8.24]

Analysis 52.1. Comparison 52 Bupropion + any NRT vs bupropion - rs1329650 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 53. Bupropion + any NRT vs bupropion - rs1028936 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	533	Risk Ratio (M-H, Random, 95% CI)	1.18 [0.92, 1.50]
1.1 Homozygous Major	2	359	Risk Ratio (M-H, Random, 95% CI)	1.09 [0.86, 1.37]
1.2 Heterozygous	2	159	Risk Ratio (M-H, Random, 95% CI)	1.30 [0.62, 2.75]
1.3 Homozygous Minor	2	15	Risk Ratio (M-H, Random, 95% CI)	2.17 [0.51, 9.18]

Analysis 53.1. Comparison 53 Bupropion + any NRT vs bupropion - rs1028936 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 54. Bupropion + any NRT vs bupropion - rs1028936 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	87	Risk Ratio (M-H, Random, 95% CI)	0.63 [0.33, 1.20]
1.1 Homozygous Major	2	76	Risk Ratio (M-H, Random, 95% CI)	0.59 [0.30, 1.15]
1.2 Heterozygous or Homozygous Minor	2	11	Risk Ratio (M-H, Random, 95% CI)	1.2 [0.17, 8.24]

**Analysis 54.1. Comparison 54 Bupropion + any NRT vs bupropion - rs1028936
- non-Hispanic black or African American, Outcome 1 End of Treatment.** **Comparison 55. Bupropion + any NRT vs bupropion - rs215605 - non-Hispanic white**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	532	Risk Ratio (M-H, Random, 95% CI)	1.17 [0.93, 1.47]
1.1 Homozygous Major	2	211	Risk Ratio (M-H, Random, 95% CI)	1.28 [0.91, 1.80]
1.2 Heterozygous	2	241	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.69, 1.45]
1.3 Homozygous Minor	2	80	Risk Ratio (M-H, Random, 95% CI)	1.61 [0.64, 4.08]

**Analysis 55.1. Comparison 55 Bupropion + any NRT vs bupropion
- rs215605 - non-Hispanic white, Outcome 1 End of Treatment.**

Comparison 56. Bupropion + any NRT vs bupropion - rs215605 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2	87	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.37, 1.35]
1.1 Homozygous Major	2	49	Risk Ratio (M-H, Random, 95% CI)	0.51 [0.09, 2.94]
1.2 Heterozygous or Homozygous Minor	2	38	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.26, 1.93]

Analysis 56.1. Comparison 56 Bupropion + any NRT vs bupropion - rs215605 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 57. Active NRT - rs1051730 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	7		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	7	1559	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.71, 1.19]
1.2 Heterozygous vs Homozygous Minor	7	1650	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.75, 1.11]
2 End of Treatment	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	5	1200	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.73, 1.06]
2.2 Heterozygous vs Homozygous Minor	5	1291	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.79, 1.10]

Analysis 57.1. Comparison 57 Active NRT - rs1051730 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 57.2. Comparison 57 Active NRT - rs1051730 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 58. Active NRT - rs1051730 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	187	Risk Ratio (M-H, Random, 95% CI)	1.08 [0.26, 4.57]
1.2 Heterozygous vs Homozygous Minor	2	56	Risk Ratio (M-H, Random, 95% CI)	1.11 [0.25, 4.99]

Analysis 58.1. Comparison 58 Active NRT - rs1051730 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.

Comparison 59. Active NRT - rs16969968 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	392	Risk Ratio (M-H, Random, 95% CI)	2.24 [0.92, 5.45]
2 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	392	Risk Ratio (M-H, Random, 95% CI)	2.75 [1.08, 7.02]

Analysis 59.1. Comparison 59 Active NRT - rs16969968 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.

Analysis 59.2. Comparison 59 Active NRT - rs16969968 - non-Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 60. Active NRT - rs588765 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	3	433	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.80, 1.37]
1.2 Heterozygous vs Homozygous Minor	3	546	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.76, 1.29]
2 End of Treatment	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	3	429	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.76, 1.18]
2.2 Heterozygous vs Homozygous Minor	3	542	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.77, 1.17]

Analysis 60.1. Comparison 60 Active NRT - rs588765 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 60.2. Comparison 60 Active NRT - rs588765 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 61. Active NRT - rs2036527 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	501	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.60, 1.03]
1.2 Heterozygous vs Homozygous Minor	2	579	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.63, 1.10]
2 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	2	501	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.59, 1.35]
2.2 Heterozygous vs Homozygous Minor	2	579	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.61, 1.64]

Analysis 61.1. Comparison 61 Active NRT - rs2036527 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 61.2. Comparison 61 Active NRT - rs2036527 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 62. Active NRT - rs2036527 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	391	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.87, 1.81]
2 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	391	Risk Ratio (M-H, Random, 95% CI)	1.73 [1.20, 2.49]

Analysis 62.1. Comparison 62 Active NRT - rs2036527 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.

Analysis 62.2. Comparison 62 Active NRT - rs2036527 - non-Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 63. Active NRT - DRD-4 (exon 3 48 bp) - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	3	866	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.51, 1.76]
1.2 Heterozygous vs Homozygous Minor	3	321	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.42, 1.60]
2 End of Treatment	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	3	866	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.71, 1.23]
2.2 Heterozygous vs Homozygous Minor	3	321	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.58, 1.26]

Analysis 63.1. Comparison 63 Active NRT - DRD-4 (exon 3 48 bp) - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 63.2. Comparison 63 Active NRT - DRD-4 (exon 3 48 bp) - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 64. Active NRT - SLC6A4 (Promoter) - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	461	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.50, 1.67]
1.2 Heterozygous vs Homozygous Minor	2	649	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.66, 1.90]
2 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	2	461	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.77, 1.23]
2.2 Heterozygous vs Homozygous Minor	2	649	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.74, 1.18]

Analysis 64.1. Comparison 64 Active NRT - SLC6A4 (Promoter) - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 64.2. Comparison 64 Active NRT - SLC6A4 (Promoter) - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 65. Active NRT-NMR - non-Hispanic white or black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Normal NMR vs Slow NMR	2	718	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.37, 0.78]
2 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Normal NMR vs Slow NMR	2	718	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.58, 1.03]

Analysis 65.1. Comparison 65 Active NRT-NMR - non-Hispanic white or black or African American, Outcome 1 Six-Month Abstinence.

Analysis 65.2. Comparison 65 Active NRT-NMR - non-Hispanic white or black or African American, Outcome 2 End of Treatment.

Comparison 66. Bupropion - rs1051730 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Homozygous Major vs Homozygous Minor	4	316	Risk Ratio (M-H, Random, 95% CI)	1.27 [0.67, 2.43]
1.2 Heterozygous vs Homozygous Minor	4	390	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.65, 2.03]
2 End of Treatment	6		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	6	386	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.88, 1.50]
2.2 Heterozygous vs Homozygous Minor	6	480	Risk Ratio (M-H, Random, 95% CI)	1.04 [0.81, 1.33]

Analysis 66.1. Comparison 66 Bupropion - rs1051730 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 66.2. Comparison 66 Bupropion - rs1051730 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 67. Bupropion - rs1051730 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	63	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.36, 1.95]
2 End of Treatment	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Heterozygous or Homozygous Minor	3	84	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.51, 1.72]

Analysis 67.1. Comparison 67 Bupropion - rs1051730 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.

Analysis 67.2. Comparison 67 Bupropion - rs1051730 - non-Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 68. Bupropion - rs16969968 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	3	160	Risk Ratio (M-H, Random, 95% CI)	1.47 [0.96, 2.25]
1.2 Heterozygous vs Homozygous Minor	3	216	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.79, 1.84]

Analysis 68.1. Comparison 68 Bupropion - rs16969968 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 69. Bupropion - rs16969968 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	294	Risk Ratio (M-H, Random, 95% CI)	0.62 [0.31, 1.21]
2 End of Treatment	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Heterozygous or Homozygous Minor	3	315	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.48, 1.32]

Analysis 69.1. Comparison 69 Bupropion - rs16969968 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.

Analysis 69.2. Comparison 69 Bupropion - rs16969968 - non-Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 70. Bupropion - rs588765 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	4	304	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.52, 1.34]
1.2 Heterozygous vs Homozygous Minor	4	401	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.66, 1.21]
2 End of Treatment	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	4	304	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.69, 1.14]
2.2 Heterozygous vs Homozygous Minor	4	400	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.76, 1.22]

Analysis 70.1. Comparison 70 Bupropion - rs588765 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 70.2. Comparison 70 Bupropion - rs588765 - non-Hispanic white, Outcome 2 End of Treatment. **Comparison 71. Bupropion - rs2036527 - non-Hispanic white**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Homozygous Major vs Homozygous Minor	2	208	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.33, 1.81]
1.2 Heterozygous vs Homozygous Minor	2	269	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.51, 1.37]
2 End of Treatment	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	4	277	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.79, 1.70]
2.2 Heterozygous vs Homozygous Minor	4	361	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.61, 1.51]

Analysis 71.1. Comparison 71 Bupropion - rs2036527 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 71.2. Comparison 71 Bupropion - rs2036527 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 72. Bupropion - rs2036527 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	3	331	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.55, 1.46]
2 End of Treatment	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Heterozygous or Homozygous Minor	4	352	Risk Ratio (M-H, Random, 95% CI)	1.24 [0.87, 1.76]

Analysis 72.1. Comparison 72 Bupropion - rs2036527 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.

Analysis 72.2. Comparison 72 Bupropion - rs2036527 - non-Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 73. Bupropion - rs3733829 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	191	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.56, 1.46]
1.2 Heterozygous vs Homozygous Minor	2	161	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.65, 1.71]
2 End of Treatment	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	4	259	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.73, 1.40]
2.2 Heterozygous vs Homozygous Minor	4	237	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.70, 1.36]

Analysis 73.1. Comparison 73 Bupropion - rs3733829 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 73.2. Comparison 73 Bupropion - rs3733829 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 74. Bupropion - rs3733829 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	46	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.37, 2.99]

Analysis 74.1. Comparison 74 Bupropion - rs3733829 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 75. Bupropion - rs7937 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	3	159	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.71, 1.40]
1.2 Heterozygous vs Homozygous Minor	3	238	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.65, 1.23]

Analysis 75.1. Comparison 75 Bupropion - rs7937 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 76. Bupropion - rs7937 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	23	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.32, 4.26]
1.2 Heterozygous vs Homozygous Minor	2	27	Risk Ratio (M-H, Random, 95% CI)	0.72 [0.18, 2.93]

Analysis 76.1. Comparison 76 Bupropion - rs7937 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 77. Bupropion - rs1329650 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	3	186	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.54, 1.35]
1.2 Heterozygous vs Homozygous Minor	3	163	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.56, 1.42]

Analysis 77.1. Comparison 77 Bupropion - rs1329650 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 78. Bupropion - rs1329650 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	47	Risk Ratio (M-H, Random, 95% CI)	1.46 [0.35, 6.01]

Analysis 78.1. Comparison 78 Bupropion - rs1329650 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 79. Bupropion - rs1028936 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	3	221	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.42, 1.55]
1.2 Heterozygous vs Homozygous Minor	3	112	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.40, 1.64]

Analysis 79.1. Comparison 79 Bupropion - rs1028936 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 80. Bupropion - rs1028936 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	47	Risk Ratio (M-H, Random, 95% CI)	1.46 [0.35, 6.01]

Analysis 80.1. Comparison 80 Bupropion - rs1028936 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 81. Bupropion - rs215605 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	3	170	Risk Ratio (M-H, Random, 95% CI)	1.61 [0.87, 3.00]
1.2 Heterozygous vs Homozygous Minor	3	199	Risk Ratio (M-H, Random, 95% CI)	1.56 [0.79, 3.06]

Analysis 81.1. Comparison 81 Bupropion - rs215605 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 82. Bupropion - rs215605 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	47	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.54, 2.44]

Analysis 82.1. Comparison 82 Bupropion - rs215605 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 83. Varenicline - rs16969968 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	358	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.71, 1.25]
1.2 Heterozygous vs Homozygous Minor	2	438	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.75, 1.30]
2 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	2	358	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.78, 1.24]
2.2 Heterozygous vs Homozygous Minor	2	438	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.77, 1.22]

Analysis 83.1. Comparison 83 Varenicline - rs16969968 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 83.2. Comparison 83 Varenicline - rs16969968 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 84. Varenicline - rs588765 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	354	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.91, 1.60]
1.2 Heterozygous vs Homozygous Minor	2	465	Risk Ratio (M-H, Random, 95% CI)	1.18 [0.90, 1.54]
2 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	2	354	Risk Ratio (M-H, Random, 95% CI)	1.14 [0.91, 1.43]
2.2 Heterozygous vs Homozygous Minor	2	465	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.89, 1.37]

Analysis 84.1. Comparison 84 Varenicline - rs588765 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 84.2. Comparison 84 Varenicline - rs588765 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 85. Bupropion + any NRT - rs1051730 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	138	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.67, 1.78]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.2 Heterozygous vs Homozygous Minor	2	155	Risk Ratio (M-H, Random, 95% CI)	1.11 [0.69, 1.80]

Analysis 85.1. Comparison 85 Bupropion + any NRT - rs1051730 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 86. Bupropion + any NRT - rs1051730 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	40	Risk Ratio (M-H, Random, 95% CI)	2.26 [0.36, 14.38]

Analysis 86.1. Comparison 86 Bupropion + any NRT - rs1051730 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 87. Bupropion + any NRT - rs16969968 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	136	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.67, 1.85]
1.2 Heterozygous vs Homozygous Minor	2	153	Risk Ratio (M-H, Random, 95% CI)	1.13 [0.68, 1.86]

Analysis 87.1. Comparison 87 Bupropion + any NRT - rs16969968 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 88. Bupropion + any NRT - rs16969968 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	40	Risk Ratio (M-H, Random, 95% CI)	1.66 [0.27, 10.32]

Analysis 88.1. Comparison 88 Bupropion + any NRT - rs16969968 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 89. Bupropion + any NRT - rs2036527 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	135	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.70, 1.79]
1.2 Heterozygous vs Homozygous Minor	2	156	Risk Ratio (M-H, Random, 95% CI)	1.04 [0.65, 1.66]

Analysis 89.1. Comparison 89 Bupropion + any NRT - rs2036527 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 90. Bupropion + any NRT - rs2036527 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	28	Risk Ratio (M-H, Random, 95% CI)	0.51 [0.06, 4.51]
1.2 Heterozygous vs Homozygous Minor	2	17	Risk Ratio (M-H, Random, 95% CI)	0.70 [0.03, 15.98]

Analysis 90.1. Comparison 90 Bupropion + any NRT - rs2036527 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 91. Bupropion + any NRT - rs3733829 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	144	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.66, 1.34]
1.2 Heterozygous vs Homozygous Minor	2	153	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.55, 1.14]

Analysis 91.1. Comparison 91 Bupropion + any NRT - rs3733829 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 92. Bupropion + any NRT - rs3733829 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	40	Risk Ratio (M-H, Random, 95% CI)	0.36 [0.13, 0.99]

Analysis 92.1. Comparison 92 Bupropion + any NRT - rs3733829 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 93. Bupropion + any NRT - rs7937 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	128	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.57, 1.10]
1.2 Heterozygous vs Homozygous Minor	2	194	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.51, 1.28]

Analysis 93.1. Comparison 93 Bupropion + any NRT - rs7937 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 94. Bupropion + any NRT - rs7937 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	40	Risk Ratio (M-H, Random, 95% CI)	1.29 [0.12, 13.56]

Analysis 94.1. Comparison 94 Bupropion + any NRT - rs7937 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 95. Bupropion + any NRT - rs1329650 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	170	Risk Ratio (M-H, Random, 95% CI)	0.64 [0.43, 0.94]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.2 Heterozygous vs Homozygous Minor	2	117	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.50, 1.03]

Analysis 95.1. Comparison 95 Bupropion + any NRT - rs1329650 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 96. Bupropion + any NRT - rs1329650 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	40	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.15, 1.94]

Analysis 96.1. Comparison 96 Bupropion + any NRT - rs1329650 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 97. Bupropion + any NRT - rs1028936 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	193	Risk Ratio (M-H, Random, 95% CI)	0.63 [0.37, 1.07]
1.2 Heterozygous vs Homozygous Minor	2	85	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.42, 1.32]

Analysis 97.1. Comparison 97 Bupropion + any NRT - rs1028936 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 98. Bupropion + any NRT - rs1028936 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	40	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.15, 1.94]

Analysis 98.1. Comparison 98 Bupropion + any NRT - rs1028936 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 99. Bupropion + any NRT - rs215605 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	148	Risk Ratio (M-H, Random, 95% CI)	1.18 [0.84, 1.66]
1.2 Heterozygous vs Homozygous Minor	2	162	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.61, 1.26]

Analysis 99.1. Comparison 99 Bupropion + any NRT - rs215605 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 100. Bupropion + any NRT - rs215605 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	40	Risk Ratio (M-H, Random, 95% CI)	0.76 [0.04, 13.56]

Analysis 100.1. Comparison 100 Bupropion + any NRT - rs215605 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 101. Placebo - rs1051730 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	6		Risk Ratio (M-H, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Homozygous Major vs Homozygous Minor	6	533	Risk Ratio (M-H, Random, 95% CI)	1.29 [0.86, 1.92]
1.2 Heterozygous vs Homozygous Minor	6	597	Risk Ratio (M-H, Random, 95% CI)	1.08 [0.72, 1.62]
2 End of Treatment	7		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	7	542	Risk Ratio (M-H, Random, 95% CI)	1.39 [0.91, 2.13]
2.2 Heterozygous vs Homozygous Minor	7	605	Risk Ratio (M-H, Random, 95% CI)	1.24 [0.81, 1.89]

Analysis 101.1. Comparison 101 Placebo - rs1051730 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 101.2. Comparison 101 Placebo - rs1051730 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 102. Placebo - rs1051730 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	63	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.08, 6.73]
2 End of Treatment	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Heterozygous or Homozygous Minor	3	83	Risk Ratio (M-H, Random, 95% CI)	0.76 [0.24, 2.45]

Analysis 102.1. Comparison 102 Placebo - rs1051730 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.

Analysis 102.2. Comparison 102 Placebo - rs1051730 - non-Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 103. Placebo - rs16969968 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	162	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.51, 2.14]
1.2 Heterozygous vs Homozygous Minor	2	211	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.32, 1.96]
2 End of Treatment	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	4	218	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.68, 3.53]
2.2 Heterozygous vs Homozygous Minor	4	276	Risk Ratio (M-H, Random, 95% CI)	1.34 [0.51, 3.53]

Analysis 103.1. Comparison 103 Placebo - rs16969968 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 103.2. Comparison 103 Placebo - rs16969968 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 104. Placebo - rs16969968 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	3	584	Risk Ratio (M-H, Random, 95% CI)	0.74 [0.42, 1.33]
2 End of Treatment	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Heterozygous or Homozygous Minor	4	596	Risk Ratio (M-H, Random, 95% CI)	0.55 [0.35, 0.86]

Analysis 104.1. Comparison 104 Placebo - rs16969968 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.

Analysis 104.2. Comparison 104 Placebo - rs16969968 - non-Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 105. Placebo - rs588765 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	5	383	Risk Ratio (M-H, Random, 95% CI)	1.04 [0.69, 1.57]
1.2 Heterozygous vs Homozygous Minor	5	470	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.72, 1.58]
2 End of Treatment	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	5	362	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.63, 1.21]
2.2 Heterozygous vs Homozygous Minor	5	404	Risk Ratio (M-H, Random, 95% CI)	1.08 [0.80, 1.46]

Analysis 105.1. Comparison 105 Placebo - rs588765 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 105.2. Comparison 105 Placebo - rs588765 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 106. Placebo - rs588765 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	566	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.80, 1.79]
2 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	566	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.71, 1.77]

Analysis 106.1. Comparison 106 Placebo - rs588765 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence.

Analysis 106.2. Comparison 106 Placebo - rs588765 - non-Hispanic black or African American, Outcome 2 End of Treatment.

Comparison 107. Placebo - rs2036527 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	160	Risk Ratio (M-H, Random, 95% CI)	1.85 [0.77, 4.44]
1.2 Heterozygous vs Homozygous Minor	2	209	Risk Ratio (M-H, Random, 95% CI)	1.58 [0.66, 3.77]
2 End of Treatment	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	4	216	Risk Ratio (M-H, Random, 95% CI)	1.98 [0.91, 4.35]
2.2 Heterozygous vs Homozygous Minor	4	275	Risk Ratio (M-H, Random, 95% CI)	1.86 [0.94, 3.69]

Analysis 107.1. Comparison 107 Placebo - rs2036527 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 107.2. Comparison 107 Placebo - rs2036527 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 108. Placebo - rs2036527 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	4	629	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.71, 1.77]
2 End of Treatment	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Heterozygous or Homozygous Minor	5	641	Risk Ratio (M-H, Random, 95% CI)	1.08 [0.71, 1.64]

Analysis 108.1. Comparison 108 Placebo - rs2036527 - non-Hispanic black or African American, Outcome 1 Six-Month Abstinence. **Analysis 108.2. Comparison 108 Placebo - rs2036527 - non-Hispanic black or African American, Outcome 2 End of Treatment.**

Comparison 109. Placebo - DRD-4 (exon 3 48 bp) - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	3	387	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.37, 3.16]
1.2 Heterozygous vs Homozygous Minor	3	212	Risk Ratio (M-H, Random, 95% CI)	0.60 [0.22, 1.63]
2 End of Treatment	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	3	387	Risk Ratio (M-H, Random, 95% CI)	1.08 [0.51, 2.29]
2.2 Heterozygous vs Homozygous Minor	3	212	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.61, 1.29]

Analysis 109.1. Comparison 109 Placebo - DRD-4 (exon 3 48 bp) - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 109.2. Comparison 109 Placebo - DRD-4 (exon 3 48 bp) - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 110. Placebo - rs3733829 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	2	162	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.46, 1.51]
1.2 Heterozygous vs Homozygous Minor	2	142	Risk Ratio (M-H, Random, 95% CI)	0.66 [0.35, 1.26]
2 End of Treatment	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major vs Homozygous Minor	4	215	Risk Ratio (M-H, Random, 95% CI)	1.23 [0.74, 2.05]
2.2 Heterozygous vs Homozygous Minor	4	203	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.57, 1.65]

Analysis 110.1. Comparison 110 Placebo - rs3733829 - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 110.2. Comparison 110 Placebo - rs3733829 - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 111. Placebo - rs7937 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	3	113	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.45, 1.45]
1.2 Heterozygous vs Homozygous Minor	3	160	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.57, 1.60]

Analysis 111.1. Comparison 111 Placebo - rs7937 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 112. Placebo - rs7937 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	29	Risk Ratio (M-H, Random, 95% CI)	1.17 [0.27, 5.04]

Analysis 112.1. Comparison 112 Placebo - rs7937 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 113. Placebo - rs1329650 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	3	129	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.18, 3.62]
1.2 Heterozygous vs Homozygous Minor	3	116	Risk Ratio (M-H, Random, 95% CI)	0.80 [0.39, 1.63]

Analysis 113.1. Comparison 113 Placebo - rs1329650 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 114. Placebo - rs1329650 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	29	Risk Ratio (M-H, Random, 95% CI)	0.72 [0.19, 2.78]

Analysis 114.1. Comparison 114 Placebo - rs1329650 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 115. Placebo - rs1028936 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	3	163	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.29, 3.14]
1.2 Heterozygous vs Homozygous Minor	3	77	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.36, 4.03]

Analysis 115.1. Comparison 115 Placebo - rs1028936 - non-Hispanic white, Outcome 1 End of Treatment.
Comparison 116. Placebo - rs1028936 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	29	Risk Ratio (M-H, Random, 95% CI)	0.49 [0.18, 1.32]

Analysis 116.1. Comparison 116 Placebo - rs1028936 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 117. Placebo - rs215605 - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Homozygous Minor	3	129	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.52, 1.82]
1.2 Heterozygous vs Homozygous Minor	3	140	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.63, 2.12]

Analysis 117.1. Comparison 117 Placebo - rs215605 - non-Hispanic white, Outcome 1 End of Treatment.

Comparison 118. Placebo - rs215605 - non-Hispanic black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major vs Heterozygous or Homozygous Minor	2	29	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.03, 38.58]

Analysis 118.1. Comparison 118 Placebo - rs215605 - non-Hispanic black or African American, Outcome 1 End of Treatment.

Comparison 119. Placebo - SLC6A4 (Promoter) - non-Hispanic white

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Homozygous Major or Heterozygous vs Homozygous Minor	2	151	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.32, 1.79]
2 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Homozygous Major or Heterozygous vs Homozygous Minor	2	151	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.83, 1.38]

Analysis 119.1. Comparison 119 Placebo - SLC6A4 (Promoter) - non-Hispanic white, Outcome 1 Six-Month Abstinence.

Analysis 119.2. Comparison 119 Placebo - SLC6A4 (Promoter) - non-Hispanic white, Outcome 2 End of Treatment.

Comparison 120. Placebo - NMR - non-Hispanic white or black or African American

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Six-Month Abstinence	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Normal NMR vs Slow NMR	2	699	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.70, 1.48]
2 End of Treatment	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Normal NMR vs Slow NMR	2	718	Risk Ratio (M-H, Random, 95% CI)	0.63 [0.35, 1.14]

Analysis 120.1. Comparison 120 Placebo - NMR - non-Hispanic white or black or African American, Outcome 1 Six-Month Abstinence.

Analysis 120.2. Comparison 120 Placebo - NMR - non-Hispanic white or black or African American, Outcome 2 End of Treatment.

ADDITIONAL TABLES

Table 1. Glossary of genetic terms

Genetic term	Explanation
Single-nucleotide polymorphism (SNP)	<p>A single base pair change in the DNA sequence at a particular point compared with the “common” or “wild-type” sequence (Attia 2009)</p> <p>Most common form of genetic variation in the genome, in which a single-base substitution has created 2 forms of a DNA sequence that differ by a single nucleotide (Pearson 2008)</p>
Alleles	Alternate forms of a gene or chromosomal locus that differ in DNA sequence (Pearson 2008)
Genome-wide association study (GWAS)	Any study of genetic variation across the entire human genome designed to identify genetic association with observable traits or the presence or absence of a disease, usually referring to studies with genetic marker density of 100,000 or more to represent a large proportion of variation in the human genome (Pearson 2008)
Genotype	The genetic constitution of an individual, either overall or at a specific gene (Attia 2009)
Hardy-Weinberg equilibrium (HWE)	Population distribution of 2 alleles (with frequencies p and q) such that the distribution is stable from generation to generation and genotypes occur at frequencies of p^2 , $2pq$, and q^2 for the major allele homozygote, heterozygote, and minor allele homozygote, respectively (Pearson 2008)
Linkage disequilibrium	Measure of association between 2 alleles located near each other on a chromosome, such that they are inherited together more frequently than would be expected by chance (Pearson 2008)
Loci	The site(s) on a chromosome at which the gene for a particular trait is located on a gene at which a particular SNP is located (Attia 2009)
Minor allele	The allele of a biallelic polymorphism that is less frequent in the study population (Pearson 2008)
Major allele	The allele of a biallelic polymorphism that is more frequent in the study population (Pearson 2008)
Pharmacogenetics	The field of studying the genetic basis of drug response and applying this knowledge to clinical practice by guiding drug prescribing
Pharmacogenomics	Similar to pharmacogenetics but uses information across the whole genome
Population stratification	A form of confounding in genetic association studies caused by genetic differences between cases and controls unrelated to disease but due to sampling from populations of different ancestries (Pearson 2008)
Wild-type allele	The allele at a particular single-nucleotide polymorphism (SNP) that is most frequent in a population, also called “common” allele (Attia 2009)

DNA = deoxyribonucleic acid; SNP = Single-nucleotide polymorphism; GWAS = Genome-wide association study; HWE = Hardy-Weinberg equilibrium

Table 2. Polymorphisms of interest, together with their major/minor alleles, stratified by race

Polymorphism		Race group			
Gene/Region	SNP or VNTR ^a	White ^b	Black or African American ^c	East Asian ^d	Mexican ^e
CHRNA3	rs1051730	G/A	G/A	G/A	G/A
CHRNA5	rs16969968	G/A	G/A	G/A	G/A
CHRNA5	rs588765	C/T	C/T	C/T	C/T
CHRNA5	rs2036527	G/A	G/A	G/A	G/A
CHRNA3	rs13280604	A/G	G/A	A/G	A/G
CYP2A6	rs4105144	T/C	T/C	T/C	T/C
CYP2B6	rs6474412	T/C	C/T	T/C	T/C
DBH	rs3025343	G/A	G/A	G/A	G/A
DRD4 (exon 3 48 bp)	SI000224I	4 (0.65), 7 (0.18), 3, 2	4 (0.75), 7 (0.14), 6, 5	4 (0.79), 2 (0.17), 5	7 (0.52), 4 (0.41), 2
EGLN2	rs3733829	A/G	A/G	A/G	G/A
EGLN2	rs7937	T/C	C/T	T/C	T/C
LOC100188947	rs1329650	G/T	G/T	T/G	G/T
LOC100188947	rs1028936	A/C	A/C	C/A	A/C
PDE1C	rs215605	T/G	G/T	G/T	T/G
SLC6A3 (3' 40 bp)	SI000156M	10 (0.69), 9 (0.31)	10 (0.73), 9 (0.21), 3, 8	10 (0.91), 9	10 (0.74), 9 (0.24)
SLC6A4 (Promoter)	SI664268G ^f	L (0.62), S (0.38)	L (0.78), S (0.07), 19 (0.15)	L (0.27), S (0.71)	L (0.42), S (0.58)

^aSNP rsID and frequencies from the 1000 Genomes Project database (<http://analysistools.nci.nih.gov/LDlink/>), VNTR UID and frequencies from ALFRED (<http://alfred.med.yale.edu/alfred/index.asp>).

^bGBR or European (PopID = 20, SampID = 20C).

^cASW or per VNTR (DRD4, Biaka (PopID = 5, SampID = 5F); SLC6A3, African American (PopID = 98R, SampID = 101C); SLC6A4, Biaka).

^dCHB + JPT, or mean of Han and Japanese, for SLC6A3 and SLC6A4, Han (SampID = 9J) and Japanese (SampID = 10B).

^eMXL or per VNTR (DRD4, see Table 2, [Aguirre-Samudio 2014](#); SLC6A3, Hispanic American from ALFRED; SLC6A4, see Table 2, [Peralta-Leal 2012](#)).

Table 2. Polymorphisms of interest, together with their major/minor alleles, stratified by race *(Continued)*

^fFor Euro, African American and East Asian, extracted from Promoter VNTR + rs25531 Table in ALFRED. L = 16 repeats, S = 14 repeats.

SNP = Single-nucleotide polymorphism; VNTR = variable number tandem repeat; G = nucleobase guanine; A = nucleobase adenine; C = nucleobase cytosine; T = nucleobase thymine; rsID=reference SNP cluster ID; UID=Unique Identifier, from ALFRED; GBR=British in England and Scotland population description code from 1000 Genomes Project; PopID=Population ID from ALFRED; SampID=Sample ID from ALFRED; ASW=Americans of African Ancestry in SW USA population description code, from 1000 Genomes Project; CHB=Han Chinese in Beijing, China population description code, from 1000 Genomes Project; JPT=Japanese in Tokyo, Japan population description code, from 1000 Genomes Project; Han=Han Chinese living in the San Francisco, California, from ALFRED; MXL=Mexican Ancestry from Los Angeles USA population description code, from 1000 Genomes Project; L=Long (16 repeats); S=Short (14 repeats)

Table 3. Data availability per treatment comparison for the outcome 6-month abstinence

Treatment comparison	SNP or VNTR ^a	Ethnicity	Number of studies (individual treatment 1/treatment 2) included	Analysis number	Significant treatment effect				P value heterogeneity genotype groups
					Letter indicates which treatment is favoured:				
					a = active NRT				
					b = bupropion				
					ba = bupropion + active NRT				
					p = placebo				
					v = varenicline				
Active NRT vs placebo					O	HoMa	Het	HoMi	
	rs1051730	NHW	3 (1023/574)	1.1	a		a	a	0.40
	rs16969968	NHB	2 (392/317)	3.1		a			0.03^a
	rs2036527	NHB	2 (391/317)	5.1					0.36 ^a
	DRD4 (exon 3 48 bp)	NHW	2 (453/447)	6.1	a		a		0.72
					O	S	N		
	NMR	NHW or NHB	2 (719/699)	7.1	a	a			0.22
Bupropion vs placebo					O	HoMa	Het	HoMi	
	rs1051730	NHW	4 (797/532)	8.1	b		b		0.77
		NHB	3 (63/63)	9.1					0.80
	rs16969968	NHB	2 (294/284)	11.1					0.22 ^a
	rs588765	NHW	4 (596/511)	12.1	b			b	0.32
	rs2036527	NHW	2 (412/326)	13.1	b			b	0.28

Table 3. Data availability per treatment comparison for the outcome 6-month abstinence (Continued)

	NHB	3 (331/329)	14.1			0.65
rs3733829	NHW	2 (307/264)	15.1	b	b	0.25

Het: heterozygous; HoMa: homozygous major; HoMi: homozygous minor; N: normal NMR; NHB: non-Hispanic black or African American; NHW: non-Hispanic white; NMR: nicotine metabolite ratio; NRT: nicotine replacement therapy; O = overall; SNP: single-nucleotide polymorphism; VNTR: variable number tandem repeat.

^aHomozygous major vs heterozygous + homozygous minor.

Table 4. Data availability per treatment comparison for the outcome abstinence at end of treatment

Treat- ment compari- son	SNP or VNTR ^a	Ethnicity	Number of studies (individual treatment 1/treatment 2) in- cluded	Analysis number	Significant treatment effect				P value hetero- geneity geno- type groups
					Letter indicates which treatment is favoured:				
					a = active NRT				
					b = bupropion				
					ba = bupropion + active NRT				
					p = placebo				
					v = varenicline				
Active NRT vs placebo					O	HoMa	Het	HoMi	
	rs1051730	NHW	2 (912/479)	1.2	a		a	a	0.004
	rs16969968	NHW	2 (784/343)	2.1			a		0.02
		NHB	2 (392/317)	3.2		a	p ^b		0.003^a
	rs588765	NHW	2 (587/336)	4.1	a				0.89
	rs2036527	NHB	2 (391/317)	5.2					0.28 ^a
	DRD4 (exon 3 48 bp)	NHW	2 (453/447)	6.2					0.79
					O	S	N		

Table 4. Data availability per treatment comparison for the outcome abstinence at end of treatment (Continued)

NMR	NHW or NHB	2 (718/699)	7.2	a	a			0.80
Bupropion vs placebo				O	HoMa	Het	HoMi	
rs1051730	NHW	6 (743/636)	8.2	b	b	b	b	0.41
	NHB	3 (84/75)	9.2					0.12
rs16969968	NHW	3 (324/233)	10.1	b		b		0.50
	NHB	3 (315/296)	11.2	b		b ^b		0.77 ^a
rs588765	NHW	4 (595/512)	12.2	b	b			0.96
rs2036527	NHW	4 (546/429)	13.2	b	b	b	b	0.20
	NHB	4 (352/341)	14.2	b	b			0.38
rs3733829	NHW	4 (440/367)	15.2	b	b	b		0.71
	NHB	2 (46/29)	16.1					0.56 ^a
rs7937	NHW	3 (324/233)	17.1	b	b			0.54
	NHB	2 (47/29)	18.1					0.92 ^a
rs1329650	NHW	3 (324/235)	19.1	b	b			0.83
	NHB	2 (47/29)	20.1					0.59 ^a
rs1028936	NHW	3 (324/235)	21.1	b	b			0.90
	NHB	2 (47/29)	22.1					0.37 ^a
rs215605	NHW	3 (324/234)	23.1	b	b			0.43
	NHB	2 (47/29)	24.1					0.92 ^a

Table 4. Data availability per treatment comparison for the outcome abstinence at end of treatment *(Continued)*

Bupropion + any NRT vs placebo				O	HoMa	Het	HoMi
rs1051730	NHW	2 (268/176)	25.1	ba		ba	0.77
	NHB	2 (40/29)	26.1				0.07 ^a
rs16969968	NHW	2 (266/175)	27.1	ba		ba	0.77
	NHB	2 (40/29)	28.1				0.35 ^a
rs2036527	NHW	2 (267/176)	29.1	ba		ba	0.95
	NHB	2 (40/29)	30.1				0.59
rs3733829	NHW	2 (266/175)	31.1	ba		ba	0.83
	NHB	2 (48/21[ES1])	32.1				0.45 ^a
rs7937	NHW	2 (268/174)	33.1	ba			0.62
	NHB	2 (40/29)	34.1				0.98 ^a
rs1329650	NHW	2 (266/176)	35.1	ba	ba		0.90
	NHB	2 (40/29)	36.1				0.78 ^a
rs1028936	NHW	2 (268/176)	37.1	ba	ba		0.88
	NHB	2 (40/29)	38.1				0.89 ^a
rs215605	NHW	2 (267/175)	39.1	ba	ba		0.79
	NHB	2 (40/28)	40.1				0.52 ^a
Bupropion + any NRT vs bupro- pion				O	HoMa	Het	HoMi
rs1051730	NHW	2 (268/265)	41.1				0.97

Table 4. Data availability per treatment comparison for the outcome abstinence at end of treatment (Continued)

	NHB	2 (40/47)	42.1		0.41 ^a
rs16969968	NHW	2 (266/265)	43.1		0.98
	NHB	2 (40/47)	44.1		0.57 ^a
rs2036527	NHW	2 (267/265)	45.1		0.99
	NHB	2 (40/47)	46.1		0.61 ^a
rs3733829	NHW	2 (267/264)	47.1		0.82
	NHB	2 (48/46)	48.1	b	0.58 ^a
rs7937	NHW	2 (268/265)	49.1		0.69
	NHB	2 (40/47)	50.1		0.85 ^a
rs1329650	NHW	2 (266/265)	51.1		0.66
	NHB	2 (40/47)	52.1		0.49 ^a
rs1028936	NHW	2 (268/265)	53.1		0.60
	NHB	2 (40/47)	54.1		0.49 ^a
rs215605	NHW	2 (267/265)	55.1		0.50
	NHB	2 (40/47)	56.1		0.75 ^a

Het: heterozygous; HoMa: homozygous major; HoMi: homozygous minor; N: normal NMR; NHB: non-Hispanic black or African American; NHW: non-Hispanic white; NMR: nicotine metabolite ratio; NRT: nicotine replacement therapy; O: overall; SNP: single-nucleotide polymorphism; VNTR: variable number tandem repeat.

^aHomozygous major vs heterozygous + homozygous minor.

^bHeterozygous + homozygous minor.

Table 5. Data availability per treatment group for the outcome 6-month abstinence

Treatment group	SNP or VNTR ^a	Ethnicity	Number of studies (individuals in homozygous major/heterozygous/homozygous minor) included	Analysis number	Significant treatment effect Letter indicates which genotype is favoured:	P value heterogeneity in genotype comparisons
-----------------	--------------------------	-----------	--	-----------------	--	---

Table 5. Data availability per treatment group for the outcome 6-month abstinence (Continued)

**ma = genotype group with 1
or more major alleles**
mi = homozygous minor
s = slow NMR
n = normal NMR

Active NRT				MaMi	HetMi
rs1051730	NHW	7 (1352/1025/310)	57.1		0.93
	NHB	2 (181/50/6)	58.1		0.98
rs16969968	NHB	2 (353/39 ^a)	59.1		N/A
rs588765	NHW	3 (286/399/147)	60.1		0.76
rs2036527	NHW	2 (369/447/132)	61.1		0.79
	NHB	2 (232/159 ^a)	62.1		N/A
DRD4 (exon 3 48 bp)	NHW	3 (798/253/68)	63.1		0.74
SLC6A4 (Promoter)	NHW	2 (277/465/184)	64.1		0.62
Normal vs slow					
NMR	NHW and NHB	2 (400/318)	65.1	s	N/A
Bupropion					
rs1051730	NHW	4 (220/294/96)	66.1		0.82
	NHB	2 (43/20 ^a)	67.1		N/A
rs16969968	NHB	2 (261/33 ^a)	69.1		N/A
rs588765	NHW	4 (195/292/109)	70.1		0.80
rs2036527	NHW	2 (143/204/65)	71.1		0.87

Table 5. Data availability per treatment group for the outcome 6-month abstinence (Continued)

	NHB	3 (187/144 ^a)	72.1	N/A
rs3733829	NHW	2 (146/116/45)	73.1	0.65
Varenicline				
rs16969968	NHW	2 (269/349/89)	83.1	0.81
rs588765	NHW	2 (234/345/120)	84.1	0.90
Placebo				
rs1051730	NHW	6 (377/441/156)	101.1	0.54
	NHB	2 (49/14 ^a)	102.1	N/A
rs16969968	NHW	2 (132/181/30)	103.1	0.63
	NHB	3 (519/65 ^a)	104.1	N/A
rs588765	NHW	5 (253/340/130)	105.1	0.92
	NHB	2 (275/291 ^a)	106.1	N/A
rs2036527	NHW	2 (117/166/43)	107.1	0.81
	NHB	4 (373/256 ^a)	108.1	N/A
DRD4 (exon 3 48 bp)	NHW	3 (361/186/26)	109.1	0.44
rs3733829	NHW	2 (122/102/40)	110.1	0.60
SLC6A4 (Promoter)	NHW	2 (128/23 ^a)	119.1	N/A
Normal vs slow				
NMR	NHW and NHB	2 (389/310)	120.1	N/A

HetMi: heterozygous vs homozygous minor; MaMi: homozygous major vs homozygous minor; NHB: non-Hispanic black or African American; NHW: non-Hispanic white; NMR: nicotine metabolite ratio; NRT: nicotine replacement therapy; NS: normal NMR vs slow NMR; SNP: single-nucleotide polymorphism; VNTR: variable number tandem repeat.

^aHeterozygous and homozygous minor combined.

Table 6. Data availability per treatment group for the outcome abstinence at end of treatment

Treatment group	SNP or VNTR ^a	Ethnicity	Number of studies (individuals in homozygous major/heterozygous/homozygous minor) included	Analysis number	Significant treatment effect		P value heterogeneity in genotype comparisons
					Letter indicates which genotype is favored:		
					ma = genotype group with 1 or more major alleles		
					mi = homozygous minor		
					s = slow NMR		
					n = normal NMR		
Active NRT					MaMi	HetMi	
	rs1051730	NHW	5 (917/1008/283)	57.2			0.64
	rs16969968	NHB	2 (353/39 ^a)	59.2	ma ^b		N/A
	rs588765	NHW	3 (286/399/147)	60.2			0.97
	rs2036527	NHW	2 (369/447/132)	61.2			0.74
		NHB	2 (232/159 ^a)	62.2	ma ^b		N/A
	DRD4 (exon 3 48 bp)	NHW	3 (798/253/68)	63.2			0.72
	SLC6A4 (Promoter)	NHW	2 (277/465/184)	64.2			0.83
					Normal vs slow		
	NMR	NHW and NHB	2 (400/318)	65.2			N/A
Bupropion							
	rs1051730	NHW	6 (263/357/123)	66.2			0.59
		NHB	3 (58/26 ^a)	67.2			N/A

Table 6. Data availability per treatment group for the outcome abstinence at end of treatment *(Continued)*

rs16969968	NHW	3 (108/164/52)	68.1	0.51
	NHB	3 (279/36 ^a)	69.2	N/A
rs588765	NHW	4 (195/292/109)	70.2	0.65
rs2036527	NHW	4 (185/269/92)	71.2	0.53
	NHB	4 (200/152 ^a)	72.2	N/A
rs3733829	NHW	4 (203/181/56)	73.2	0.87
	NHB	2 (35/11 ^a)	74.1	N/A
rs7937	NHW	3 (86/165/73)	75.1	0.66
	NHB	2 (20/24/3)	76.1	0.62
rs1329650	NHW	3 (161/138/25)	77.1	0.90
	NHB	2 (42/5 ^a)	78.1	N/A
rs1028936	NHW	3 (212/103/9)	79.1	1.00
	NHB	2 (42/5 ^a)	80.1	N/A
rs215605	NHW	3 (125/154/45)	81.1	0.94
	NHB	2 (31/16 ^a)	82.1	N/A
Varenicline				
rs16969968	NHW	2 (269/349/89)	83.2	0.94
rs588765	NHW	2 (234/345/120)	84.2	0.84
Bupropion + any NRT				
rs1051730	NHW	2 (113/130/25)	85.1	0.96

Table 6. Data availability per treatment group for the outcome abstinence at end of treatment (Continued)

	NHB	2 (33/7 ^a)	86.1		N/A
rs16969968	NHW	2 (113/130/23)	87.1		0.98
	NHB	2 (36/4 ^a)	88.1		N/A
rs2036527	NHW	2 (111/132/24)	89.1		0.82
	NHB	2 (23/12/5)	90.1		0.87
rs3733829	NHW	2 (114/123/30)	91.1		0.52
	NHB	2 (30/10 ^a)	92.1	mi ^b	N/A
rs7937	NHW	2 (74/140/54)	93.1		0.95
	NHB	2 (13/27 ^a)	94.1		N/A
rs1329650	NHW	2 (149/96/21)	95.1	mi	0.67
	NHB	2 (34/6 ^a)	96.1		N/A
rs1028936	NHW	2 (183/75/10)	97.1		0.67
	NHB	2 (34/6 ^a)	98.1		N/A
rs215605	NHW	2 (105/119/43)	99.1		0.25
	NHB	2 (18/22 ^a)	100.1		
Placebo					
rs1051730	NHW	7 (378/441/164)	101.2		0.71
	NHB	3 (63/20 ^a)	102.2		N/A
rs16969968	NHW	4 (169/227/49)	103.2		0.83
	NHB	4 (530/66 ^a)	104.2	mi ^b	N/A
rs588765	NHW	5 (254/296/108)	105.2		0.34

Table 6. Data availability per treatment group for the outcome abstinence at end of treatment (Continued)

	NHB	2 (277/289 ^a)	106.2	N/A
rs2036527	NHW	4 (154/213/62)	107.2	0.90
	NHB	5 (378/263 ^a)	108.2	N/A
DRD4 (exon 3 48 bp)	NHW	3 (361/186/26)	109.2	0.65
rs3733829	NHW	4 (164/152/51)	110.2	0.53
rs7937	NHW	3 (73/120/40)	111.1	0.67
	NHB	2 (18/11 ^a)	112.1	N/A
rs1329650	NHW	3 (119/106/10)	113.1	0.99
	NHB	2 (21/8 ^a)	114.1	N/A
rs1028936	NHW	3 (158/72/5)	115.1	0.79
	NHB	2 (23/6 ^a)	116.1	N/A
rs215605	NHW	3 (94/105/35)	117.1	0.70
	NHB	2 (18/11 ^a)	118.1	N/A
SLC6A4 (Promoter)	NHW	2 (128/23 ^a)	119.2	N/A
Normal vs slow				
NMR	NHW and NHB	2 (400/318)	120.2	N/A

HetMi: heterozygous vs homozygous minor; MaMi: homozygous major vs homozygous minor; NHB: non-Hispanic black or African American; NHW: non-Hispanic white; NS: normal NMR vs slow NMR; SNP: single-nucleotide polymorphism; VNTR: variable number tandem repeat; NMR = nicotine metabolite ratio.

^aHeterozygous and homozygous minor combined.

^bHomozygous major vs heterozygous and homozygous minor.

WHAT'S NEW

Date	Event	Description
26 February 2018	Amended	Significance of heterogeneity amended in Summary of Findings tables

CONTRIBUTIONS OF AUTHORS

SPD and AWB conceived the study. ES, OAP, MRM, DAB, AWB, and SPD wrote the protocol and designed the study. LS, AWB, and SPD searched the literature and identified relevant studies. ES and SPD independently checked the abstracts and, if relevant, retrieved the full texts of records and reviewed them for data. SPD contacted study authors to ask them to share their study data and, in close collaboration with ES, OAP, AWB, and SPD, extracted study characteristics and assessed risk of bias. ES extracted data and performed statistical analyses in RevMan 5.3 in close collaboration with OAP, AWB, and SPD. ES, OAP, AWB, and SPD drafted a first version of the manuscript. All review authors commented on consecutive versions of the manuscript, and read and agreed on submission of the final version of the manuscript.

DECLARATIONS OF INTEREST

ES: none known.

OAP: none known.

MRM: has received grant funding from Pfizer through its Investigator Initiated Research programme.

DAB: none known.

AWB: is an employee of BioRealm, LLC, which intends to commercialise an analysis platform for substance use disorder studies.

SPD: has received funding for study medication from Pfizer through its Investigator Initiated Research programme and is a scientific advisor for BaseHealth.

SOURCES OF SUPPORT

Internal sources

- No sources of support supplied

External sources

- Netherlands Organisation for Scientific Research, Netherlands.

ES acknowledges past support from the Netherlands Organisation for Scientific Research grant 825.14.001.

- NIH, USA.

AWB acknowledges past support from NIH grants DA020830, DA028793, DA033813 and DA041211, and a Visiting Professorship at the University of Bristol.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We refrained from assessing reporting bias and performing subgroup analyses and sensitivity analyses because this version of the review includes too few studies and too few participants within genotype groups for these analyses to yield reliable results.

INDEX TERMS

Medical Subject Headings (MeSH)

*Genotype; *Tobacco Use Cessation Devices; Genetic Markers; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Smoking [*drug therapy] [*genetics]; Smoking Cessation [*methods] [statistics & numerical data]; Time Factors

MeSH check words

Adult; Humans